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AIMS
Basal cell carcinoma (BCC) is the most common cancer in white-skinned people with 
increasing incidence rates, burden of disease and health care costs worldwide. In 
addition, a significant part (≥30%) of patients with a first BCC will develop at least 
a second new BCC or another ultraviolet radiation related cutaneous malignancy in 
time (i.e., metachronous skin cancers). Therefore it is an important topic for patients, 
physicians and policy makers. Unfortunately it is still unclear which patients are at 
risk of a metachronous BCC (mBCC) and who need follow-up in the future. Both non-
genetic and genetic epidemiological studies of primary/prevalent BCCs have been 
conducted but studies are scarce when considering patients with mBCC. In this thesis 
I studied the epidemiology of mBCC using robust methodological approaches. The 
following main questions addressed in this thesis are presented below:
1. What is already known about the epidemiology of BCC and where are the gaps?
2. What are the non-genetic and genetic predictors of a superficial first BCC?
3. How to deal with the competing risk of death when analyzing metachronous BCCs?
4. What are the non-genetic predictors, absolute risks and cumulative incidences of 
metachronous BCCs?
5. What are the genetic predictors of multiple/metachronous BCCs?
OuTlINE
In chapter 2 of this thesis a scholarly (i.e., non-systematic) review of the scientific 
literature on the epidemiology of BCC is presented. In this review we discussed 
incidences, trends and differences, burden of disease, risk factors, prevention and 
health policies, and gaps in existing knowledge were uncovered. 
In chapter 3 we raised the issue of a lack of well-designed and large population-
based cohort studies to unravel the epidemiology of mBCC patients.
In chapter 4 the non-genetic and genetic risk factors of the superficial subtype of 
BCC were investigated, because previous studies pointed out that this subtype could 
have a different etiology compared the other BCC subtypes and may be associated with 
mBCC. The reproducibility of previously found predictors was tested and potential new 
predictors (both non-genetic and genetic) were studied.
In chapter 5 we discussed a common problem in survival analysis regarding 
multiple event data (e.g., mBCC), namely competing risk of death, and showed how to 
overcome this problem when calculating the probability of a new event. In chapter 6 
and 7 we used this knowledge and chose models that could take competing risk into 
account and produce valid effect measures for the included predictors.
Chapter 1 
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In chapters 6 and 7 the primary objective was to develop a prognostic model 
for predicting the absolute risk of mBCC. An extensive literature search showed no 
other prediction models existed for mBCC. We included non-genetic predictors while 
adjusting for the competing risk of death. In chapter 6 the prognostic model was 
developed for predicting the absolute risk of a second new BCC, whereas in chapter 
7 the follow-up was extended and a third, fourth and fifth new BCC were included 
as well to see whether the predictors of a second BCC were predictive for the risk 
of further mBCC. In addition, the frequency and timing of mBCC (i.e., cumulative 
incidences) was determined.
In the previous two chapters the focus was on non-genetic predictors of mBCC 
(i.e., patient, lifestyle and tumor-specific characteristics), but genetic predisposition 
could play a role as well. Therefore (chapter 8 and 9) we performed candidate gene 
approaches with known BCC loci and genome-wide association studies (GWASs) to 
identify single nucleotide polymorphisms associated with multiple BCC (now called 
“multiple” instead of “metachronous” because a small part of the included patients only 
had multiple BCCs on their first diagnosis date and no further BCCs in time), something 
which had not been done before. In chapter 8 previously found BCC loci were tested in 
patients with multiple BCC and a pilot GWAS was conducted to identify susceptibility 
single nucleotide polymorphisms for multiple BCC. In chapter 9 we added patients 
with squamous cell carcinomas to our group with BCC patients, as both tumors are 
keratinocyte carcinomas, to increase our power and performed both a candidate gene 
approach and GWAS on multiple keratinocyte carcinomas in collaboration with three 
different USA cohort studies.
Finally, in chapter 10, I answer the five research questions using results derived 
from this thesis. In addition, limitations of our studies are discussed and implications 
and future perspectives are given.
DATA SOuRCES
In order to answer the five research questions formulated above I have used several 
data sources, which will be briefly described below. More details can be found in the 
corresponding chapters.
For the scholarly review in chapter 2 and to a lesser extent for the commentary in 
chapter 3 we have used different comprehensive search strategies in PubMed.
Chapters 4-8 are based on histopathologically confirmed skin cancer data gathered 
through a linkage between the Rotterdam Study and the Dutch Pathology Registry 
(PALGA). The Rotterdam Study is an ongoing prospective population-based cohort 
study of primarily white-skinned people aged 45 years or older living in a well-defined 
11
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district of Rotterdam, the Netherlands.1 The Rotterdam Study started in 1989 and now 
comprises 14,926 participants. Detailed data were acquired by interviews and by 
thorough examinations of the participants in a specially built research facility in their 
district. These steps were repeated every 3-4 years. PALGA is the Dutch nationwide 
network and registry of histopathology and cytopathology, which was founded in 1971 
and achieved complete national coverage in 1991.2 The skin cancer information of the 
Rotterdam Study participants was obtained up to 31 December 2013 and over a 1,000 
BCC patients could be included in both non-genetic and genetic analyses. 
Chapter 9 has also been based upon the data described above, with the addition 
of data of several USA prospective cohort studies. We collaborated with the research 
teams of the Nurses’ Health Study (NHSI and II) and the Health Professionals Follow-up 
Study,3 as well as the research team of the Framingham Heart Study.4
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ABSTRACT
Basal cell carcinoma (BCC) is the most common cancer in white-skinned individuals 
with increasing incidence rates worldwide. Patients with BCC place a large burden on 
healthcare systems, because of the high incidence and the increased risk of synchronous 
and metachronous BCCs and other ultraviolet radiation (UVR) related skin cancers (i.e., 
field cancerization). As a result, the disability-adjusted life years and healthcare costs 
have risen significantly in recent decades. BCC is a complex disease, in which the 
interplay between UVR, phenotype (UVR-sensitive) and genotype (somatic mutations 
and germline mutations/polymorphisms) fulfils a key role in the aetiopathogenesis. 
Prevention programmes with continual refinements and improvements could be of 
major importance in tackling the growing skin cancer problem. To provide the most 
appropriate BCC care, physicians should engage in shared decision-making and choose 
their treatments wisely.
15
Epidemiology of basal cell carcinoma 
INCIDENCE, TRENDS AND GEOGRAPhIC DIffERENCES
Basal cell carcinomas (BCCs) do not have a precursor lesion and most likely arise 
from stem cells within hair follicles and interfollicular epidermis.1,2 There are 
different histopathological subtypes, of which nodular is the most frequent, followed 
by superficial and infiltrative, and mixed types are frequently found as well.3–5 The 
frequencies reported depend on the classification system used and period.3,6 Most 
BCCs occur in the head and neck region (i.e., sun exposed), followed by trunk and 
extremities (i.e., relatively sun-unexposed).3,4
Incidence per region, trends and differences
BCC is the most common cancer in white-skinned people with increasing incidence 
rates worldwide.7 Although reliable BCC incidence estimates are needed to monitor 
trends and allocate healthcare services, it is remarkable how few countries register 
BCCs in national/regional cancer registries. This registration gap can be explained 
by the tumour’s high volume and low mortality, along with an inability to include 
nonhistopathologically confirmed BCCs and high incidence of synchronous and 
metachronous BCCs. 
Comparisons of incidence rates between countries is difficult because different 
standardization methods are used. The incidence of BCC is strongly inversely related 
to the country’s geographic latitude combined with the pigment status of its inhabitants 
(Table 1). The rates in Europe have increased approximately 5% annually over recent 
decades.7 In the U.S.A., rates have increased about 2% per year leading to over 2.5 
million patients with BCC treated annually.7–9 The highest rates are seen in Australia, 
where over one in two inhabitants will be diagnosed with BCC by the time they are 70 
years old, but the increasing incidence in Australia appears to be reaching a plateau, as 
the rates for people below 60 years of age have stabilized.7,10,11 In non- Western regions, 
such as Asia and South America, incidence rates are ten to hundred-folds lower, but 
have also increased.12,13
The increase in incidence can be explained by an increased awareness in the general 
population and among physicians, more surgical treatments (e.g., more excisions with 
histopathological confirmation instead of cryotherapy or electrodessication), improved 
registration, an ageing population and changes in the distribution of risk factors such as 
ultraviolet radiation (UVR) exposure patterns. The latter is often a matter of debate, but is 
underlined by the observation that the incidence of UVR-related skin tumours increased 
significantly and more steeply compared with other cutaneous malignancies.14 
BCC incidence increases significantly with age, but the most remarkable increase 
has been observed in young women in both Europe (Netherlands and Denmark) and 
the U.S.A., resulting in a reversed male : female ratio (female > male) in younger 
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populations compared with older populations (male > female).15–17 This discrepancy 
between men and women could be a result of the higher use of tanning beds by young 
women18,19 and of women paying closer attention to their appearance and the health of 
their skin, which may result in more medical visits.20
Multiple basal cell carcinomas
In line with the concept of field cancerization,21 patients diagnosed with a first BCC have 
an increased risk of developing a second BCC and other UVR-related skin cancers.22,23 
Patients with a BCC have a 17-fold increased risk of a subsequent BCC compared 
with the general population, followed by a threefold increased risk of a subsequent 
squamous cell carcinoma (SCC) and a twofold increased risk of a melanoma.23 The 
majority of patients with skin cancer are prone to develop the same type (i.e., BCC 
or SCC) of skin cancer.24 Approximately one-third of all patients with a first BCC 
will develop at least a second BCC, 4% an SCC and 0.5% a melanoma, but these 
elevated risks also vary geographically and reflect the underlying incidence rates.23 The 
likelihood of subsequent UVR-related cancers supports the concept that skin cancer 
shows similarities with other chronic conditions, something which has been coined 
‘actinic neoplasia syndrome’ by Weinstock et al.25
BuRDEN Of DISEASE
Global skin cancer burden
The World Health Organization (WHO) quantifies the burden of a disease with the 
disability-adjusted life year (DALY).26 This time-based measure aggregates years of life 
lost through premature death (YLL) and years lived with disability (YLD). One DALY 
equals the loss of 1 year of life lived in full health. 
The mortality of BCC is extremely low as it rarely metastasizes, with rates ranging 
from 0.0028% to 0.55%, and will therefore hardly affect YLL.27 However, the high and 
increasing BCC incidence, the decreasing age at first BCC, and the high occurrence of 
multiple BCCs (mBCC) and other UVR-related skin cancers puts a strain on healthcare 
services. The WHO Global Burden of Disease (GBD) project showed that the age-
standardized YLD rates for nonmelanoma skin cancers (NMSCs) increased significantly 
between 1990 and 2013 (42.5%, to 126 200) and are comparable with the rates of 
oesophageal, ovarian or thyroid cancer.28 Unfortunately, the GBD project does not 
differentiate between the various NMSC subtypes. 
A GBD on UVR exposure computed a BCC-specific DALY and estimated that 58 
000 DALYs were lost globally in 2000.29 A Dutch study of keratinocyte cancer (KC; 
both BCC and SCC) burden showed that the world standardized DALY rates for BCC 
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in both sexes doubled between 1989 and 2008, from two to four per 100 000 person-
years.30 However, both studies included only the first BCC and therefore will have 
underestimated the true burden.
healthcare costs
Results of cost analysis studies of different BCC treatments are usually not generalizable, 
because of the different healthcare systems between countries. Nonetheless, a 2015 
systematic review summarized the healthcare expenditure for different countries and 
national cost estimates were adjusted for country-specific inflation and presented in 
2013 euros.31 In absolute terms, the U.S.A. spends the most money on KC (~ 600 
million), followed by Australia (> 350 million), Germany (> 150 million) and the U.K. 
(> 100 million).31 However, the KC costs relative to the size of the population were 
highest for Australia, followed by New Zealand, Sweden and Denmark, whereas Brazil 
and Canada had the lowest.31 
A U.S.A. Medicare expenditure study showed that NMSC was the fifth most costly 
cancer between 1992 and 1995.32 One U.S.A. study estimated the productivity loss 
per BCC case and reported an estimated cost of $1235.33 A recent report estimated the 
average annual cost of treating NMSC in the U.S.A. at $4.8 billion from 2007 to 2011, 
which is a 74% increase compared with the 2002–06 estimate.34 A relatively large 
part of the U.S.A. treatment costs (> $2 billion) comprise Mohs micrographic surgery 
(MMS), a treatment which has grown exponentially in recent decades.35,36 MMS is a 
cost-effective treatment as long as it is performed by skilled physicians and used in 
properly selected patients, such as patients with recurrent or aggressive histological 
BCCs in the H-zone (temporal, retro- and pre-auricular, orbital and infranasal areas, ears 
and nose).35,37,38 From at least a cost perspective, usage of MMS should be monitored 
to prevent over-usage. 
Another potential cost driver of BCC care is methylaminolaevulinate photodynamic 
therapy (MAL-PDT). In the Netherlands, MAL-PDT was used very frequently, in part 
due to a very profitable reimbursement.39 This changed after a Dutch single-blind, 
noninferiority, randomized controlled trial (RCT) demonstrated that the much less 
costly topical fluorouracil and imiquimod were not inferior to MAL-PDT for clearance 
of superficial BCC after 12 months.40,41
RISk fACTORS
BCC is a complex disease because the likelihood of developing this tumour depends 
on the interplay between constitutional predisposition (genotypic and phenotypic 
characteristics) and subsequent exposure to environmental risk factors. Figure 1 
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shows the most important genetic, phenotypic and environmental risk factors for the 
development of BCC (see Supporting Information, Table S1, for more details). Because 
BCC is a complex disease, most risk factors studied have small effect sizes and it is very 
possible that several of the observed associations are false-positive and/or clinically 
irrelevant.42
Complex disease: environmental risk factors
Ultraviolet radiation
UVR is the major environmental risk factor for BCC (population attributable fraction > 
90%43), but its assessment is problematic (i.e., exposure pattern, timing and amount), 
its exposure varies but is universal and its effect sizes are small. Nevertheless, it seems 
that intense intermittent UVR exposure (e.g., outdoor recreational activities and beach 
holidays), in particular during childhood and adolescence, leads to a significant 
increase in the risk of BCC.44–49 The amount of UVR exposure is positively associated 
with BCC risk, but this effect levels off or even decreases after a certain amount of 
exposure.46,47 The skin’s ability to tan modulates the UVR-induced risk. 
A systematic review and meta-analysis showed that indoor tanning is significantly 
associated with an increased risk of BCC [relative risk 1.29; 95% confidence interval 
BCC
Phenotype
Higher age
Male sex
Light pigment status*
Low ability to tan
Sunburns (childhood)
Signs of actinic damage
Personal/family history of skin cancer
Environment
Intense intermittent UVR (childhood)
Indoor tanning
PUVA/UVB therapy
Ionizing radiation
Arsenic
Systemic immunosuppresion
Genotype
SNPs (pigment +/- effects)
Mutations (e.g. NBCCS, XP)
interaction
figure 1. Main nongenetic risk factors of BCC
This flowchart shows the main genotypic, phenotypic and environmental risk factors for BCC. 
The arrows show how the different risk factor categories exert effects on each other and on BCC. 
BCC, basal cell carcinoma; SNPs, single nucleotide polymorphisms; NBCCS, naevoid basal cell 
carcinoma syndrome; XP, xeroderma pigmentosum; UVR, ultraviolet radiation; PUVA, psoralen 
plus ultraviolet-A radiation; UVB, ultraviolet B radiation. * Consists of complexion, hair colour 
and eye colour.
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(CI) 1.08–1.53; I2 = 37%; no evidence of publication bias], especially if used early in 
life.50 Patients with psoriasis who have had a high number (> 100–200) of psoralen plus 
UVA radiation (PUVA) treatments develop significantly more BCCs than expected and 
this risk seems to persist over time.51–53 UVB therapy (> 300 treatments) has also been 
associated with modest risk increases in the risk of developing BCC.51,54
Photosensitizing drugs
Photosensitizing medication has the ability to induce a phototoxic and/or photo-
allergic reaction upon UVR exposure. In addition to psoralen, other photosensitizing 
medications (e.g., diuretics, tetracyclines and nonsteroidal anti-inflammatory drugs) 
were shown to be positively associated with BCC in several pharmaco-epidemiological 
studies.55–57 However, most of these studies suffered from important limitations and no 
dose–response relationships were observed.
Ionizing radiation
Patient groups at risk are those irradiated in the past for benign disorders such as 
tinea capitis, acne and otitis serosa,58–61 and those irradiated for different types of 
cancer, including childhood cancer survivors and haematopoietic cell transplantation 
survivors.62,63 Nonmedical groups at risk are atomic bomb survivors and occupational 
groups such as radiological technologists.64,65 The elevated BCC risks are confined to 
the site of radiation exposure.66 
Ionizing radiation (IR)-induced BCC risk appears to increase with a person’s skin 
susceptibility to UVR and younger age at exposure (i.e., basal layer more sensitive to 
radiation carcinogenesis). 58,59,61 The development of mBCC in irradiated skin occurs 
frequently as well.61
Chemicals
Arsenic is a carcinogen that appears naturally (i.e., well water), medicinally and in the 
workplace (e.g., mining and agriculture).67 Chronic exposure to arsenic can induce 
BCC formation, especially on the trunk, and BCC multiplicity occurs frequently as 
well.67–69
Smoking
A systematic review and meta-analysis showed that smoking is not significantly 
associated with BCC, with no evidence of publication bias [odds ratio (OR) 0.95; 95% 
CI 0.82–1.09; I2 = 59%].70 A less rigorous meta-analysis suggested that ‘ever smokers’ 
compared with ‘never smokers’ had slightly elevated risks of BCC (OR 1.02; 95% CI 
1.00–1.04; I2 = 84%).71 Overall, it seems that smoking has little to no effect on BCC 
development.
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Human papillomaviruses
In contrast to SCC, some observational studies have found a significant positive 
association between human papillomavirus (HPV) DNA or seropositivity and BCC.72–74 
However, most case–control studies did not find a clear association between different 
cutaneous oncogenic HPV types and BCC.75–77 For now, the evidence that viral 
oncogenesis plays a role in BCC development is far from conclusive.78
Diet and drinks
The epidemiological literature on the role of dietary factors in the development of 
BCC is inconsistent and insufficient for most of the factors studied.79 The evidence 
for protective effects of selenium, carotenoids and vitamins on BCC development is 
inconsistent.80–84 
Several studies on the relationship between alcohol and BCC have been conducted, 
showing conflicting evidence and beverage-dependent relations.85–89 Caffeine intake 
(e.g., coffee) has been associated with a reduced risk of BCC and mBCC.90–92 Whether 
caffeine really inhibits photocarcinogenesis or is just a proxy for global health and 
lifestyle needs to be differentiated.93
Systemic immunosuppression
Over recent decades, the number of chronic immune-suppressed patients, who are 
at an elevated risk of SCC and to a lesser extent of BCC, has grown consistently as a 
result of the increasing number of organ transplant recipients, the immunosuppressive 
agents used in different diseases (e.g., inflammatory bowel disease and non-Hodgkin 
lymphoma) and the increased longevity of these chronic immune-suppressed 
patients.94–96 The overall BCC incidence in renal transplant recipients was7–16 (depending 
on geographic location) times greater than in the general population.94,97,98 The extent 
of UVR exposure and UVR-induced DNA damage prior to transplantation (i.e., UVR-
induced DNA mutations) combined with an impaired cutaneous immune surveillance 
results in an elevated field risk and metachronous BCCs and SCCs.99
Complex disease: phenotypic risk factors
Increasing age and male sex (at older age) are well-known host characteristics that 
increase the risk of BCC.17,100 The ability to repair (UVR-induced) DNA damage reduces 
with age, which leads to an accumulation of damage and an increased incidence of 
BCC in older people.101,102 
The highest BCC risks can be found in people with a personal and/or family history 
of skin cancer, who are (highly) sensitive to UVR exposure and are exposed to intense 
intermittent UVR. This sensitivity is determined by the combination of a fair complexion, 
light hair colour and light eye colour, and low ability to tan.47–49,103–108 
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Acute effects of excessive UVR exposure such as (childhood) sunburns and more 
long-lasting signs of actinic damage such as melanocytic naevi, freckles, solar elastosis, 
solar lentigines and actinic keratoses are also significant predictors of an increased BCC 
risk.44,48,109–111 These manifestations of photodamage could be a warning sign of field 
cancerization.
Risk factors for different histopathological subtypes
Multiple observational studies have found body area, age and sex preferences for 
certain histopathological BCC subtypes (see Supporting Information, Table S1). 
Superficial BCCs are predominantly located on the trunk and patients diagnosed with 
a superficial BCC are significantly younger and more often female than patients with 
other subtypes.3,4,6 These results could indicate that the different subtypes have other 
aetiologies with respect to UVR exposure and the interaction between constitutional 
characteristics and other environmental risk factors. In addition, truncal BCCs have 
been associated with acute intense intermittent exposure patterns.112,113
Risk factors for multiple basal cell carcinomas
Higher age at initial BCC, male sex and a history of BCC have all been found to be 
positively associated with metachronous BCCs (see Supporting Information, Table 
S1).22,114,115 The value of other phenotypic (e.g., skin type) and environmental (e.g., 
UVR) characteristics in predicting a new BCC is under debate22,114,116,117 and studies 
may be hindered by the index event bias.118 
A recently developed prediction model for a second BCC showed that the risk factor 
profile differs between a first and second BCC.92 The most discriminating predictor 
was the presentation of mBCC at first BCC diagnosis.92 Other factors associated with a 
second BCC were age at first BCC (parabolic relation with maximum risk at 68 years), 
male sex, superficial subtype of the first BCC and coffee consumption.92 An update of 
this prediction model, including up to five metachronous BCCs, is in preparation.
GENETIC PREDISPOSITION
Somatic mutations
UVR-induced cancers such as BCC and melanoma exhibit the highest prevalence of 
somatic mutations, of which the majority show ‘UV signatures’, of all cancers.119,120 
Acquired mutations in RAS oncogenes do not seem to play an important role in BCC 
pathogenesis.121–123 However, two tumour suppressor genes are important in sporadic 
BCC carcinogenesis, namely patched 1 (PTCH1) and tumour protein p53 (TP53). 
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The key evidence of a crucial role of PTCH1 in BCC development came from 
patients with naevoid basal cell carcinoma syndrome (NBCCS). PTCH1 (chromosome 
9q22) encodes a protein that is the receptor for sonic hedgehog, a secreted molecule 
implicated in the formation of embryonic structures and in tumorigenesis.124,125 Loss of 
heterozygosity on chromosome 9q22 is the most frequent (58-69%) genetic alteration 
in sporadic BCCs.126–128 Inactivation of PTCH1 and upregulation of hedgehog signalling 
are most likely pivotal events in BCC carcinogenesis.129,130 
TP53 (chromosome 17p13) encodes a tumour suppressor protein that can induce 
several processes, such as cell cycle arrest, senescence, apoptosis and DNA repair.131 
Mutations in this gene play a role in carcinogenesis in a wide variety of tissues.132 
Direct DNA sequencing of the TP53 gene in BCCs revealed mutations in approximately 
44–65% of tumours.127,133,134
Germline polymorphisms
The melanocortin 1 receptor gene (MC1R) is a major determinant of skin colour and 
hair colour, and MC1R variants are significantly associated with BCC risk, even after 
correcting for skin pigmentation.135–137 This pleiotropy suggests that MC1R variants 
exert carcinogenic pigmentation independent effects. Pigmentation pathway single-
nucleotide polymorphisms (SNPs) in tyrosinase (TYR) and agouti signalling protein 
(ASIP) confer risk of BCC as well.138 Studies investigating a possible link between 
defects in DNA repair genes and BCCs have yielded conflicting results.130 
The first genome-wide association study in patients with BCC was conducted in 2008 
and since then, six have been performed in total, finding 17 different risk-increasing 
SNPs mapped to 16 different chromosomal regions (Table 2).139– 144 The ORs found are 
small overall, between 1.15 and 1.55 (except for TP53 variants), and it is not surprising 
that much of the genetic variability is still unexplained. New approaches such as exome 
sequencing and epigenetic studies will further explain heritability. 
The genetic predisposition of mBCC is not well documented and may involve 
genetic changes different from those associated with a primary BCC.145 The cytochrome 
(CYP) supergene family and the glutathione S-transferase (GST) supergene family are 
involved in different metabolizing and detoxification processes, such as detoxification 
of products of oxidative stress.146 Polymorphisms in these genes have been associated 
with increasing BCC numbers.147–149
Germline mutations
NBCCS is an autosomal dominant disorder characterized by mBCC, odontogenic 
keratocysts of the jaws, palmar and/or plantar pits and skeletal abnormalities.150–152 The 
majority of patients with NBCCS start developing their BCCs from puberty onwards 
and affected individuals may develop from a few up to over a thousand BCCs.150,151 
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Patients exposed to IR or high levels of UVR become even more susceptible to BCC 
formation.150,151 Using family-based linkage studies of NBCCS kindreds, the causative 
locus was first mapped to 9q22 and then to the PTCH1 gene.124–126 
Patients suffering from xeroderma pigmentosum (XP) have germline mutations in 
their nucleotide excision repair genes, which are of crucial importance for removing 
UVR-induced DNA damage.153 They have high risks of developing mBCC and other 
skin cancers during childhood.154 
A few other genodermatoses can also cause development of mBCC early in life, 
namely Bazex Dupre–Christol syndrome155,156 and Rombo syndrome.157,158
Table 2. Genome-wide significant risk SNPs for BCCa
SNPb Risk 
allele
frequency Context Region Mapped geneb OR (95% CI)
rs7538876 A 0.35 intron 1p36.13 PADI6 1.28 (1.19-1.37)
rs801114 G 0.33 downstream gene 1q42.13 RHOU, 
LOC105373143
1.28 (1.19-1.37)
rs401681 C 0.56 intron 5p15.33 CLPTM1L 1.25 (1.18-1.34)
rs7335046 G 0.12 downstream gene 13q32.3 UBAC2, LINC01232 1.26 (1.18-1.34)
rs1805007 T 0.07 missense 16q24.3 MC1R 1.55 (1.45-1.66)
rs12210050 T 0.17 intergenic 6p25.3 LOC105374875 1.24 (1.17-1.31)
rs78378222 C NR 3’ UTR 17p13.1 TP53 2.16 (1.83-2.54)
rs214782 G 0.17 intron 20p13 LOC105372503, 
TGM3
1.29 (1.22-1.37)
rs7006527 A 0.86 intron 8q22.2 RGS22 1.3 (1.22-1.41)
rs59586681 T 0.61 intergenic 20p13 LOC388780 1.16 (1.11-1.22)
rs2151280 G NR intron 9p21.3 CDKN2B-AS1 1.2 (1.14-1.27)
rs157935 T NR intron 7q32.3 LINC-PINT 1.23 (1.15-1.31)
rs57244888 T 0.90 intergenic 2p24.3 LOC105373443, 
LOC105373444
1.32 (1.22-1.43)
rs13014235 C 0.46 missense 2q33.1 ALS2CR12 1.15 (1.10-1.20)
rs28727938 C 0.94 intron 8q21.13 LINC01111, MRPL9P1 1.43 (1.30-1.59)
rs73635312 G 0.87 Upstream gene 10p14 LOC105376400 1.35 (1.25-1.45)
rs11170164 T 0.09 missense 12q13.13 KRT5 1.29 (NR)
BCC, basal cell carcinoma; SNP, single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% 
confidence interval; NR, not reported; 3’ UTR, three prime untranslated region. 
a This table has been based on data available at www.ebi.ac.uk/gwas, accessed 20-02-2016 with 
the search term “basal cell carcinoma”.222 
b Mapped to dbSNP Build 146 and Genome Assembly GRCh38.p5.
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PREVENTION
Primary prevention
The goal of primary prevention is to reduce the incidence of a first BCC. Even though 
UVR exposure is not solely responsible for the development of BCC, a considerable 
risk reduction is expected by adequate sun protection.159 However, an Australian 
community-based RCT demonstrated that the daily application of sunscreen did not 
reduce the risk of BCC.160 This finding could be partly explained by the occurrence 
of BCCs on sites that were not treated with sunscreen and the relatively high age of 
the included participants, and underlines the complex association between UVR and 
BCC.160 Multiple national campaigns have been initiated to create public awareness, 
improve professional education and start behavioural change, such as the SunSmart 
programme in Australia.161,162 Initially, these campaigns focused on informing people 
about the harmful effects of UVR exposure but now more actively try to influence 
behaviour. In addition, they target children and adolescents at schools, because 
minimizing (excessive) UVR exposure at an early age is a very important preventive 
measure.161,163 At a legislative level, local governments were encouraged to adopt 
sun protection policies such as sales tax exemption for approved sunscreens and the 
creation of sufficient shade at schools and other public open spaces.161,162 Commercial 
indoor tanning salons in Australia were banned completely as of 1 January 2015 and 
multiple other countries have restricted the use of indoor tanning as well.164 
Although the awareness of the hazardous effects of excessive UVR exposure has 
increased over time, the incidence of most UVR-related skin cancers is still increasing, 
suggesting that people have not fully adopted this knowledge in their behavior (i.e., 
‘knowledge–behaviour gap’). Nevertheless, Australian studies reported the stabilization 
of NMSC rates for people younger than 60 years10 and also showed a significant decline 
in excision rates for KCs in men and women younger than 45 years.165 The positive 
effects of primary prevention programmes might become more evident over time, as 
the follow-up is still relatively short since the initiation of these programmes. 
In addition to behavioural changes, the use of natural, synthetic or biological 
chemical agents to reverse, suppress or prevent carcinogenic progression to invasive 
cancer (i.e., chemoprevention) could be promising in reducing the BCC burden as 
well.166 Chemoprevention could be used as both a primary and secondary prevention 
measure. Whether an agent is a good chemoprophylactic candidate is determined 
by the risk : benefit ratio. Many agents, such as beta carotene, selenium, synthetic 
retinoids (tretinoin, isotretinoin) and nonsteroidal anti-inflammatory drugs have been 
tested but showed no chemopreventive effect on BCC development.160,167–172 However, 
when retinoids were used in patients with genodermatoses (NBCCS, XP) a more 
promising protective effect was seen on BCC development.173–175 Another systemic 
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chemoprophylactic that works well in patients with NBCCS is the hedgehog pathway 
inhibitor vismodegib, but adverse events occur frequently.176
Secondary prevention
The goal of secondary prevention is to detect skin cancer at an early stage (screening) 
and to prevent metachronous skin cancers. Taking the Wilson and Jungner principles 
for population-based disease screening into consideration, BCC screening by itself is 
not likely to be cost-effective because the costs of case-finding (including diagnosis 
and treatment) are most likely in a nonacceptable relation to the overall healthcare 
costs.177 In addition, the U.S. Preventive Services Task Force recently (2016) concluded 
that: ‘the current evidence is insufficient to assess the balance of benefit and harms of 
screening for skin cancer in adults with a clinical visual skin examination’.178 However, 
the German skin cancer screening programme showed that the skin cancer incidence 
went up during the screening period, but this does not necessarily mean that it was 
(cost) effective.179 
A way of increasing the cost-effectiveness of screening is restricting screening to 
high-risk patients such as those with a history of BCCs. Recently, a prediction was 
developed that could reasonably assess the absolute risk of a second BCC using 
simple phenotypic, lifestyle and tumour-specific characteristics.92 Further improving 
these prediction models in the coming years could help physicians identify these high-
risk patients and give them the right follow-up. The downside of targeted screening 
approaches in high-risk patients is the so-called ‘prevention paradox’ in which you 
address the high-risk individual but not the overwhelming majority of low-risk patients 
that develop BCCs.180
Tertiary prevention
The goal of tertiary prevention is to soften the impact of (advanced/metastatic) BCC on 
patients’ lives. A small group (about 1%) of patients have BCCs that have progressed to 
an inoperable stage or have metastasized, and these advanced BCCs were associated 
with a significant disease burden.181,182 In order to improve their ability to function, their 
quality of life and their life expectancy, MMS, radiotherapy and vismodegib could be 
used.
IMPlICATIONS fOR hEAlTh POlICIES
Overall impact
Although BCC-related mortality is low, both tumour growth and treatment can cause 
considerable functional and cosmetic morbidity. The recent U.S.A. initiative to rename 
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BCC to ‘indolent lesion of epithelial origin (IDLE)’ may be understandable from a 
public health perspective, but is inappropriate on an individual level because it falsely 
reassures patients.183 In addition, the lay press recently minimized the consequences 
that BCC can have on the well-being of a patient, confirming the downgrading of BCC 
as a nonissue.184 These controversial opinions could be a warning sign that policy- 
makers are developing a different view on BCC care.
Treatment-related impact
To provide the most appropriate BCC care, physicians should individualize the 
management of BCCs, taking tumour, patient and treatment characteristics into account, 
and combine this with patient preferences and needs (i.e., shared decision-making).185 
The dermatologist should be the lead of skin cancer management, but needs to combine 
diagnostic expertise with a high level of surgical skills to provide the optimal care. In 
addition to dermatologists, the general practitioner (GP) also can play an important role 
in BCC management. In countries such as Australia, where skin cancer poses a large 
burden on the healthcare systems, trained GPs with a special interest in skin cancer 
are functioning as specialized primary care physicians to detect and treat skin cancer. 
A Dutch study showed that the majority of GPs questioned were willing to extend their 
role in skin cancer care, including surgical excision of low-risk BCCs, but that they 
requested additional skin cancer training.186 
Choosing the most cost-effective treatment for BCC wisely becomes increasingly 
important.187 The positioning and appropriate use of MMS in the management strategy 
of BCC is crucial, because it drives the increment in costs related to BCC care.35,188 
Appropriate use of more costly treatments is warranted to ensure access to this more 
expensive treatment over the long term. Linos et al. have raised another controversial 
issue in BCC management among patients with limited life expectancy.189 In a U.S.A. 
prospective cohort study, they showed that most NMSCs were treated surgically, 
regardless of the patient’s life expectancy.189 Although it remains a controversial topic, 
it should stimulate clinicians to provide individualized care in line with patients’ needs, 
especially for certain subgroups of patients with BCC.
follow-up-related impact
The underlying rationale to monitor patients with BCC is to identify recurrences and 
new tumours, educate and psychologically support and reassure patients.190 This 
multidimensional rationale makes it difficult to generate consensus about frequency 
and duration of follow-up. For example, most clinical recurrences appear within 3 
years, but up to 20% may occur within 5–10 years,191,192 whereas the psychological 
stress often peaks in the first years after a cancer diagnosis.193,194 In addition, the risk of 
metachronous BCCs is highest in the first 3 years after diagnosis, but remains elevated 
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over time.115,195,196 The Dutch BCC guideline differentiates between high- and low-risk 
BCCs and recommends annual follow-up for high-risk BCCs.197 In contrast, the U.K. 
guideline concludes, ‘Clearly, within the British health care system it is not possible to 
offer long-term follow-up to all patients who have had their first and only primary BCC 
treated’.198 Again, there is very little data to support both recommendations, but the 
costs of annual monitoring by dermatologists is a very expensive surveillance method 
because of the tumour’s high incidence. 
In contrast, there exists enough data that support that both the dermatologist and the 
GP should perform total body skin examinations in patients presenting with a primary 
BCC, because the chance of finding another synchronous BCC is significant.115,199 
Clinicians should also be aware of the increase in BCC incidence in younger (female) 
patients,15 which could lead to an exponential increase in its occurrence in the future 
elderly population, because those with a history of BCC are likely to develop more of 
these tumours.23 
A more cost-effective approach could be to invest in providing personalized 
information on BCC and its treatment, and educate patients on important risk factors, 
risks of metachronous skin cancer, sun avoidance measures, skin self-examination, and 
train GPs in after care of patients with skin cancer, but this needs to be studied in more 
detail as has been done for other cancers.
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SuPPORTING INfORMATION
Table S1. Main nongenetic risk factors for basal cell carcinoma (BCC), superficial BCC and 
multiple BCCs
BCC Superficial 
BCC
Multiple BCCs
Phenotypic factors
Age + (higher)1-8 + (lower)9-12 + (higher)13-22
Sexa + (male)4 + (female)10,11 + (male)13,17,19,20,23-26
Light pigment statusb +1-3,6-8,27-43
Low ability to tan (i.e., burn easily) +1-3,7,27,31,34-39,41,43-47
Painful/blistering sunburns +6,8,30,31,34,40,43,46,48
Childhood painful/blistering sunburns +28,29,35,36,38,39,49,50
Signs of actinic damage +3,4,6-8,28-31,33-35,38,41,44,45,51-53
Personal history of skin cancer +6,35,41 +13,21,54
Family history of skin cancer +6,7,28,35,45,55,56
Truncal (first) BCC +9-12,57 +18,19,37,58,59
Multiple BCCs at (initial) presentation +22,60
Environmental factors
Childhood intense intermittent UVR 
exposure 
+29,34,35,39,46,55,61
(Adult) intense intermittent UVR 
exposure
+8,35,38-41,46,50,56,62
Indoor tanning +63-68
PUVA therapy +69-74 +75
UVB therapy +71,73,76,77
Medical ionizing radiation +35,71,78-88 +84
Non-medical ionizing radiation +89-92
Arsenic +93,94 +95
Organ transplant recipients +96-100 +101
Immunosuppressive agents +102-105
“+” means positively associated with the outcome and an empty cell means no (clear) association. 
References are shown in superscript. BCC, basal cell carcinoma; AK, actinic keratosis; PUVA, 
psoralen and ultraviolet-A; UVB, ultraviolet B. 
a analyses were frequently adjusted for age and sex, but papers often don’t report the effect sizes. 
However, from incidence studies it is clear that both age and sex are significantly associated with 
BCC. 
b Consists of complexion, hair colour and eye colour.
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ABSTRACT
A previous keratinocyte carcinoma is probably the strongest predictor of developing 
new keratinocyte carcinomas, which makes these patients an interesting population for 
prevention interventions. Investing in large cohort studies and consortia might increase 
the validity of observational findings and should stimulate scientists to investigate the 
underlying mechanisms in detail.
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It is well known that the risk of a subsequent cutaneous malignancy is increased in 
patients with a previous keratinocyte carcinoma (KC). A recent meta-analysis showed 
that 29% of patients with a history of basal cell carcinoma (BCC) developed a subsequent 
BCC and 4% a subsequent squamous cell carcinoma (SCC), whereas 13% of patients 
with a history of SCC developed a subsequent SCC and 16% a subsequent BCC (Flohil 
et al., 2013). The majority of studies on multiple cutaneous malignancies calculated 
risks of a subsequent or second primary skin cancer but did not calculate risks of 
additional skin cancers. In this issue, Adèle Green’s research group selected a cohort of 
1,191 white-skinned Australian residents from their Nambour skin cancer prevention 
trial, without KC, before or at the start of this trial, to determine the proportion who 
developed a BCC exclusively, SCC, or both (Keim et al., 2014). The original cohort 
consisted of 1,621 residents of the subtropical city Nambour, who were selected at 
random in 1986, and therefore the cohort reflects a general population sample from 
Australia followed prospectively between 1992 and 2007. Besides the type of skin 
cancer, the investigators also assessed anatomic site distributions and other clinical 
features such as pigmentary characteristics and signs of actinic damage. This study 
demonstrated that about 21% of the study population developed a first KC and 47% of 
this group developed at least a second KC. The majority of this latter group developed 
exclusively BCCs (56%), 28% developed both, 16% developed SCCs exclusively, with 
age as the most important predictor of increasing incidence rates (Keim et al., 2014). 
Participants who developed SCC exclusively were the most distinct group, because 
they had significantly higher prevalences of easily sunburned skin, propensity to tan 
without burning, and freckling of the back than did the BCC only and mixed groups. 
The skin, eye, and hair color characteristics showed no significant differences among 
the three groups. In those with BCCs exclusively or both BCC and SCC, the head and 
neck area were the predominant sites of development, whereas in the SCC only group 
the limbs were the predominant sites of development. These differences may be the 
result of differences in UVR exposure or genetic susceptibilities, and they suggest 
different tumor biologies. 
Major strengths of this study are 16 years of follow-up, a clear case definition (i.e., 
histopathologically confirmed tumors), full-body skin examinations, and detailed 
information on clinical features. However, the main limitation lies in the small sample 
of patients with multiple cutaneous malignancies, especially the group who developed 
SCCs exclusively (n = 28). Small sample sizes result in wide confidence intervals 
and a possible type II error (i.e., no power calculation shown). Although the cohort 
was followed for 16 years, the study population was young (mean age 46 years) at 
enrollment, suggesting that the majority of the patients had not yet reached the age in 
which the incidence of cutaneous malignancy is highest.
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ACTINIC NEOPlASIA SyNDROME
Martin Weinstock coined the term ‘‘actinic neoplasia syndrome’’ to emphasize that 
cutaneous (pre-)malignancies are not a single event but often reflect a field dysplasia 
from which patients suffer chronically (Weinstock et al., 2009). After the 1992 landmark 
study on this subject (Karagas et al., 1992), many observational studies of different 
populations demonstrated that almost half of patients with cutaneous malignancy will 
develop at least a second KC, and even more will show other signs of chronic actinic 
skin damage (e.g., actinic keratosis, solar elastosis) due to the relatively high levels 
of acute, intermittent, and/or cumulative UVR exposure during their lives. Therefore, 
a previous cutaneous malignancy is probably the strongest predictor of developing 
subsequent malignancies, making this an interesting population for studies of prevention 
intervention. One might argue that the occurrence of multiple malignancies might pose 
a greater problem to both patients and health-care systems compared with disease 
progression or recurrence. 
The benefits of primary prevention programs should become evident only after 
decades (Staples et al., 1998). Even though people become more and more aware 
of the harmful effects of UVR, they do not seem to change their attitude toward it 
(i.e., knowledge–behavior gap; Ma et al., 2007). For now, it seems that primary 
prevention is not meeting its expectations, as the incidence of skin cancer continues 
to increase worldwide, with the possible exception of Australia, which has a highly 
active public education campaign (Lomas et al., 2012). As primary prevention falls 
short, secondary prevention offers a good alternative strategy. This prevention method 
will be most successful when high-risk populations are defined and screening strategies 
for specific patient groups constructed. Well-calibrated, discriminating, and validated 
prediction models could provide physicians with a tool to find high-risk patients, such 
as patients with histories of skin cancer, and give them appropriate right follow-up and 
tailored instructions. If there indeed exists a type-specific skin cancer susceptibility, 
as suggested by Keim et al. (2014), different prediction models should be developed, 
combining environmental, phenotypic, and genotypic risk factors. However, there also 
exists a significant group of patients who develop both BCCs and SCCs, which is not 
surprising, as they share many risk factors (Figure 1). Although the risk factor profiles of 
the different cutaneous (pre-)malignancies are well documented, the extent to which 
these risk factors are applicable to subsequent tumors is not certain. On the basis of 
Rothman’s sufficient- component cause model, it could be argued that the contribution 
of the conventional risk factors for a first event is not applicable to subsequent events, 
defined as the index event bias (Dahabreh and Kent, 2011). In recent decades, huge 
steps have been made in understanding the genetic predisposition (germline and 
somatic mutations) for BCC and to a lesser extent for SCC and actinic keratosis. 
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However, our genetic understanding of these very common keratinocyte malignancies 
lags behind melanoma. Except for a few candidate gene studies and a genome-wide 
association study, no studies have investigated the common or rare genetic variants 
found in patients with multiple keratinocyte malignancies. There is hope, because an 
international consortium has been established to explore the genetics of patients with 
multiple skin cancers and to develop prediction models that include genetic variation.
PROSPECTIVE fOllOw-uP STuDIES
As dermato-epidemiologists, we noticed another important element in this study (Keim 
et al., 2014), which is the enormous return on investment seen in this prospective 
Nambour skin cancer study. Clinical epidemiology includes experimental and 
observational research that might aid our understanding of diseases through a 
quantitative approach of clinical problems. The Nambour skin cancer trial started as an 
experimental study (a randomized fi eld trial) but extended its follow-up as a prospective 
cohort study. The advantages of that type of design are the possibility of calculating risk 
measures (absolute and relative risk) and a relatively low risk of bias compared with 
other observational designs. The classical argument against cohort studies is that they 
are too expensive, but large (population-based) prospective cohort studies such as the 
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figure 1. Risk factor profi les of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)
UVR, ultraviolet radiation; HPV, human papilloma virus; BCNS, basal cell nevus syndrome; EV, 
epidermodysplasia verruciformis; XP, xeroderma pigmentosum.
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Nambour Skin Cancer Study, the Rotterdam Study, Nurses’ Health Study, the Health 
Professionals Follow-up Study, and the PUVA Follow-up Study have a tremendous 
scientific return on investment in many diseases, including skin cancer (Nan et al., 
2011; Stern and Study PF-U, 2012; Hofman et al., 2013; Keim et al., 2014). We are 
strong advocates of investing in well-designed and large cohort studies (including drug 
or disease specific registries), but at the same time we encourage investigators to form 
a consortia to increase sample size and to replicate each other’s findings. Collaborative 
efforts increase the validity of the observational findings and should stimulate laboratory 
scientists even more strongly to investigate the underlying mechanisms in detail.
In conclusion, good research raises more questions than it answers, and it lifts the 
bar for scientific progress.
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ABSTRACT
Background: several observational studies have suggested differences in the risk 
factor profile between patients with superficial basal cell carcinomas (BCCs) and non-
superficial BCCs.
Objective: to test the reproducibility of previous study findings and to find new genetic 
and non-genetic predictors for patients with a superficial first BCC.
Methods: 14.628 participants of northwestern European descent aged 45 years or 
older from a prospective population-based cohort study (Rotterdam Study) were linked 
with the Dutch Pathology Registry (PALGA) of whom 1,528 were identified as BCC 
patients. After exclusion, 948 eligible BCC patients remained for further non-genetic 
analyses and 1,014 for genetic analyses. We included 11 phenotypic, environmental 
and tumor-specific characteristics, and 20 candidate single nucleotide polymorphisms 
(SNP) as potential predictors for patients with a superficial first BCC. We performed 
binary logistic multivariable regression analyses.
Results: we found that patients with a superficial first BCC were significantly younger, 
almost two times more often female and 12-18 times more likely to have their BCC 
on the trunk or extremities than patients with a non-superficial first BCC. One SNP 
(rs12203592), mapped to IRF4, looked promising (OR 1.83, 95% CI 1.13-2.97, p-value 
<0.05), but after adjustment for multiple testing, no significant differences in genetic 
make-up between superficial BCC and non-superficial BCC patients were found.
Conclusion: we conclude that patients with a superficial BCC differ from non-
superficial BCC patients with respect to environmental factors (tumor localization as a 
proxy for UVR exposure) and phenotypic characteristics (age and sex), but we found 
no difference in genotype. As superficial BCC patients develop their first BCCs at a 
younger age, they could be at higher life-time risk for subsequent skin cancers and 
therefore be an interesting group for secondary prevention.
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INTRODuCTION
Patients with basal cell carcinoma (BCC) put a strain on health care services worldwide, 
as a result of the high and increasing BCC incidence, especially in young white-skinned 
women, and the increased risk of synchronous and metachronous BCCs and other 
ultraviolet radiation (UVR) related skin cancers (i.e., field cancerization).1-3 In addition, 
the disability adjusted life years and health care costs for BCC have risen significantly 
as well.4,5
There are different histopathological subtypes of BCC, based on the growth pattern(s) 
found within the tumor tissue. The nodular pattern is most frequently found histological 
subtype (>50%), followed by superficial (~20%) and infiltrative (~10%) and about 
20% of the tumors show a mixed type.6-11 The frequencies reported depend on the 
used pathological classification system and period of the study, because classification 
systems and subtype incidences changed over time.12,13 BCCs mostly occur on the head 
and neck area (i.e., chronically sun exposed; >70%), followed by the trunk (~20%) and 
extremities (~10%), which are both areas intermittently exposed to UVR.7-10,14 Several 
observational studies have identified associations between age, sex and anatomical 
site, and BCC subtypes.6-9,13 Patients with a superficial BCC have more often their BCC 
on the trunk and extremities than in the head and neck region,6-9,13 are younger7-9,13 
and more often female.8,9 In addition, patients with an initial truncal superficial BCC 
developed metachronous BCCs at a faster rate than patients with other anatomical site 
and histology combinations.15
These results could indicate that different BCC subtypes, in particular superficial, 
have other etiologies with respect to environmental factors (e.g., UVR exposure), 
phenotypic characteristics (e.g., age and sex) and genetic predisposition. However, 
only a few studies have studied other predictors than age, sex and anatomical site, with 
conflicting results.10,16,17
The objective of this study is to test the reproducibility of these findings and to 
find potentially new predictors for patients with a superficial first BCC (sBCC). We 
hereto analyzed the data of almost 1,000 white-skinned participants with a BCC of a 
prospective population-based cohort study (Rotterdam Study).
MATERIAlS AND METhODS
Study population
The Rotterdam Study is a prospective population-based cohort study of 14,926 
participants (divided over three cohorts) aged 45 years or older, living in a well-defined 
suburb of Rotterdam, the Netherlands.18 The cohorts predominantly consist of people 
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of northwestern European descent. All the participants were interviewed and examined 
at baseline and these examinations were repeated about every 4 years. The Rotterdam 
Study has been approved by the Medical Ethics Committee of the Erasmus MC and 
by the Ministry of Health, Welfare and Sport of the Netherlands , implementing the 
Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study) and it was 
conducted in accordance with the Declaration of Helsinki. All participants provided 
written informed consent to participate in the study and to obtain information from 
their treating physicians.
Phenotype / Case definition
The method by which we identified BCCs has been described in detail previously.19 
In short, the study database was linked to the Dutch nationwide network and 
registry of histopathology and cytopathology (PALGA) to retrieve medical history of 
all participants on histopathologically confirmed BCCs between 1 July 1989 and 31 
December 2013.20 Of the 14,926 RS participants, 298 did not sign informed consent 
for a linkage and could not be linked to PALGA. The pathology excerpts we received, 
contained information on date of diagnosis, anatomical location, body side, type of 
procedure (i.e., biopsy or excision), radicality, and diagnosis. The majority of these 
excerpts showed a subtyping of the BCC and these subtypes were coded based on the 
World Health Organization’s histological classification of keratinocytic skin tumors.21 
If there was a subtype discrepancy between a biopsy and an excision or a biopsy/
excision included more than one subtype, we coded it as a mixed type BCC and 
noted the concerned subtypes. Patients with a missing subtype were excluded and 
patients with a mixed type first BCC with a superficial component were excluded as 
well, because it was unclear to which subtype these belong (i.e., superficial or non-
superficial). Metachronous BCCs that occurred within 6 months of the first BCC were 
counted as additional tumors at the date of the initial diagnosis, as those BCCs were 
most likely present at this earlier date. We randomly selected a BCC for participants 
with synchronous BCCs on their first diagnosis date.
Selection of non-genetic candidate predictors
A literature search up to May 2016 for English publications on phenotypic, environmental 
and tumor specific factors previously involved in BCC subtypes was done in PubMed. 
Four phenotypic factors were included, namely age at first BCC, sex, pigment status 
and tendency to develop sunburn.7-10,13 The latter was a combination of eye color and 
hair color when young (e.g., a participant with blue eyes and red hair was scored 
as light). Five environmental characteristics were chosen and concerned a history of 
being outdoor for over 4 hours per day during more than 25 years, sun protective 
behavior measured by wearing sunglasses or a hat, smoking, alcohol consumption and 
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coffee consumption.10,22,23 Finally, two tumor related variables were included, namely 
localization of the first BCC and the number of BCCs at first date of diagnosis.6-9,13,15 All 
selected variables (except tumor-specific characteristics) were measured at study entry 
or at a study visit closest to study entry.
Selection of candidate single nucleotide polymorphisms
A literature search up to May 2016 for English genome-wide association study (GWAS) 
publications of loci that confer risk of BCC or non-melanoma skin cancer was done in 
PubMed. There was no GWAS of the histopathological subtypes of BCC. To reduce the 
burden of multiple testing, all selected single nucleotide polymorphisms (SNPs) had 
to be at least borderline genome-wide significant (p-value < 7.0x10-8) and had to be 
replicated in another cohort. This resulted in a list of 20 candidate SNPs located in 17 
different chromosomal regions (eTable 1).24 
Genotype
DNA was isolated from whole blood, further processed and quality checked following 
standard protocols.18 The Illumina Infinium II HumanHap550 BeadChips and the 
Illumina Human610-Quad BeadChips were used to genotype the RS participants. 
Quality control criteria included removing SNPs with Hardy-Weinberg equilibrium 
deviations (p-value < 0.0001), genotyping call rate < 97%, gender mismatch and a high 
mean autosomal heterozygosity. SNPs were not included if they had a minor allele 
frequency of less than 1% and/or an imputation r² of less than 0.3.
For the candidate SNP approach we used genotypes that were estimated from the 
imputed 1000Genomes, GIANT Phase I version 3 dosage data18 using the Genome-
wide Complex Trait Analysis (GCTA) software with default parameters.25 All selected 
candidate SNPs were included in our genetic database.
Statistical analysis
Non-genetic binary logistic regression analysis of sBCC vs non-superficial BCC 
(nsBCC)
All the assumptions of a binary logistic regression analysis were tested and we found 
no violations. There existed no strong (multi)collinearity between the selected non-
genetic candidate predictors. A few outliers in the coffee consumption and alcohol 
consumption variables were found using the outlier labeling rule,26 but all values were 
realistic. There was sufficient power to include the 11 selected candidate predictors in 
the multivariable binary logistic regression analysis.
We could safely assume that missing predictor values were missing at random (i.e., 
missing data points were not related to the missing data itself, but to the observed 
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data). Missing predictor values could therefore be imputed using multiple imputation 
(30 times) by an iterative Markov Chain Monte Carlo method. The imputation model 
included all candidate predictors, the outcome, the body mass index (kg/m2), the level 
of education, the side of the first BCC and the Rotterdam Study cohort number. After 
the imputations we did both univariable and multivariable binary logistic regression 
analyses. No selection methods were used for the multivariable analysis.
All of the data management and the non-genetic binary logistic regression analyses 
were done in IBM® SPSS® Statistics for Windows version 21 (Chicago, IL).
Genetic (SNP-based) binary logistic regression analysis of sBCC vs nsBCC
All the assumptions of a binary logistic regression analysis were tested and we found 
one violation, namely collinearity between two selected candidate SNPs. A bivariate 
correlation matrix showed a Pearson correlation coefficient of 0.86 between rs12210050 
and rs12202284, which means that these predictors were highly correlated. A few 
outliers in the age and principal component variables were found using the outlier 
labeling rule,26 but all values were realistic. There was insufficient power to include 
the 20 selected candidate SNPs, age, sex and four principal components (PCs) in the 
multivariable binary logistic regression analysis. Therefore, we adjusted our analyses 
for multiple testing using the false discovery rate (FDR).27 PCs were included to adjust 
for possible population stratification.
The SNP-based association analyses were performed on the imputed dosage data 
using a binary logistic regression with an additive model. The multivariable logistic 
regression analysis was adjusted for age at BCC diagnosis, sex and four PCs. No 
selection methods were used for the multivariable analysis. 
The genetic data were prepared on our genetic servers and IBM® SPSS® Statistics 
for Windows version 21 (Chicago, IL) was used for the analyses.
Sensitivity analyses of sBCC vs. nodular BCC
We performed sensitivity analyses by doing the same non-genetic and genetic regression 
analyses as for sBCC versus nsBCC, but now including only patients with superficial or 
nodular first BCC.
RESulTS
Study population for non-genetic analyses
Of the 14,628 RS participants linked to PALGA, 1,528 had at least one BCC. After the 
exclusion of patients with a missing subtype (n = 71), patients with a mixed superficial 
first BCC (n = 58) and patients who developed at least one BCC before study entry (n = 
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451), 948 eligible BCC patients remained for further analyses. We randomly selected 
a BCC for participants with synchronous BCCs on their first diagnosis date (n = 125). 
Of the included patients, 137 (14%) had a superficial first BCC, 496 (52%) a nodular 
first BCC and the remaining 315 (33%) another subtype (infiltrative, micronodular or 
non-superficial mixed type; Table 1 and eTable 2).
Patients with a superficial first BCC were younger than patients with a non-superficial 
first BCC (median age 70.2 vs 75.5 years) and the proportion females (64%) was higher 
in sBCC patients than in nsBCC patients (54%; Table 1). Approximately 4 out of 5 
Table 1. Non-genetic characteristics of 948 Rotterdam Study patients with a first BCC
Patient and tumor 
characteristics
Coding Overall1 Superficial 
BCC
Non-superficial 
BCC
Number of patients 948 (100%) 137 (100%) 811 (100%)
Age at first BCC (years) Median (IQR) 74.6 (67.9-
81.2)
70.2 (64.3-
76.0)
75.5 (68.9-81.8)
Sex Female 526 (55%) 87 (64%) 439 (54%)
Pigment status Dark 153 (16%) 24 (18%) 129 (16%)
Intermediate 447 (47%) 70 (51%) 377 (46%)
Light 213 (22%) 30 (22%) 183 (23%)
Missing 135 (14%) 13 (9%) 122 (15%)
Easily sunburned Yes 319 (34%) 53 (39%) 266 (33%)
Missing 65 (7%) 5 (4%) 60 (7%)
Outdoor work Yes 124 (13%) 14 (10%) 110 (14%)
Missing 274 (29%) 42 (31%) 232 (29%)
Sun protection No, never or hardly 
ever
357 (38%) 44 (32%) 313 (39%)
Missing 60 (6%) 4 (3%) 56 (7%)
Smoking Current or former 623 (66%) 92 (67%) 531 (65%)
Missing 17 (2%) 1 (1%) 16 (2%)
Alcohol consumption (glasses/
day)
Median (IQR) 0.6 (0.1-1.7) 0.6 (0.1-1.4) 0.6 (0.1-1.8)
Missing 215 (23%) 18 (13%) 197 (24%)
Coffee consumption (cups/
day)
Median (IQR) 3.3 (2.0-4.5) 3.3 (1.5-4.0) 4.0 (2.0-5.0)
Missing 215 (23%) 18 (13%) 197 (24%)
>1 BCC at initial diagnosis Yes 125 (13%) 24 (18%) 101 (12%)
Localization of first BCC Head and neck 630 (66%) 24 (18%) 606 (75%)
Extremities 128 (14%) 54 (39%) 74 (9%)
Trunk 184 (19%) 58 (42%) 126 (16%)
Missing 6 (1%) 1 (1%) 5 (1%)
1 Participants with a mixed-type BCC with a superficial component were excluded.
BCC, basal cell carcinoma; IQR, interquartile range.
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sBCCs were located on the extremities (39%) or trunk (42%) as opposed to 1 in 4 of 
the nsBCCs.
Non-genetic binary logistic regression analyses of sBCC vs. nsBCC
Of the 11 candidate predictors, 3 were significantly associated with a superficial first 
BCC in the univariable binary logistic regression analyses, namely a younger age at 
first BCC diagnosis (OR: 0.94, 95% CI: 0.92-0.96 per year), female gender (OR: 1.47, 
95% CI: 1.01-2.14) and localization on the trunk (OR: 11.44, 95% CI: 6.85-19.10) or 
extremities (OR: 18.07, 95% CI: 10.56-30.93; Table 3).
These associations remained strongly significant after the multivariable binary 
logistic regression analysis and no other predictors became significant (Table 3). Female 
gender gave an even stronger risk increase for sBCC (OR: 1.88, 95% CI: 1.16-3.03, 
p-value < 0.05), but localization remained the strongest predictor (truncal OR: 12.20, 
95% CI: 7.08-21.03, p-value < 0.001; extremities OR: 17.57, 95% CI: 10.06-30.70, 
p-value < 0.001). The 11 predictors together explained 19.7% (Cox and Snell R2) of 
total variability of a superficial first BCC compared to a non-superficial first BCC.
Study population for genetic analyses
Of the 14,628 RS participants linked to PALGA, 1,257 were genotyped and had at least 
one BCC. After the exclusion of patients with a missing subtype (n = 181) and patients 
with a mixed superficial first BCC (n = 62), 1,014 eligible BCC patients remained 
for further analyses. We randomly selected a BCC for participants with synchronous 
BCCs on their first diagnosis date (n = 126). Of the included patients, 159 (16%) had 
a superficial first BCC, 522 (51%) a nodular first BCC and the remaining 333 (33%) 
another subtype (infiltrative, micronodular or non-superficial mixed type; Table 2 and 
eTable 3).
Patients with a superficial first BCC were younger than patients with a non-superficial 
first BCC (median age 68.0 vs 73.5 years) and the proportion females (65%) was higher 
in sBCC patients than in nsBCC patients (53%).
Table 2. Genetic characteristics of 1,014 Rotterdam Study patients with a first BCC
Patient and tumor 
characteristics
Coding Overall1 Superficial BCC Non-superficial 
BCC
Number of patients 1,014 (100%) 159 (100%) 855 (100%)
Age at first BCC (years) Median (IQR) 72.9 (64.4-79.8) 68.0 (60.8-75.6) 73.5 (65.5-80.5)
Sex Female 556 (55%) 103 (65%) 453 (53%)
1 Participants with a mixed-type BCC with a superficial component were excluded.
BCC, basal cell carcinoma; IQR, interquartile range.
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Genetic (SNP-based) binary logistic regression analyses of sBCC vs. 
nsBCC
Of the 20 candidate SNPs, 2 were borderline significantly associated with a first sBCC 
in the univariable SNP-based binary logistic regression analyses, namely rs8015138 
(OR: 0.76, 95% CI: 0.60-0.97) and rs12203592 (OR: 1.55, 95% CI: 1.01-2.37; Table 4).
Before the multivariable SNP-based binary logistic regression analyses, we excluded 
rs12210050 because it was highly correlated (Pearson’s r: 0.86) with rs12202284 and 
both SNPs were also in strong linkage disequilibrium (r2: 0.73) with each other. The 
multivariable analysis resulted in 1 promising SNP, namely rs12203592 (OR: 1.83, 95% 
CI: 1.13-2.97, p-value 0.014) mapped to pigmentation gene IRF4, but after adjustment 
for multiple testing (FDR) this SNP lost its significance as well. No other SNPs were 
significantly associated to sBCC (Table 4).
The 19 candidate SNPs together explained 1.6%, of which rs12203592 explained 
0.4% (Cox and Snell R2), of the total variability of a superficial first BCC compared to a 
non-superficial first BCC.
Table 3. Associations between predictors and occurrence of superficial first BCC (n = 948)1
Patient and tumor 
characteristics
Coding univariable models2 Multivariable model2,3
Age at first BCC (years) Continuous 0.94 (0.92-0.96)*** 0.95 (0.93-0.98)***
Sex Female 1.47 (1.01-2.14)* 1.88 (1.16-3.03)*
Pigment status Dark Reference Reference
Intermediate 1.01 (0.61-1.67) 0.91 (0.50-1.64)
Light 0.92 (0.51-1.65) 0.80 (0.40-1.61)
Easily sunburned Yes 1.22 (0.83-1.78) 1.13 (0.70-1.81)
Outdoor work Yes 0.77 (0.42-1.38) 0.85 (0.43-1.69)
Sun protection No or hardly ever 0.70 (0.48-1.04) 0.80 (0.51-1.26)
Smoking Current or former 1.03 (0.70-1.52) 1.41 (0.85-2.33)
Alcohol consumption (glasses/
day)
Continuous 0.90 (0.77-1.05) 0.84 (0.70-1.01)
Coffee consumption (cups/day) Continuous 0.92 (0.82-1.02) 0.90 (0.79-1.02)
>1 BCC at initial diagnosis Yes 1.49 (0.92-2.43) 1.41 (0.79-2.52)
Localization of first BCC Head and neck Reference Reference
Extremities 18.07 (10.56-30.93)*** 17.57 (10.06-30.70)***
Trunk 11.44 (6.85-19.10)*** 12.20 (7.08-21.03)***
1 Compared to nodular, micronodular, infiltrative and mixed-type BCCs; all mixed-type BCCs 
with a superficial component were excluded.
2 Pooled ORs with 95% CIs between parentheses.
3 Full model, no selection procedures used.
* P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001.
BCC, basal cell carcinoma.
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Sensitivity analyses of sBCC vs. nodular BCC
After the non-genetic multivariable binary logistic regression analysis comparing sBCC 
to nodular BCC, the same predictors (age at first BCC diagnosis, sex and a localization 
on the trunk or extremities) were significantly associated with a superficial first BCC 
with similar effect sizes (eTable 4). The explained variability increased by 4.3% to 
25.0% (Cox and Snell R2).
The multivariable SNP-based binary logistic regression analysis comparing sBCC 
to nodular BCC resulted in 2 promising SNPs, namely rs12203592 (OR: 2.11, 95% 
Table 4. Associations between predictors and occurrence of superficial first BCC (n = 1,014)1
Patient and tumor 
characteristics
Coding univariable 
models2
Multivariable 
models2,3
Multivariable 
model2,4
Age at first BCC (years) Continuous 0.97 (0.95-0.98)*** 0.96 (0.95-0.98)***
Sex Female 1.63 (1.15-2.32)** 1.67 (1.16-2.40)**
rs73635312 Yes 1.11 (0.74-1.67) 1.08 (0.71-1.64) 1.07 (0.70-1.63)
rs11170164 Yes 0.88 (0.57-1.35) 0.93 (0.59-1.45) 0.95 (0.61-1.49)
rs7335046 Yes 0.95 (0.67-1.36) 0.92 (0.64-1.32) 0.89 (0.61-1.29)
rs8015138 Yes 0.76 (0.60-0.97)* 0.78 (0.61-1.00) 0.79 (0.62-1.02)
rs1805007 Yes 0.96 (0.60-1.55) 0.96 (0.59-1.57) 0.95 (0.58-1.56)
rs78378222 Yes 0.89 (0.38-2.10) 0.95 (0.40-2.52) 0.98 (0.41-2.36)
rs7538876 Yes 1.06 (0.82-1.36) 1.02 (0.79-1.32) 1.02 (0.78-1.32)
rs801114 Yes 0.96 (0.75-1.23) 1.03 (0.80-1.33) 1.00 (0.77-1.30)
rs214782 Yes 0.89 (0.66-1.19) 0.91 (0.68-1.22) 0.93 (0.69-1.26)
rs13014235 Yes 1.07 (0.84-1.36) 1.07 (0.83-1.37) 1.07 (0.83-1.38)
rs57244888 Yes 1.06 (0.67-1.67) 1.11 (0.70-1.78) 1.12 (0.70-1.80)
rs401681 Yes 1.05 (0.82-1.33) 1.00 (0.78-1.28) 0.98 (0.76-1.26)
rs12203592 Yes 1.55 (1.01-2.37)* 1.55 (1.01-2.39)* 1.83 (1.13-2.97)*
rs12202284 Yes 0.92 (0.64-1.32) 0.92 (0.63-1.33) 0.72 (0.47-1.08)
rs12210050 Yes 1.00 (0.71-1.40) 1.03 (0.73-1.46)
rs157935 Yes 0.95 (0.73-1.24) 0.94 (0.72-1.23) 0.95 (0.72-1.26)
rs28727938 Yes 0.89 (0.52-1.53) 0.78 (0.45-1.34) 0.75 (0.43-1.32)
rs7006527 Yes 0.81 (0.58-1.13) 0.79 (0.56-1.12) 0.79 (0.55-1.12)
rs2151280 Yes 1.09 (0.86-1.38) 1.13 (0.89-1.44) 1.14 (0.89-1.46)
rs59586681 Yes 1.09 (0.85-1.40) 1.13 (0.88-1.46) 1.10 (0.85-1.44)
1 Compared to nodular, micronodular, infiltrative and mixed-type BCCs; all mixed-type BCCs 
with a superficial component were excluded.
2 Odds ratios with 95% confidence intervals between parentheses.
3 Included one SNP at a time, adjusted for age at first BCC, sex and first 4 principal components.
4 Full model, adjusted for age at first BCC, sex and first 4 principal components. No selection 
procedures used.
* P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001.
BCC, basal cell carcinoma.
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CI: 1.25-3.58, p-value 0.005) and rs12202284 (OR: 0.55, 95% CI: 0.35-0.88, p-value 
0.012), both mapped to the IRF4 – EXOC2 region, but were not in strong linkage 
disequilibrium (r2: 0.18) with each other (eTable 5). However, after adjustment for 
multiple testing (FDR) both SNPs lost their significance.
DISCuSSION
This prospective population-based cohort study replicates some previous non-genetic 
findings and shows that there are significant differences between patients with a 
superficial first BCC and a non-superficial first BCC. Patients who presented with a 
sBCC were younger, more often female and had their BCCs more frequently on the 
extremities and trunk than patients with nsBCCs. This study also looked into potential 
genetic differences. One SNP, mapped to IRF4, looked promising, but after adjustment 
for multiple testing, no significant differences in genetic make-up between sBCC and 
nsBCC patients were found.
The associations found between the non-genetic predictors and the occurrence of a 
superficial first BCC were in line with several other older and more recent observational 
studies from Europe and Australia.6-10,13 However, most of these non-genetic studies on 
histopathological BCC subtypes did not adjust for potential confounders.6-9,13 Therefore, 
it is possible that the associations found, were spurious. We included 11 potential 
confounders in our non-genetic multivariable model and found that patients with a 
superficial first BCC were significantly younger, almost twice as likely to be female and 
12-18 times more likely to have their BCC on the trunk or extremities than patients with 
a non-superficial first BCC. These differences in age, sex and localization could suggest 
that a different pattern of UVR exposure, namely intense intermittent, plays a role in 
the etiology of sBCC as compared to nsBCC. A British and Australian cohort study 
showed that excessive recreational UVR exposure significantly increased the risk of 
truncal (superficial) BCCs,17,28 whereas Dutch and Italian case-control studies showed 
no relation between cumulative lifetime UVR exposure and sBCC.10,16 
Another potential explanation for the significantly higher risk of sBCC in younger 
women could be behavior. Women tend to use tanning beds more often than men29,30 
and pay closer attention the their health and physical appearance than men, which may 
lead to more medical visits.31
It is also possible that tumor biology differs at various anatomical sites. A Dutch 
renal transplant study showed that transplant recipients more often developed sBCCs 
and that their BCCs were located more frequently on the trunk and extremities than in 
the non-immunosuppressed, which may point at role for the immune system.8
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Superficial first BCC patients were significantly younger (approximately 5 years) than 
non-superficial first BCC patients and developed their BCCs more often on relatively 
sun-unexposed sites, which could mean that they have a different genetic predisposition 
which makes them more vulnerable to develop (superficial) BCC. It is possible that 
they, for example, have a reduced DNA repair capacity or other risk increasing DNA 
differences.32 Hence, we compared carefully selected BCC candidate SNPs between 
these two patient groups. Of the 19 included candidate SNPs in the multivariable 
regression analysis, rs12203592 looked most promising (OR: 1.83, 95% CI: 1.13-2.97, 
p-value 0.014), but lost its significance after adjusting the FDR. This SNP is an intron 
variant mapped to the interferon regulatory factor 4 (IRF4) gene, which belongs to a 
well-known family of transcription factors that are important in the regulation of the 
immune system. It is possible that certain SNPs downregulate the immune system which 
could lead to the formation of sBCC in relatively sun-unexposed areas earlier in life. A 
recent genetic analysis of melanoma patients showed a significant association with the 
bimodal (early- and late-onset) age distribution of melanoma for different rs12203592 
genotypes.33 In addition, IRF4 also plays a key role in the pigmentation pathway and in 
the formation of (pre)malignancies of the skin.34-36 These pre-malignancies (i.e., actinic 
keratosis) have a superficial growth pattern which is comparable to that of sBCCs.
limitations
Misclassification of BCC subtypes by pathologists most likely occurred throughout the 
study period, but it is unlikely that this misclassification was differential. However, we 
could not check the tissue samples as we only received excerpts from PALGA.
The total number of BCCs could have been underestimated, since we only included 
histopathologically confirmed BCCs. This underestimation will be most pronounced 
for superficial BCCs, because physicians could diagnose these BCCs visually and treat 
them non-invasively. However, a recent Dutch observational study showed that only 
a small percentage (ca. 7%) of patients with metachronous BCCs had subsequent 
non-histologically confirmed BCCs.37 In addition, the evidence-based BCC guideline 
from the Dutch Society for Dermatology and Venereology states that histopathological 
verification is needed for all for BCC suspicious lesions.38 Finally, the distribution 
pattern of the histopathological subtypes in our study population is in line with other 
studies, with the nodular type being the most common, followed by the superficial 
type and infiltrative type, while mixed types were frequently found as well.6-11 Our 
candidate SNP approach likely lacked sufficient power (26 degrees of freedom used 
and 159 patients with a superficial first BCC) despite the FDR approach taken. Detailed 
information about other limitations of the Rotterdam Study, the phenotype collection 
and the non-genetic and genetic predictors can be found in two earlier publications.19,39
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Conclusion
Patients with a superficial first BCC differ from non-superficial first BCC patients with 
respect to environmental factors (tumor localization as a proxy for UVR exposure) and 
phenotypic characteristics (age and sex), but (as far as we could find) not in genotype. 
As sBCC patients develop their first BCCs at a younger age, they could be at higher 
risk for subsequent skin cancers. Further study of the interplay between environmental, 
phenotypic and genotypic predictors and BCC subtypes may provide useful knowledge 
for BCC pathogenesis and the design of programs for prevention and early detection 
of BCC.
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eTable 2. Non-genetic characteristics of 633 Rotterdam Study patients with a primary BCC
Patient and tumor 
characteristics
Coding Overall1 Superficial 
BCC
Nodular BCC
Number of patients 633 (100%) 137 (100%) 496 (100%)
Age at first BCC (years) Median (IQR) 74.0 (67.3-
80.4)
70.2 (64.3-
76.0)
75.4 (68.2-81.5)
Sex Female 339 (54%) 87 (64%) 252 (51%)
Pigment status Dark 106 (17%) 24 (18%) 82 (17%)
Intermediate 296 (47%) 70 (51%) 226 (46%)
Light 151 (24%) 30 (22%) 121 (24%)
Missing 80 (13%) 13 (9%) 67 (14%)
Easily sunburned Yes 219 (35%) 53 (39%) 166 (33%)
Missing 38 (6%) 5 (4%) 33 (7%)
Outdoor work Yes 83 (13%) 14 (10%) 69 (14%)
Missing 173 (27%) 42 (31%) 131 (26%)
Sun protection No, never or hardly 
ever
234 (37%) 44 (32%) 190 (38%)
Missing 34 (5%) 4 (3%) 30 (6%)
Smoking Current or former 422 (67%) 92 (67%) 330 (67%)
Missing 9 (1%) 1 (1%) 8 (2%)
Alcohol consumption (glasses/
day)
Median (IQR) 0.5 (0.04-1.8) 0.6 (0.1-1.4) 0.5 (0.03-2.1)
Missing 126 (20%) 18 (13%) 108 (22%)
Coffee consumption (cups/
day)
Median (IQR) 3.3 (2.0-4.0) 3.3 (1.5-4.0) 4.0 (2.0-4.5)
Missing 126 (20%) 18 (13%) 108 (22%)
>1 BCC at initial diagnosis Yes 86 (14%) 24 (18%) 62 (13%)
Localization of first BCC Head and neck 393 (62%) 24 (18%) 369 (74%)
Extremities 101 (16%) 54 (39%) 47 (9%)
Trunk 135 (21%) 58 (42%) 77 (16%)
Missing 4 (1%) 1 (1%) 3 (1%)
1 Participants with a mixed-type BCC with a superficial component were excluded.
BCC, basal cell carcinoma; IQR, interquartile range.
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eTable 3. Genetic characteristics of 681 Rotterdam Study patients with a primary BCC
Patient and tumor 
characteristics
Coding Overall1 Superficial BCC Nodular BCC
Number of patients 681 (100%) 159 (100%) 522 (100%)
Age at first BCC (years) Median (IQR) 72.2 (63.1-79.0) 68.0 (60.8-75.6) 73.3 (64.8-80.3)
Sex Female 363 (53%) 103 (65%) 260 (50%)
1 Participants with a mixed-type BCC with a superficial component were excluded.
BCC, basal cell carcinoma; IQR, interquartile range.
eTable 4. Associations between predictors and occurrence of superficial primary BCC (n = 633)1
Patient and tumor 
characteristics
Coding univariable models2 Multivariable model2,3
Age at first BCC (years) Continuous 0.95 (0.93-0.97)*** 0.96 (0.94-0.99)**
Sex Female 1.69 (1.14-2.49)** 2.29 (1.36-3.83)**
Pigment status Dark Reference Reference
Intermediate 1.07 (0.63-1.80) 0.99 (0.52-1.86)
Light 0.89 (0.49-1.63) 0.73 (0.35-1.52)
Easily sunburned Yes 1.19 (0.80-1.77) 1.17 (0.71-1.95)
Outdoor work Yes 0.77 (0.41-1.42) 0.99 (0.47-2.10)
Sun protection No or hardly ever 0.72 (0.48-1.08) 0.89 (0.54-1.45)
Smoking Current or former 1.00 (0.66-1.49) 1.33 (0.77-2.29)
Alcohol consumption (glasses/
day)
Continuous 0.88 (0.75-1.04) 0.85 (0.70-1.04)
Coffee consumption (cups/day) Continuous 0.92 (0.81-1.03) 0.92 (0.80-1.05)
>1 BCC at initial diagnosis Yes 1.49 (0.89-2.49) 1.34 (0.72-2.52)
Localization of first BCC Head and neck Reference Reference
Extremities 17.34 (9.83-30.59)*** 15.92 (8.80-28.80)***
Trunk 11.38 (6.67-19.43)*** 13.28 (7.40-23.82)***
1 Compared to nodular BCCs only; all mixed-type BCCs with a superficial component were 
excluded.
2 Pooled ORs with 95% CIs between brackets.
3 Full model, no selection procedures used.
* P-value < 0.05; ** P-value < 0.01 ; *** P-value < 0.001.
BCC, basal cell carcinoma.
Model fit
Cox and Snell R2:    25.0%   
Nagelkerke R2:    38.6%   
Hosmer and Lemeshow Test:   0/30 had a p-value < 0.05  
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eTable 5. Associations between predictors and occurrence of first superficial BCC (n = 681)1
Patient and tumor 
characteristics
Coding univariable 
models2
Multivariable 
models2,3
Multivariable 
model2,4
Age at first BCC (years) Continuous 0.97 (0.95-0.98)*** 0.97 (0.95-0.98)***
Sex Female 1.85 (1.28-2.68)** 1.95 (1.32-2.87)***
rs73635312 Yes 1.02 (0.67-1.56) 0.99 (0.64-1.53) 0.97 (0.63-1.51)
rs11170164 Yes 0.94 (0.59-1.48) 0.95 (0.59-1.53) 0.99 (0.60-1.61)
rs7335046 Yes 0.83 (0.57-1.22) 0.79 (0.53-1.18) 0.78 (0.51-1.19)
rs8015138 Yes 0.78 (0.61-1.01) 0.81 (0.63-1.06) 0.83 (0.64-1.08)
rs1805007 Yes 0.97 (0.59-1.59) 0.93 (0.56-1.55) 0.92 (0.54-1.55)
rs78378222 Yes 0.77 (0.31-1.92) 0.82 (0.32-2.08) 0.84 (0.32-2.19)
rs7538876 Yes 1.06 (0.82-1.38) 1.03 (0.78-1.34) 1.03 (0.78-1.36)
rs801114 Yes 0.94 (0.72-1.22) 1.01 (0.77-1.33) 0.99 (0.75-1.32)
rs214782 Yes 0.91 (0.67-1.23) 0.93 (0.68-1.26) 0.95 (0.69-1.31)
rs13014235 Yes 1.05 (0.81-1.35) 1.04 (0.80-1.35) 1.05 (0.80-1.38)
rs57244888 Yes 0.96 (0.59-1.57) 1.02 (0.62-1.69) 1.05 (0.63-1.76)
rs401681 Yes 1.00 (0.78-1.29) 0.93 (0.72-1.21) 0.92 (0.70-1.21)
rs12203592 Yes 1.50 (0.97-2.33) 1.50 (0.94-2.32) 2.11 (1.25-3.58)**
rs12202284 Yes 0.79 (0.53-1.17) 0.73 (0.49-1.10) 0.55 (0.35-0.88)*
rs12210050 Yes 0.88 (0.61-1.26) 0.86 (0.60-1.24)
rs157935 Yes 0.97 (0.73-1.28) 0.95 (0.71-1.27) 0.95 (0.71-1.29)
rs28727938 Yes 0.87 (0.49-1.53) 0.74 (0.41-1.32) 0.70 (0.38-1.27)
rs7006527 Yes 0.76 (0.53-1.09) 0.72 (0.50-1.05) 0.72 (0.49-1.06)
rs2151280 Yes 1.15 (0.90-1.47) 1.15 (0.89-1.49) 1.18 (0.91-1.53)
rs59586681 Yes 1.07 (0.82-1.38) 1.10 (0.84-1.44) 1.07 (0.81-1.42)
1 Compared to nodular BCCs only; all mixed-type BCCs with a superficial component were 
excluded.
2 Odds ratios with 95% confidence intervals between parentheses.
3 Included one SNP at a time, adjusted for age at first BCC, sex and first 4 principal components.
4 Full model, adjusted for age at first BCC, sex and first 4 principal components. No selection 
procedures used.
* P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001.
BCC, basal cell carcinoma.
Model fit full multivariable model
Cox and Snell R2:    6.9%   
Nagelkerke R2:    10.4%  
Hosmer and Lemeshow Test:   p-value 0.802
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Competing risk of death in Kaplan-Meier curves
To the Editor 
We have read with great interest the article by Wehner et al1 about the timing 
of subsequent new keratinocyte carcinomas in patients who present with basal cell 
carcinoma (BCC) or cutaneous squamous cell carcinoma (SCC).1 The authors estimated 
the probability of developing a subsequent KC by calculating 1 minus the Kaplan-
Meier (KM) survival probability. The use of the KM method for other end points than 
overall mortality can lead to a violation of a key assumption, which is the independent 
censoring assumption. In a KM curve with subsequent KC as the event of interest, 
patients who die are censored. The independent censoring assumption means that we 
assume that patients who are censored at time t have the same risk of developing the 
event of interest as those patients who are still in follow-up at time t. It is impossible to 
develop a KC after death, and not adjusting for this will lead to an overestimation of the 
probability of developing a new KC. 
One possibility to take the competing risk of death into account, is to compute a 
cumulative incidence curve (CIC). Other methods are also available and described 
elsewhere.2-4 A CIC is calculated by the sum of the multiplication of the overall survival 
probability with the hazard of a subsequent KC at each time point. 
To show the difference between both methods (KM and CIC), we used data from 
the Rotterdam Study.5 We calculated 1 minus the KM survival probability and the CIC 
of the second metachronous KC (BCC or SCC, including keratoacanthoma but no in 
situ SCC) between January 1, 1990, and December 31, 2013, among 1644 patients 
with a first KC. After 10 years of follow-up the probability of a subsequent KC was 40% 
using the KM method (Figure 1). This probability was an overestimation—the actual 
probability was 34% using the CIC. Twenty years after diagnosis, the difference was 
even larger (74% for KM vs 52% for CIC) because the problem of competing risk due 
to death became larger. 
In conclusion, the problem of competing risk can occur for all end points other than 
overall mortality when using the KM method (eg, melanoma-specific death—patients 
cannot first die due to other causes and then due to melanoma). It especially occurs in 
older populations (ie, higher probability of other competing events such as death) and 
when the follow-up time is long. 
We would like to ask if Wehner et al1 could re-analyze their data using the CIC 
method.
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Figure 1. Kaplan-Meier Curve vs. Cumulative Incidence Curve
of the Probability of Developing a Second Keratinocyte Carcinoma (KC)
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figure 1. Kaplan-Meier Curve vs Cumulative Incidence Curve of the Probability of Developing a 
Second Keratinocyte Cancer (KC)
The solid line represents the biased Kaplan-Meier estimate of the probability of a subsequent 
KC due to the competing risk of death. The dotted line represents the correct probability of a 
subsequent KC using a cumulative incidence curve, taking the competing risk of death into 
account.
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ABSTRACT
A third of basal cell carcinoma (BCC) patients will develop subsequent BCCs. We 
aimed to develop a simple model to predict the absolute risk of a second BCC. We 
observed 14,628 participants of Northern European ancestry from a prospective 
population-based cohort study. BCCs were identified using a linkage with the Dutch 
Pathology Registry (Pathological Anatomy National Automated Archive). Predictors for 
a second BCC included 13 phenotypic, lifestyle, and tumor-specific characteristics. 
The prediction model was based on the Fine and Gray regression model to account for 
the competing risk of death from other causes. Among 1,077 participants with at least 
one BCC, 293 developed a second BCC at a median of 3 years. Several well-known 
risk factors for a first BCC were not prognostic for a second BCC, whereas having more 
than one initial BCC was the strongest predictor. Discriminative ability at 3 years was 
reasonable (bootstrap validated c-index= 0.65). Three groups were created, with 7, 
12, and 28% risk of a second BCC within 3 years. We conclude that a combination of 
readily available clinical characteristics can reasonably identify patients at high risk of 
a second BCC. External validation and extension with stronger predictors is desirable 
to further improve risk prediction.
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INTRODuCTION
Patients with previously treated basal cell carcinoma (BCC) have a high risk of subsequent 
BCCs (Epstein, 1973). A recent meta-analysis showed that 29% of the patients with a 
first BCC will develop at least one more BCC (Flohil et al., 2013b). The increasing 
incidence of BCC, with ~ 5% annually, suggests that primary prevention campaigns 
have not been very effective so far (Lomas et al., 2012). Secondary prevention (i.e., 
detecting new BCCs at an early stage among patients with a prior BCC) is important 
to reduce the high disease burden (i.e., morbidity and costs) associated with this very 
common cancer (Housman et al., 2003; Flohil et al., 2013a; Hollestein et al., 2014). 
The most well-known risk factor for a BCC is UVR, in particular acute and intermittent 
exposure (Kricker et al., 1995; Armstrong and Kricker, 2001). Recently, Weinstock 
coined the term “actinic neoplasia syndrome” to underline the fact that patients with a 
keratinocyte carcinoma (BCC or squamous cell carcinoma) frequently develop another 
keratinocyte carcinoma and various other signs of cutaneous photodamage (e.g., solar 
keratosis and actinic keratosis) due to the field dysplasia (Weinstock et al., 2009). 
However, BCC is a complex disease and not only UVR-related factors are important in 
its carcinogenesis. 
In contrast to risk factors for a first BCC, prognostic factors for a second BCC are less 
well documented. Male sex, higher age at initial BCC, and a history of BCC have been 
found associated with metachronous BCCs (Karagas et al., 1992; Richmond-Sinclair 
et al., 2010; Flohil et al., 2011). The value of other phenotypic (e.g., skin type) and 
environmental (e.g., UVR) characteristics in predicting a new BCC is under debate 
(Robinson, 1987; Karagas et al., 1992; Lovatt et al., 2005; Kiiski et al., 2010; Richmond-
Sinclair et al., 2010). However, no prediction models have been developed yet that 
allow for individualized risk stratification. 
The objective of this study is to develop a prognostic model for predicting the 
occurrence of a second BCC. We hereto analyzed a prospective population-based 
cohort (Rotterdam Study; RS) including over a 1,000 BCC patients.
MATERIAlS AND METhODS
Study population
The RS is a prospective population-based cohort study of people aged 45 years or older 
(Hofman et al., 2013). From July 1989 to September 1993, the first cohort of 7,983 
recruited persons (RS-I, 78% of the invitees) aged 55 years or older was realized. In 
2000– 2001, another 3,011 participants (RS-II, 67% of the invitees) who had become 
55 years of age or older, or applied to this age minimum and had moved into the 
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district, were added to the cohort. The last addition of 3,932 Ommoord inhabitants 
(RS-III, 65% of the invitees) aged 45–54 years took place during 2006–2008. These 
three cohorts together comprise 14,926 participants. Data were acquired by interviews 
at home and by thorough examinations in a specially built research facility in their 
district. These examinations were repeated every 3–4 years. The RS has been approved 
by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, 
Welfare and Sport of The Netherlands, implementing the Wet Bevolkingsonderzoek: 
ERGO (Population Studies Act: RS). All participants provided written informed consent 
to participate in the study and to obtain information from their treating physicians. The 
RS was conducted according to the Declaration of Helsinki Principles.
Case definition
The RS participants were linked to the Dutch nationwide network and registry 
of histopathology and cytopathology (PALGA) to retrieve their medical history of 
histopathologically confirmed BCCs. PALGA was founded in 1971 and achieved 
complete national coverage in 1991 (i.e., since 1991 all Dutch histopathology 
laboratories are linked to this databank; Casparie et al., 2007). Every pathology 
excerpt located on PALGA’s central databank contains encrypted patient data and a 
PALGA diagnosis line derived from the Systematized Nomenclature of Medicine. In 
collaboration with a dermatopathologist, the following information from the excerpts 
was retrieved: date of diagnosis, anatomical location, body side, type of procedure 
(i.e., biopsy or excision), radicality, and diagnosis (including tumor subtype). To obtain 
all pathology reports concerning BCC, we used the PALGA diagnosis lines attached to 
all subtypes of BCC (i.e., M80903, M80913, M80923, M80933, M80943, M80963, 
M80973, and M80983). 
The linkage was done using encrypted patient data both available in the RS and 
PALGA. This encrypted data consisted of the patient’s date of birth, gender, and first 
four to eight letters of the (maiden) family name. The combination of these identifiers 
produced a linkage key. This key showed 98% sensitivity and 98% positive predictive 
value in earlier record linkage research (Van den Brandt et al., 1990). 
Of the 14,926 RS participants, 298 did not sign informed consent for a linkage 
and could not be linked to PALGA. Every BCC excerpt between 1 July 1989 and 31 
December 2013 was retrieved from the network of PALGA. Participants who had 
developed a BCC before entering the RS were excluded from the analyses. 
All excerpts mentioned a date of diagnosis, and, the majority of excerpts included 
a precise anatomical location and information about the type of procedure and the 
radicality of the excision, which made it possible to distinguish between different BCCs 
over time. If information about location was not available, we assumed that a biopsy 
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followed by an excision within a logical time frame (<3 months) concerned the same 
BCC. 
The next tumor following a radical excision was always scored as a new BCC. If 
an excision was irradical, the next reported tumor on the same or adjacent location 
was regarded as the same tumor. Metachronous BCCs occurring within 6 months of 
the first BCC were counted as additional tumors at the date of the initial diagnosis, as 
those BCCs were most likely present at this earlier date. If a BCC consisted of different 
histopathological subtypes, a superiority rule was used, namely infiltrative greater than 
micronodular greater than nodular greater than superficial. Unclear excerpts were 
discussed with an experienced dermatologist, and, if available, missing information 
was obtained from medical records.
Candidate predictors
Three phenotypic factors were selected—namely, age at first BCC (years), sex, and 
pigment status (Robinson, 1987; Karagas et al., 1992). The latter was a combination of 
eye color and hair color when young (e.g., a participant with blue eyes and red hair was 
scored as light). Hair color for RS-III was determined during the second examination 
round. 
Three questions related to UVR exposure were selected and concerned the tendency 
to develop sunburn, a history of outdoor work for at least 4 hours per day during at least 
25 years, and sun protective behavior measured by wearing sunglasses or a hat (Karagas 
et al., 1992). A history of outdoor work was not included in the questionnaire for the 
RS-II cohort. All UVR-related questions for RS-III were determined during the second 
examination round. In addition, smoking, alcohol consumption (glasses per week), 
coffee consumption (cups per day), and BMI (kg/m2) were selected as other lifestyle 
factors (Freedman et al., 2003; Gerstenblith et al., 2012; Miura et al., 2014). Alcohol 
and coffee consumption for RS-II were determined during the third examination round. 
Finally, three variables concerning BCC characteristics were included: localization 
of the first BCC, superficial histopathological subtype of the first BCC, and the number 
of BCCs at first date of diagnosis (Karagas et al., 1992; Lovatt et al., 2005).
Model development
All included participants had at least a first BCC and therefore have a date of first BCC 
diagnosis that served as starting point of the follow-up. Participants were followed from 
this point forward until they developed a second BCC, died, or reached the end of the 
linkage period (31 December 2013) without developing a subsequent BCC. Mortality 
dates were obtained from the municipal register. The localization and histopathological 
subtype of the first BCC of participants who had more than one BCC at the first date of 
diagnosis were randomly selected before the analyses. 
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Missing predictor values were imputed 50 times using multivariate imputation by 
chained equations (Van Buuren, 2012). The imputation model included all candidate 
predictors, the outcome (i.e., second BCC or censored), the follow-up time, the side of 
the first BCC, the level of education, and the RS cohort number. 
As a large proportion (28%) of the elderly participants with a first BCC died before 
they could have developed a second BCC, the analyses were adjusted for competing 
risk of death from other causes (Wolbers et al., 2009). We used the Fine and Gray 
semiparametric proportional hazards model to estimate univariable and multivariable 
regression coefficients (Fine and Gray, 1999). The subdistribution hazard of the event 
of interest (i.e., second BCC) is the absolute risk of a second BCC. We explored the 
association of the continuous predictors with the risk of metachronous BCCs by plotting 
several transformations (e.g., linear, natural logarithm, or square). 
We entered all (possibly transformed) candidate predictors in a multivariable model, 
independent of their p-values in the univariable models. To reduce the multivariable 
model with backward stepwise selection, we used Wald tests based on Rubin’s rules 
for combining estimated regression coefficients and variances from the 50 different 
completed data sets (Vergouwe et al., 2010). To reduce selection bias, we used a liberal 
P-valueo0.20 to include predictors (Steyerberg et al., 2000; Steyerberg, 2009). No 
significant interactions were observed among the included predictors. The regression 
coefficients in the final model were multiplied with a shrinkage factor, which was 
estimated with bootstrapping (Steyerberg, 2009). Shrinkage was applied to prevent that 
predictions for new patients were too extreme (i.e., low predictions being too low and 
high predictions being too high). 
We performed a sensitivity analysis by including only participants with complete 
data in the multivariable modeling.
Model performance
We focused on discrimination as a key aspect of model performance. The discriminative 
ability of the model was evaluated using the c-index. In the available survival data, the 
c-index represents the probability that, for a randomly chosen pair of patients, the 
patient who experiences a second BCC earlier in time has a higher predicted risk. A 
c-index of 0.5 is equivalent to a coin toss, whereas 1.0 implies perfect predictability. 
We corrected the c-indices for optimism using a bootstrap procedure (500 replications; 
Steyerberg, 2009).
Clinical application
For illustrative purposes, we divided patients in three risk groups (low, intermediate, 
and high) using the 25th and 75th percentiles of the risk score distribution as cut 
points. Next, a score chart was developed to facilitate clinical application of the final 
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prediction model. Scores were based on the shrunken regression coefficients, which 
were multiplied by 6.7 and then rounded to an integer. A constant was subtracted or 
added to rescale the scores conveniently. 
IBM SPSS Statistics for Windows version 21.0 (Chicago, IL) was used for data 
management and R version 3.1.1 for more advanced statistical analysis (R Core Team, 
2013), using the cmprsk and riskRegression libraries.
RESulTS
Study population
After the linkage between Pathological Anatomy National Automated Archive (PALGA) 
and the RS, 1,528 patients with at least one BCC were identified. Of those, 451 were 
excluded because they developed at least one BCC before entry of the RS. Overall, 
1,077 patients were included, of whom 293 developed a second BCC during a median 
follow-up of 3.0 years, 479 did not develop a new BCC before the end of follow-up 
(median 3.8 years), and 305 died before they reached the end of follow-up (median 
4.6 years; Table 1). The median age at first BCC in the overall group was 74.5 years, 
whereas in the group of participants who died it was 80.0 years. In all groups, there 
were more females than males.
Age at first BCC diagnosis
When using ordinary Cox models, there appeared a nonlinear relationship between 
age at first BCC diagnosis and the hazard of developing a second BCC (Figure 1a) 
and a linear relationship between age and the hazard of dying (Figure 1b). The 
subdistribution hazard of a second BCC—using the Fine and Gray model—also had a 
nonlinear relationship with age (Figure 1c). Compared with the cause-specific hazard, 
the subdistribution hazard of developing a second BCC is lower for older age, because 
it takes into account the fact that people may die and therefore are no longer at risk of a 
second BCC. The nonlinear relation between age at first BCC diagnosis and developing 
a second BCC could best be approximated by adding a squared term for age to the 
model.
Predictors for a second BCC
Of the 13 potential predictors, a lower age at first BCC (hazard ratio (HR): 1.6, 95% 
confidence interval (CI): 1.3–2.0 for 13 years younger) and two tumor-specific factors 
(i.e., superficial subtype of the first BCC and more than one BCC at first date of 
diagnosis) were significantly associated with an increased risk of a second BCC in 
the univariable analyses (Table 2). Furthermore, several other characteristics showed 
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borderline significant associations with an increased risk of a new BCC, namely male 
sex, easily sunburned, and truncal localization of the first BCC. In contrast, an increase 
in coffee consumption of 3 cups per day (HR: 0.8, 95% CI: 0.6–1.0) was borderline 
significantly associated with a decreased risk of a second BCC.
After backward selection, five predictors remained in the reduced multivariable 
model: age at first BCC, sex, coffee consumption, superficial subtype of the first BCC, 
and more than one BCC at first date of diagnosis (Table 2). None of the UVR-related 
predictors were associated with a second BCC. Being “easily sunburned” also lost its 
significance after adjustment for all other predictors. The strongest predictor was having 
more than one BCC at first date of diagnosis (adjusted HR: 2.5, 95% CI: 1.9–3.3). 
Coffee consumption remained significantly associated with a decreased risk of a 
second BCC (adjusted HR: 0.7, 95% CI: 0.6–0.9). A complete case analysis on 567 
participants resulted in the same reduced multivariable model and comparable HRs 
(data not shown).
The apparent concordance index (c-index) of the multivariable model was 0.66 
(95% CI: 0.58–0.73) at 1 year, 0.67 (95% CI: 0.62–0.72) at 3 years, and 0.65 (95% 
CI: 0.61–0.69) at 5 years after first BCC diagnosis. After correction for optimism, the 
c-index of the model was 0.64 at 1 year, 0.65 at 3 years, and 0.63 at 5 years after first 
BCC diagnosis. When using the score chart for predictions, the apparent c-indices were 
nearly identical to those of the original model (0.65 at 1 year, 0.67 at 3 years, and 0.65 
at 5 years after first BCC diagnosis).
figure 1. Relationships between age at first BCC diagnosis and risk of a second BCC or death
(a) Cause-specific hazard of second BCC. Nonlinear relation between age at first BCC (x axis) 
and the logarithmic transformation of the cause-specific hazard of developing a second BCC 
(y axis) using a Cox model. The dotted lines represent the 95% confidence intervals. (b) Cause-
specific hazard of death. Linear relation between age at first BCC (x axis) and the logarithmic 
transformation of the cause-specific hazard of dying (y axis) using a Cox model. The dotted lines 
represent the 95% confidence intervals. (c) Subdistribution hazard of second BCC. Non-linear 
relation between age at first BCC (x axis) and the logarithmic transformation of the subdistribution 
hazard of developing a second BCC (y axis) using a Fine and Gray model. The dotted lines 
represent the 95% confidence intervals. BCC, basal cell carcinoma.
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Clinical application
The observed cumulative incidence curve of the high-risk group showed a distinct 
pattern compared with the observed cumulative incidence curves of the other risk 
groups (Figure 2). Table 3 shows the score chart that was based on the shrunken 
regression coefficients of the final prediction model; the estimated shrinkage factor 
was 0.88. Using the score chart, the physician can easily calculate the predicted risk 
of a second BCC for a patient currently having a first BCC. The patient obtains a score 
for each predictor, and these are added up to form a total score. The corresponding 
predicted risks of a second BCC (within 1, 3, and 5 years) can be found in Table 3 
as well. For example, a 63-year-old (two points, when age is rounded to 65 years) 
man (one point) who drinks no coffee (two points) presenting with one (zero points) 
Table 2. Associations between predictors and occurrence of a second BCC (n=293) using the Fine 
and Gray model for competing risks
Patient and tumor characteristics Coding univariable models Multivariable model1
Age at first BCC (years) 68 versus 812 1.6 (1.3-2.0) *** 1.6 (1.3-2.0)
Sex Male 1.3 (1.0-1.6) * 1.2 (0.9-1.5)
BMI (kg/m2) 24 versus 292 1.1 (0.9-1.3) -
Pigment status Dark Reference -
Intermediate 1.2 (0.8-1.6) -
Light 1.4 (0.9-2.0) -
Easily sunburned Yes 1.3 (1.0-1.6) -
Outdoor work Yes 1.1 (0.8-1.5) -
Sun protection
No or almost 
never 0.9 (0.7-1.2) -
Smoking Ever 1.1 (0.8-1.3) -
Alcohol consumption (glasses/
week)3 10 versus 02 1.1 (0.8-1.6) -
Coffee consumption (cups/day) 5 versus 22 0.8 (0.6-1.0) * 0.7 (0.6-0.9)
Localization of first BCC Head Reference -
Extremities 1.1 (0.8-1.5) -
Trunk 1.3 (1.0-1.7) * -
Superficial first BCC Yes 1.5 (1.1-2.0) ** 1.3 (0.9-1.7)
>1 BCC at first diagnosis date Yes 2.6 (2.0-3.4) *** 2.5 (1.9-3.3)
Abbreviations: BCC, basal cell carcinoma; BMI, body mass index.
The baseline cumulative subdistribution hazard is 0.035 at 1 year, 0.106 at 3 years, and 0.170 
at 5 years.
* P-value <0.05, **P-value <0.01, and ***P-value <0.001.
1 After backward selection.
2 Interquartile range.
3 Truncated at 10 glasses per week.
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superficial (one point) BCC has a total score of 6, which corresponds to a 3-year risk 
of 21%.
figure 2. Observed cumulative incidence curves of the three risk groups
Observed cumulative incidence (y axis) curves of the three risk groups (low, intermediate, and 
high-risk) with follow-up time (x axis) using the 25th and 75th percentiles of the risk score 
distribution as cut points. Below the figure are the numbers at risk at start of follow-up and at 1, 
3, and 5 years of follow-up for each risk group.
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DISCuSSION
This prospective population-based cohort study shows that the absolute risk of a second 
BCC could be predicted with reasonable accuracy using simple phenotypic, lifestyle 
and tumor-specific characteristics. The strongest predictor of a second BCC in time was 
having more than one BCC at initial BCC diagnosis. Participants were 2.5-fold more 
likely to develop a new BCC compared with individuals who only had one BCC at the 
initial date of diagnosis. From the concept of field cancerization, this observation is 
Table 3. On the left, score chart for predicting an individual’s risk of a second BCC at the time of 
a first BCC. On the right, total scores and corresponding absolute risks of a second BCC at the 
time of a first BCC
Predictor Value Score Total score 1-year risk 3-year risk 5-year risk
Age at first BCC1 (years) ≤ 55 0 ≤ -5 1% 4% 6%
60 1 -4 2% 5% 8%
65 2 -3 2% 6% 9%
70 2 -2 2% 6% 10%
75 1 -1 2% 7% 11%
80 0 0 3% 9% 13%
85 -3 1 3% 10% 16%
≥ 90 -5 2 4% 11% 18%
Sex Female 0 3 5% 13% 20%
Male 1 4 5% 15% 23%
Daily intake of cups of coffee 0 2 5 6% 18% 28%
1 1 6 8% 21% 32%
2 1 ≥ 7 10% 27% 40%
3 0
4 -1
5 -1
≥ 6 -2
Superficial subtype of first BCC No 0
Yes 1
> 1 BCC at first date of 
diagnosis
No 0
Yes 5
Total score …
Abbreviation: BCC, basal cell carcinoma.
The predicted risk (%) of a second BCC within 1 year after the primary BCC was determined by: 
P = [1−(exp(−exp(B) × 0.035))] × 100%, where
B = 0.285 × age − 0.002 × age2 + 0.152 (if male sex) − 0.093 × coffee cups per day + 0.209 (if 
superficial subtype) + 0.796 (if more than one BCC).
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expected. It is consistent with the results from the Skin Cancer Prevention Study Group 
and a retrospective Spanish study demonstrating that the total number of prior BCCs 
was strongly associated with the risk of metachronous BCCs (Karagas et al., 1992; 
Graells, 2004).
A superficial subtype of the first BCC gave a participant a significantly higher 
(+30%) risk to develop a second BCC, which is in accordance with data from a British 
retrospective cohort study (Lovatt et al., 2005). In previous studies, the histopathological 
subtype of a BCC has also been associated with tumor localization, as most of the truncal 
BCCs are superficial, and most of the head and neck BCCs are nodular (Bastiaens et al., 
1998; Scrivener et al., 2002). We noted a similar pattern, suggesting a good validity of 
these predictors. 
A nonlinear (parabolic) relationship between age at first BCC diagnosis and the risk 
of a second BCC was detected. As expected, the risk of a second BCC increased with 
age, but this risk decreased after approximately 68 years of age. Several other cohort 
studies have shown a similar risk increase with age but not a risk decrease as patients 
get even older. Reasons could be that they analyzed a younger cohort and/or changed 
age into a categorical variable so that a possible nonlinear relationship was hidden 
(Karagas et al., 1992; Richmond-Sinclair et al., 2010; Flohil et al., 2011).
After adjusting for other factors in the multivariable model, male gender was a 
modest prognostic factor for a second BCC. Other cohorts demonstrated weak to strong 
relations between male sex and risk of a subsequent BCC, but they did not adjust for 
tumor characteristics, such as histological subtype and/or localization, that differ across 
gender (Karagas et al., 1992; Richmond-Sinclair et al., 2010; Flohil et al., 2011). 
Remarkably, coffee consumption reduced the risk of a second BCC (adjusted HR 
per increase in three cups per day: 0.7, 95% CI: 0.6–0.9). Although caffeinated and 
decaffeinated coffee consumers could not be differentiated in the overall population, 
~ 90% of the coffee consumers in RS-I, which accounts for most of the included 
participants, used caffeinated coffee. Several observational studies investigated the 
association between coffee intake and BCC development. Recently, a large prospective 
follow-up study from Australia showed protective effects of coffee consumption (Miura 
et al., 2014), whereas two European case–control studies did not find a significant 
association with BCC development (Corona et al., 2001; Milan et al., 2003). Animal 
studies have shown that oral and topical administration of caffeine inhibit UVB-induced 
carcinogenesis and selectively increase apoptosis in squamous cell carcinomas (Huang 
et al., 1997; Lu et al., 2002). In vitro research on human keratinocytes has demonstrated 
that this inhibitory effect of caffeine may be due to the induction of apoptosis in UVB-
damaged keratinocytes (Heffernan et al., 2009; Han et al., 2011). However, people 
consuming more coffee may also differ from those drinking less coffee for which the 
analyses were unable to adjust for (i.e., residual confounding). A recent review argues 
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that coffee intake reflects an, often unmeasured, healthy life style and is indirectly 
associated with multiple health outcomes (Mirza et al., 2014).
It is interesting that no significant influence was found for pigment status and UVR-
related characteristics (easily sunburned, outdoor work, and sun protection) on the 
development of a second BCC. The lack of this association was consistent with earlier 
studies (Lovatt et al., 2005; Richmond-Sinclair et al., 2010). A reason for this apparently 
paradoxical observation could be the so-called index event bias (Dahabreh and Kent, 
2011). UVR is a strong risk factor for a first BCC, and participants who have been exposed 
to high levels of UVR could have a relatively favorable risk factor profile with respect 
to the other known and unknown risk factors for a first BCC. This relatively favorable 
risk profile could, with respect to the other risk factors in the statistical analysis, show a 
seemingly nonsignificant or an even protective relation with the development of a new 
BCC within this group with high UVR exposure compared with the group without high 
levels of UVR exposure. 
The prediction model and simple score chart allow for identification of high-risk 
patients for more intensive follow-up, while excluding the low-risk patients from 
subsequent follow-up visits. This will lower the strain that the group of BCC patients 
is putting on the limited (specialized) health care. In addition, an earlier detection of 
BCCs most likely leads to smaller tumor sizes, which in turn will reduce treatment-
related morbidity and costs (Mudigonda et al., 2010). Our 1-year (0.64), 3-year (0.65), 
and 5-year (0.63) discriminative ability is far from perfect, which suggests that other 
(unknown) predictors also have a role in the development of a second BCC. Combining 
genetic and non-genetic predictors into one model might increase the c-index.
limitations
Cohort members may have developed BCCs prior to the complete national coverage 
of the pathology database (PALGA) in 1991, leading to misclassification bias, which 
reduces the generalizability. However, between 1971 and 1991 partial coverage was 
achieved and the mean age of the included participants in 1991 was 61 years, which is 
seven years younger compared with the mean BCC age of diagnosis (Arits et al., 2011), 
suggesting that the impact of this bias is at most modest. In addition, approximately 
30% of the participants with a first BCC developed at least a second BCC, which is in 
line with another Dutch PALGA study and a recent meta-analysis (Flohil et al., 2011; 
Flohil et al., 2013b), suggesting excellent internal validity of the study design.
Because we obtained our BCC cases through a linkage with PALGA, we have missed 
BCC diagnoses that were not made based on histopathology. However, a recent study 
showed that only a small percentage (ca. 7%) of patients with metachronous BCCs 
had subsequent non-histologically confirmed BCCs (Flohil et al., 2013c). In addition, 
the evidence-based guideline regarding BCC from the Dutch Society for Dermatology 
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and Venereology (NVDV) states that all biopsied/excised BCCs should be sent for 
a histopathological diagnosis (http://www.nvdv.nl/wp-content/uploads/2014/08/
Richtlijn-Basaalcelcarcinoom-2014.pdf). 
The UVR-related items in the questionnaires for this study may not have been 
optimal but probably picked up major differences in UVR exposure between 
participants. Although lifestyle characteristics may change over a lifetime, we only 
measured UVR-related variables, smoking, alcohol consumption, coffee consumption, 
and BMI at baseline for most participants. However, we do not believe that non-UVR-
related behavior changes after a first BCC diagnosis, as most patients do not associate 
predictors such as smoking, alcohol consumption, and coffee consumption with BCC 
development. UVR-related behavior may change, but most of the UV damage has 
already been done years before diagnosis. We did not have UVR exposure information 
during childhood and adolescence, which is important in the etiopathogenesis of BCC, 
but because of the potential recall bias this information is often inaccurate (Glanz et 
al., 2010). 
We have tried to find an external cohort for validation of our prediction model 
(Leiden Skin Cancer Study, Nurses’ Health Study and Framingham Heart Study). 
Unfortunately, multiple BCC data and detailed information on our predictors are scarce.
Conclusion
The risk factor profile for a second BCC differs from that of a first BCC. The strongest 
predictor is the presentation of multiple BCCs at index date. Other factors associated 
with a second BCC are age at first BCC, male gender, coffee consumption, and superficial 
subtype of the first BCC. These simple variables provide a tool to assist physicians to 
identify high-risk patients, to give a tailored follow-up, and to give information on the 
risk of subsequent BCCs. External validation and improvement of the discriminative 
ability are needed.
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ABSTRACT
Background: A third of patients with a first basal cell carcinoma (BCC) will develop 
subsequent (metachronous) BCCs. 
Objectives: To study the prognostic effect of the number of previous BCC diagnosis 
dates a patient has experienced to derive a prediction model to assess the risk of 
metachronous BCCs that may inform individualized decision making on surveillance.
Methods: We considered participants of north-western European ancestry from a 
prospective population-based cohort study (Rotterdam Study). After linkage with the 
Dutch Pathology Registry, 1077 patients with a first BCC were included. Candidate 
predictors for metachronous BCCs included patient, lifestyle and tumour characteristics. 
The prognostic model was developed with Fine and Gray regression analysis to account 
for competing risk of death. We used bootstrapping to correct for within-patient 
correlation and statistical optimism in predictive performance.
Results: Second to fifth BCCs occurred in 293, 122, 58 and 36 patients, with median 
follow-up times of 3.0, 2.1, 1.7 and 1.8 years after the previous BCC, respectively. 
The risk of a new BCC was higher for patients with more metachronous BCCs. Having 
more than one BCC at diagnosis was another strong predictor of metachronous BCCs. 
Discriminative ability of the model was reasonable with an optimism-corrected c-index 
of 0.70 at 3 years.
Conclusions: The number of previous BCC diagnosis dates was a strong prognostic 
factor and should be considered when predicting the risk of metachronous BCCs. 
When the number of previous BCC diagnosis dates is combined with other readily 
available characteristics into a prognostic model, patients at high risk of a new BCC 
can be identified.
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INTRODuCTION
Basal cell carcinoma (BCC) places a large burden on healthcare systems, resulting 
from the high incidence of new tumours over time (metachronous BCCs), which need 
treatment and follow-up.1–4 The incidence of BCC is increasing, which is reflected in 
the significant increase in disability-adjusted life years and costs in different countries 
in the last decades.2,5,6 Patients tend to develop subsequent skin cancers of the same 
type, illustrating the concept of field cancerization.4,7,8 Most metachronous BCCs occur 
within the first 3 years after diagnosis, but the risk remains elevated over time.4,9,10 
A meta-analysis selected nine studies and found a pooled mean 5-year cumulative 
risk of a metachronous BCC of 36%, which was comparable with the most recent 
observational study published.3,4
We recently developed a prognostic model to discriminate between patients with 
a low risk and a high risk of a second BCC. Having more than one BCC at initial 
diagnosis was the strongest risk factor, followed by age, superficial first BCC and male 
sex.11 These predictors have been found associated with metachronous BCCs in other 
observational research.4,7,10,12–14 Previous studies have typically focused on the first 
metachronous BCC, whereas patients frequently develop more metachronous BCCs.4,10 
A prognostic model for metachronous BCCs could identify high-risk patients who need 
active surveillance, improving secondary prevention. 
The question arises of whether the predictors of a second BCC will be predictive for 
the risk of metachronous BCCs. At least the number of previous BCC diagnosis dates 
a patient has experienced might be an important addition to the prognostic model. 
The purpose of our study was to determine the frequency and timing of metachronous 
BCCs with cumulative incidence curves and to develop a prognostic model to predict 
the absolute risk of metachronous BCCs. We analysed a prospective population-
based cohort (Rotterdam Study)including > 1000 patients with BCC. In the model 
development, we considered death as a competing risk and adjusted for the multiple 
events per patient. Reporting was according to the TRIPOD Statement.15,16
MATERIAlS AND METhODS
Study population
The Rotterdam Study is a prospective population-based follow-up study in a well-
defined district of Rotterdam in the Netherlands and comprises 14 926 participants 
aged 45 years or older.17 The cohort started in July 1989 and predominantly consists of 
people of north-western European ancestry. All the participants were interviewed and 
examined at baseline and these examinations were repeated about every 4 years. The 
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Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing 
the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All 
participants provided written informed consent to participate in the study and for us to 
obtain information from their treating physicians.
Case definition
Identification of BCC cases has been described previously.11 In short, the Rotterdam 
Study participants were linked to the nationwide network and registry of histo- and 
cytopathology in the Netherlands (PALGA) to obtain their medical history of 
histopathologically confirmed BCCs until 1 January 2014. PALGA was founded in 
1971 and achieved complete national coverage in 1991.18 The pathology excerpts 
we received contained information on date of diagnosis, anatomical location, body 
side, type of procedure (biopsy or excision), radicality (whether or not the BCC was 
completely excised with no tumour cells in the studied transection margins according 
to the pathologist) and diagnosis [including subtype(s)]. We used this information 
to distinguish metachronous BCCs from recurrent BCCs (i.e., irradically treated). 
Furthermore, if a new BCC was diagnosed within 6 months of an earlier BCC, it was 
considered to be present at the previous diagnosis date. This rule was applied during 
the entire follow-up period. 
Of the 14 926 Rotterdam Study participants, 298 did not sign informed consent 
for a linkage and could not be linked to PALGA. To maintain the prospective design, 
participants who had a BCC before Rotterdam Study entry were excluded from the 
analyses. 
All included patients had a first BCC with a date of diagnosis that served as starting 
point of the follow-up. Participants were followed from this point forward until they 
died, or reached the end of the linkage period (31 December 2013). We considered a 
maximum of four metachronous BCCs per patient, to have strata with at least 50 patients 
at time of prediction. Mortality dates were obtained from the municipal registry. Figure 
1 shows the data structure of the BCC patients.
Candidate predictors
The same candidate predictors were considered as in our prognostic model for a second 
BCC: age at BCC diagnosis, sex, pigment status, tendency to develop sunburn, history 
of outdoor work, sun-protective behaviour, BCC localization, superficial subtype and 
having more than one BCC at date of diagnosis.11 We added one new categorical 
predictor: the number of previous BCC diagnosis dates (0, 1, 2 or 3). More specifically, 
this predictor represents the number of previous diagnosis dates on which one or 
more BCCs were diagnosed. Pigment status was a combination of eye colour and hair 
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colour when young. Mixed-type BCCs with a superfi cial component were coded as 
superfi cial. When participants had more than one BCC at a certain date of diagnosis, 
the localization and histopathological subtype at this date were randomly selected 
before the analyses. The latter was the case for 12– 25% of the patients, depending on 
the number of previous BCC diagnosis dates.
Model development
Missing predictor values were imputed 20 times using multivariate imputation by 
chained equations.19 The imputation model included all candidate predictors, the 
outcome (i.e., new BCC, death or censored) and the follow-up time. 
As a large proportion of the patients died during follow-up (24.5%), time to event 
analyses were adjusted for the competing event ‘death’.20 We used the Fine and Gray 
semiparametric proportional hazards model to estimate univariable and multivariable 
regression coeffi cients.21 The subdistribution hazard of a new BCC corresponded to the 
absolute risk of a new BCC. 
The proportionality of subdistribution hazards was tested for all predictors.22 The 
assumption was not met for age, but adding an interaction term between age and time 
did not show suffi cient relevance according to the likelihood ratio test to extend the 
model beyond the main effect of age. We explored the association of the continuous 
predictors with the risk of metachronous BCCs by plotting several transformations 
(linear, natural logarithm and square). Only the predictor age showed a nonlinear 
relationship with the outcome, which could be approximated by adding a quadratic 
term. To allow for event-specifi c effects of the predictors, we tested the interactions 
between the number of previous BCC diagnosis dates and each of the other predictors 
with likelihood ratio tests. None of these was of suffi cient relevance to change the 
model specifi cation.
1st BCC
n = 1,077
2nd BCC
n = 293
3rd BCC
n = 122
4th BCC
n = 58
5th BCC
n = 36
Death
 
n = 50
t = 3.8 yrs
n = 21
t = 2.2 yrs
n = 4
t = 1.5 yrs
t = 3.0 yrs t = 2.1 yrs t = 1.7 yrs t = 1.8 yrs
n = 305
t = 4.6 yrs
figure 1. Structure of the metachronous basal cell carcinoma (BCC) dataset with numbers of 
patients (n) and median follow-up times in years (t)
Censoring occurred for 479, 121, 43 and 18 patients after having a fi rst, second, third and fourth 
BCC diagnosis date, respectively.
Chapter 7
108
The Fine and Gray model does not account for within-patient correlation resulting 
from multiple events per patient. Consequently, variance estimates of the regression 
coefficients will be too low and confidence intervals (CIs) will be too narrow. To adjust 
for the within-patient correlation, we assessed SEs with bootstrapping.23 For each 
imputed dataset, we drew 1000 bootstrap samples. Backward stepwise selection was 
based on a liberal P-value (< 0.20), to reduce selection bias.24 The regression coefficients 
in the final model were multiplied with a heuristic shrinkage factor.25 Shrinkage was 
applied to prevent predictions for new patients being too extreme (i.e., low predictions 
being too low and high predictions being too high).
Model performance
We focused on discrimination as a key aspect of model performance. The discriminative 
ability of the model was evaluated using the concordance index (c-index) adapted 
for competing risks data.26 In our survival data, the c-index represents the probability 
that, for a randomly chosen pair of patients, the patient who experiences a new BCC 
earlier in time has a higher predicted risk. A c-index of 0.5 is equivalent to a coin toss, 
whereas 1.0 implies perfect discrimination. We corrected the c-indices for optimism 
using a bootstrap procedure with 500 replications, including the backward selection 
procedure.25
Clinical application
We developed a score chart to facilitate clinical application of the final prognostic 
model. Scores were based on the shrunken regression coefficients, which were 
multiplied by 7.1 and then rounded to an integer. A constant was subtracted or added 
to rescale the scores conveniently. IBM SPSS Statistics for Windows version 21.0 (IBM, 
Armonk, NY, U.S.A.) was used for data management and R version 3.2.0 for more 
advanced statistical analysis,27 using the ‘cmprsk’ and ‘riskRegression’ libraries.
RESulTS
Study population
After linkage, 1528 patients with at least one BCC were identified. Of those, 451 were 
excluded because they developed at least one BCC before entry into the Rotterdam 
Study. Included patients (n = 1077) had a median age of 75 years and 45% were 
male. Among them 293, 122, 58 and 36 developed a second, third, fourth and fifth 
BCC, respectively. The median follow-up until the next BCC was 3.0, 2.1, 1.7 and 1.8 
years, respectively (Figure 1). In total, 380 patients died during a median follow-up for 
survivors of 5.0 years. The cumulative incidence of a metachronous BCC at 3 years 
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was 15%, 34%, 45% and 67% for the second, third, fourth and fifth BCC, respectively 
(Figure 2).
Predictors for metachronous basal cell carcinomas
The frequency of known predictors for a first BCC – such as light pigment status, 
easily sunburned and no sun protection-increased when patients experienced more 
metachronous BCCs (Table 1). More than one BCC at diagnosis was a strong predictor 
in the univariable analyses together with the number of previous BCC diagnosis dates a 
patient had experienced (Table 2). The effect of the localization of the BCC was similar 
for trunk and extremities. 
Nine of the 14 candidate predictors remained in the multivariable model: age 
at BCC diagnosis, sex, pigment status, easily sunburned, coffee consumption, more 
than one BCC at diagnosis, superficial subtype of BCC, localization of BCC and the 
number of previous BCC diagnosis dates (Table 2). The apparent overall c-index of the 
multivariable model was 0.68 (95% CI 0.63–0.72) at 1 year; 0.71 (95% CI 0.69–0.74) 
at 3 years; and 0.69 (95% CI 0.67–0.72) at 5 years after any BCC diagnosis. Optimism-
corrected c-indices were 0.67 (95% CI 0.62–0.71), 0.70 (95% CI 0.68–0.73) and 0.68 
(95% CI 0.66–0.71), respectively.
figure 2. Cumulative incidence functions per basal cell carcinoma (BCC) diagnosis date sequence 
number
Below the figure are the number of patients at risk at the specific time points.
Chapter 7
110
Table 1. Distribution of candidate predictor values at first and metachronous basal cell carcinomas 
(BCCs)
At 1st BCC
N = 1077
At 2nd BCC
N = 293
At 3rd BCC
N = 122
At 4th BCC
N = 58
Age at BCC 
diagnosis 
Years 75 (68-81) 77 (71-83) 79 (73-84) 77 (73-85)
Gender Male 484 (45%) 143 (49%) 68 (56%) 31 (53%)
Pigment status Totala 928 255 105 52
Dark 174 (19%) 42 (17%) 13 (13%) 6 (11%)
Intermediate 514 (55%) 138 (54%) 56 (53%) 27 (52%)
Light 240 (26%) 75 (29%) 36 (34%) 19 (37%)
Easily sunburned Totala 1009 273 111 54
Yes 365 (36%) 111 (41%) 55 (50%) 30 (56%)
Sun protection Totala 1014 274 111 54
Yes 404 (40%) 108 (39%) 35 (31%) 17 (31%)
Outdoor work Totala 783 203 86 44
Yes 142 (18%) 40 (20%) 19 (22%) 9 (20%)
BMI Totala 1000 278 118 56
Kg per m2 26.0 (23.8-28.6) 25.9 (23.8-28.1) 25.8 (24.0-27.8) 26.6 (24.4-29.0)
Smoking Totala 1059 284 117 56
Ever 705 (67%) 188 (66%) 80 (68%) 36 (64%)
Alcohol 
consumption 
Totala 836 241 101 48
Glasses per 
week
3.8 (0.4-10.0) 3.5 (0.5-10.0) 4.0 (0.6-10.0) 2.5 (0.5-9.9)
Coffee consumption Totala 836 241 101 48
Cups per 
day
3.3 (2.0-5.0) 3.3 (2.0-4.0) 3.3 (2.0-4.0) 4.0 (2.9-4.0)
More than 1 BCC at 
diagnosis
Yes 132 (12%) 40 (14%) 30 (25%) 12 (21%)
Superficial BCC Totala 1001 287 119 56
Yes 199 (20%) 77 (27%) 37 (31%) 18 (32%)
Localization of BCC Totala 1065 289 122 57
Head 663 (62%) 165 (57%) 63 (52%) 25 (44%)
Trunk 265 (25%) 84 (29%) 36 (29%) 24 (42%)
Extremities 137 (13%) 40 (14%) 23 (19%) 8 (14%)
Data are n (%) unless otherwise indicated. IQR, interquartile range; BMI, body mass index. a For 
predictors with missing values, the number of observed values is given.
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Clinical application
A score chart was based on the regression coefficients of the final prognostic model 
(with shrinkage by a factor 0.89). The patient obtained a score for each predictor, and 
these were added to form a total score (Table 3). The corresponding predicted risks of a 
metachronous BCC are shown for 1, 3 and 5 years [Figure. 3; Table S1 (see Supporting 
Information)]. For example, a 75-year-old (4 points) male patient (1 point) with light 
pigment status (2 points), who sunburns easily (1 point), who drinks no coffee (4 points) 
and who presents for the first time (0 points) with one (0 points) superficial (1 point) 
BCC located at the head (0 points) has a total score of 13, which corresponds to a 
3-year risk of 26% of experiencing a metachronous BCC. If this same male patient 
had presented with exactly the same BCC but already experienced three previous 
Table 2. Uni- and multivariable associations between predictors and occurrence of metachronous 
basal cell carcinomas (BCCs) using the Fine and Gray model for competing risks
univariable models Multivariable model
Patient, lifestyle, and tumour 
characteristics
Coding hR (95% CI)a
hR (95% CI)a
Age at BCC diagnosis, years 69 versus 82b 1.3 (1.1-1.6) 1.4 (1.2-1.7)
Gender Male 1.3 (1.0-1.6) 1.2 (1.0-1.4)
Pigment status Dark 1.0 1.0
Intermediate 1.3 (1.0-1.8) 1.2 (0.9-1.5)
Light 1.6 (1.1-2.2) 1.3 (1.0-1.7)
Easily sunburned Yes 1.4 (1.1-1.7) 1.2 (1.0-1.4)
Sun protection Yes 0.8 (0.7-1.0) —
Outdoor work Yes 1.1 (0.9-1.4) —
BMI, kg per m2 24 versus 29b 1.0 (0.9-1.1) —
Smoking Ever 1.1 (0.8-1.3) —
Alcohol consumption, glasses per week 10 versus 0b 1.1 (0.8-1.4) —
Coffee consumption, cups per day 5 versus 2b 0.8 (0.7-0.9) 0.8 (0.7-0.9)
> 1 BCC at diagnosis Yes 2.2 (1.8-2.6) 1.9 (1.5-2.4)
Superficial BCC Yes 1.5 (1.3-1.9) 1.2 (0.9-1.5)
Localization of BCC Head 1.0 1.0
Trunk 1.5 (1.2-1.9) 1.2 (1.0-1.5)
Extremities 1.4 (1.1-1.9) 1.3 (1.0-1.7)
Number of previous BCC diagnosis dates 0 1.0 1.0
1 2.1 (1.7-2.6) 2.1 (1.7-2.6)
2 2.8 (2.1-3.8) 2.6 (1.9-3.5)
3 4.8 (3.4-6.9) 3.9 (2.5-6.2)
HR, hazard ratio; CI, confidence interval. a Based on 1000 bootstrap samples; b interquartile 
range.
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BCCs, his score would be 22, corresponding to a 3-year risk of 59% of experiencing a 
metachronous BCC.
DISCuSSION
We studied the occurrence of metachronous BCCs and developed a prognostic model 
to predict the absolute risk of metachronous BCCs. The number of previous BCC 
Table 3. Score chart for predicting metachronous basal cell carcinomas (BCCs)
Predictor Value Score
Age at BCC diagnosis, years ≤ 55 4
60-70 5
75 4
80 3
85 2
≥ 90 0
Gender Female 0
Male 1
Pigment status Dark 0
Intermediate 1
Light 2
Easily sunburned No 0
Yes 1
Daily intake of cups of coffee 0 4
1-2 3
3-4 2
5-6 1
≥ 7 0
More than 1 BCC at diagnosis No 0
Yes 4
Superficial BCC No 0
Yes 1
Localization of BCC Head 0
Trunk 1
Extremities 2
Number of previous BCC diagnosis dates 0 0
1 5
2 6
3 9
Total score …
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diagnosis dates a patient experienced was the strongest prognostic factor. The risks of 
a third, fourth and fifth BCC increased compared with the risk of a second BCC. The 
number of previous BCC diagnosis dates was combined with easily obtainable patient, 
lifestyle and tumour-specific characteristics into a prognostic model. 
Most predictors that were included in the current model and in our previous model 
for predicting a second BCC had similar effect sizes.11 Three additional predictors with 
moderate effects were included in the model for metachronous BCC: pigment status, 
easily sunburned and localization of BCC. 
The risk of a metachronous BCC was high in the first 2 years after a diagnosis, as 
illustrated by the cumulative incidence curves. Up to 50% of patients with a fourth BCC 
will develop a fifth within 24 months of follow-up. Indeed, previous studies have also 
shown that most metachronous BCCs occur within the first 2–3 years after diagnosis, 
but the risk remains elevated over time.4,9,10 The model may guide in assessing 
individualized surveillance: who should be monitored and when, and extends our 
previous prognostic model, where we ended the follow-up after the first metachronous 
BCC (i.e., second BCC).11 
Patients who experienced more previous BCCs were far more likely to develop a 
new BCC than patients who were diagnosed with their first BCC (Figure. 2). The number 
of previous BCC diagnosis dates and the number of BCC diagnosis dates at diagnosis 
figure 3. Total score obtained from the score chart (x-axis) and corresponding absolute risks of a 
metachronous basal cell carcinoma (BCC; y-axis) within 1, 3 and 5 years after the current BCC 
diagnosis date
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could be proxies of field cancerization, a well-known concept in patients with recurrent 
and multiple primary oral squamous cell cancers.28 Like the oral cavity, the skin is 
one of the predominant sites of oncogenesis because it comes into direct contact with 
many carcinogens, in particular ultraviolet radiation (UVR). Throughout life, large fields 
of UVR-exposed skin accumulate genetically altered cells and become preneoplastic, 
which is analogous to, for example, head and neck squamous cell carcinoma of the 
digestive system.29 Normal-looking human skin and epithelial tissue surrounding BCCs 
often contains precancerous changes, such as TP53 mutations.30–32 Thus, physicians 
should always perform a full-body skin examination at first BCC diagnosis, because 
of the high likelihood of synchronous BCCs, and follow those who have a history of 
synchronous and/or metachronous BCCs. Our results are in line with other prospective 
U.S.-based follow-up studies, where the number of previous BCC diagnosis dates was 
the strongest predictor for metachronous BCCs in multivariable adjusted analyses.7,33 
A U.K. case–control study showed that the presence of more than one BCC at first 
presentation was significantly associated with a decreased time to the next BCC.34
Two other tumour-specific characteristics – histopathological subtype and 
localization – were also predictive of metachronous BCCs. The findings are comparable 
with U.K. case–control and cohort studies.12,35 The results could indicate that patients 
with a superficial and/or BCC on the trunk or extremities comprise a subgroup in which 
different mechanisms are at work (e.g., different UVR exposure patterns and/or genetic 
susceptibility). However, in a Dutch retrospective cohort study both subtype and 
localization were not associated with a second BCC after multivariable adjustment.36 
Previous studies found that superficial BCCs are predominantly located on the trunk, 
whereas nodular BCCs are found more often in the head and neck area.37–39 We noted 
a similar distribution of the different subtypes and localizations in our study. 
The risk of metachronous BCCs increased with age but decreased again after 
approximately 68 years of age. This is similar to our previous finding, when we analysed 
the follow-up until the first metachronous BCC (i.e., second BCC).11 Other prospective 
cohort studies have found a risk increase with age –but categorized age, which could 
have hidden a nonlinear relation.7,10,13,33 Moreover, these studies also did not take the 
potential competing risk of death into account, which could lead to an unrealistic 
estimation of absolute risks.20,40 
Our patients were relatively old (median age 75 years) as a result of linking the 
clinical data of the patients to the epidemiological data of the Rotterdam cohort 
containing mainly elderly people. Nevertheless, our model can be applied to patients 
from about 50 years of age, as the minimum age of our patients was 48 years. 
Coffee consumption significantly reduced the risk of metachronous BCCs, for 
each increase of three cups of coffee per day the risk decreased by 20%. As discussed 
in our previous study, this could be a true biological effect or the result of selection 
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bias.11 The findings on coffee consumption are diverse. A large prospective follow-up 
study from Australia showed protective effects of coffee consumption,41 whereas two 
somewhat older European case–control studies did not find a significant association 
with BCC development.42,43 A recent meta-analysis suggested a protective effect of 
coffee consumption, although this effect disappeared when the study that contributed 
the most heterogeneity between studies was left out of the analysis.44 Despite these 
varying findings, the strong predictive effect of coffee consumption on developing a 
second or later BCC and the ease of asking patients about their coffee use allowed us 
to include this predictor in our model. 
The apparent c-indices of our model varied between 0.68 and 0.71. As we had 
no external cohort, the c-index measured the internal validity of our model. But even 
after correcting for the possibly resulting optimism, the c-indices still varied between 
0.67 and 0.70, which indicated a reasonable discriminative ability. As there are not yet 
any tools for predicting the occurrence of metachronous BCCs, we think our model is 
a good first step. We propose that the simple score chart can help physicians identify 
high-risk patients to prevent serious morbidity and high healthcare costs.5,6 A cost-
effectiveness analysis may identify a threshold value that justifies active surveillance 
and a reasonable frequency of follow-up.
The existing follow-up protocols differ per country and even per hospital within a 
country. Nevertheless, our model may well assist clinicians to better identify patients at 
high risk of metachronous BCC and to determine surveillance frequencies accordingly. 
For example, BCC patients in the Netherlands usually are not under follow-up, because 
‘only’ 30% will get a next BCC and BCC is rarely lethal. Moreover, following up every 
patient would be unrealistic because of insufficient capacity and high costs. However, 
when clinicians can use our model to estimate an individual patient’s absolute risk, 
they can decide to see high-risk patients regularly. 
This study has some limitations. Some cohort members may have developed 
BCCs prior to the complete national coverage of PALGA; BCC diagnoses that were 
not based on pathology were missed (most likely only a small percentage);45 and the 
UVR-related items in the questionnaires may not have been optimal. These issues were 
also encountered when we developed a model for a second BCC, but were shown to 
have little or no effect on the internal validity of the study design.11 We did not have 
the availability of an external validation cohort and had to rely on bootstrap validation 
to support our claims of predictive performance in new patients. Future studies should 
validate the proposed score and try to improve the discriminative ability.46 
To accommodate both competing risks and repeated events, we based our prognostic 
model on the Fine and Gray model. We corrected the variances of the predictor estimates 
post hoc to account for the within-patient correlation between metachronous BCCs. 
Other advanced techniques might have been used, such as the multistate model or the 
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joint frailty model.47,48 Unfortunately, absolute risk calculation for repeated events is 
not yet readily possible with these techniques in currently available statistical software. 
In conclusion, the absolute risk of a metachronous BCC can be predicted with 
reasonable accuracy using a prognostic model that consists of a combination of patient, 
lifestyle and tumour-specific characteristics. The number of previous BCC diagnosis 
dates a patient has experienced is the strongest prognostic factor with higher risk of 
a metachronous BCC, when patients have experienced more previous metachronous 
BCCs. When proven to be valid at external validation, the model can assist clinicians 
in identifying high-risk patients and in tailoring surveillance frequencies for individual 
patients.
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Table S1. Formula to calculate the individual absolute risks of metachronous basal cell 
carcinomas.
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To the editor
Among the millions of people who develop a first basal cell carcinoma (BCC) 
annually, ~30% will get subsequent BCCs (Flohil et al., 2013). The majority of BCCs 
occur on the head and neck, where tumor growth and surgery can lead to functional 
and cosmetic morbidity. Because of the high incidence, risk of multiple tumors, and 
morbidity, the disease burden and healthcare costs are considerable (Housman et al., 
2003; Hollestein et al., 2014). 
Several candidate gene approaches (CGAs) suggest that polymorphisms in the genes 
encoding cytochrome P450, glutathione S-transferase, and HLA are implicated in the 
development of multiple BCCs (mBCC; Cerimele et al., 1988; Rompel et al., 1995; Lear 
et al., 1996; Ramachandran et al., 2000). Most of these studies have a small sample 
size and include only a few variants per gene. To date, there are no studies investigating 
whether more recently identified BCC loci also confer susceptibility to mBCC. We 
investigated whether single-nucleotide polymorphisms (SNPs) previously associated 
with BCC increase the risk of mBCC using a CGA. In addition, we conducted a genome-
wide association study (GWAS) to identify previously unreported loci associated with 
the risk of mBCC. 
A detailed description of all the methods is presented in the Supplementary Material 
online. We used participants from the Rotterdam Study (RS), which is a population-based 
follow-up study that consists of three cohorts (RS-I, II, and III; Hofman et al., 2013). The 
Medical Ethics Committee of the Erasmus Medical Center and the review board of 
the Dutch Ministry of Health, Welfare and Sport have ratified the RS. All participants 
who gave informed consent were linked with a nationwide registry of histopathology 
in The Netherlands (PALGA, up to 31 December 2013) to identify histopathologically 
confirmed BCCs, squamous cell carcinomas (SCCs), and melanomas (Casparie et al., 
2007). 
DNA from whole blood was extracted and genotyped following standard protocols 
(Hofman et al., 2013). Quality control procedures were applied to the genotyped SNP 
data. The GWA data sets were imputed to the 1,000 Genomes data set using MACH-
minimac v1.0.18 (Howie et al., 2012). In total, 30,072,738 markers were genotyped 
and/or imputed. We excluded markers with a minor allele frequency <3% and an 
imputation quality <0.3. After quality control, 7,260,691 markers were available for 
analysis. 
From the 9,810 RS participants with genotype and phenotype information, 1,219 
individuals with BCC were identified, of whom 472 had mBCC (38.7%). Participants 
with mBCC had a significantly higher proportion of SCCs and/or melanomas compared 
with those with single BCC (sBCC; Supplementary Table S1 online). 
First, 19 candidate SNPs and 17 loci from well-powered GWASs/CGA of BCC 
were selected (Supplementary Table S2 and Supplementary Material online). We then 
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conducted SNP- and gene-based logistic regression analyses in two data sets, comparing 
BCC to no BCC (i.e., validation set) and mBCC to sBCC to investigate whether these 
BCC loci also increase the risk of mBCC. The analyses were adjusted for age at study 
entry or age at first BCC, sex, and four principal components (PCs). As these SNPs and 
loci were previously significantly associated with BCC, we only adjusted for multiple 
testing in the mBCC versus sBCC data set using the Bonferroni correction. All analyses 
were performed in PLINK v1.07 (Purcell et al., 2007). 
In the CGA on BCC against no BCC, 12/19 (63%) candidate SNPs and 5/17 (29%) 
loci were replicated, demonstrating a good external validity of the study (Table 1 and 
Supplementary Table S3A online). Interestingly, the CGA comparing sBCC to mBCC did 
not yield any significant associations between these BCC-related SNPs/loci and risk of 
mBCC (Table 1 and Supplementary Table S3B online). 
Table 1. SNP-based and gene-based association analyses
BCC vs. no BCC mBCC vs. sBCC
SNP locus
SNP-based
p-value
Gene-based
p-value
SNP-
based OR
SNP-based
p-value
Gene-based
p-value
SNP-
based OR
rs1126809 TYR 0.0027 0.14 1.16 0.99 0.16 1.0010
rs4911414 20q11.22 0.067 0.96 1.086 0.49 0.77 0.94
rs1015362 20q11.22 0.83 0.96 1.010 0.15 0.77 0.87
rs7538876 PADI6 0.00062 0.075 1.16 0.063 0.11 1.17
rs801114 1q42.13 0.0070 0.049 1.13 0.63 0.75 0.96
rs11170164 KRT5 0.17 0.0020 1.12 0.13 0.24 1.27
rs2151280 CDKN2B-AS1 0.0043 0.13 0.88 0.97 0.64 1.00
rs157935 LINC-PINT 0.00077 0.10 0.85 0.18 0.86 0.88
rs16891982 SLC45A2 0.0081 0.038 0.65 0.82 0.47 0.93
rs401681 CLPTM1L 0.00053 0.022 0.86 0.36 0.83 0.92
rs12210050 EXOC2 0.030 0.35 1.15 0.69 0.13 0.95
rs7335046 UBAC2 0.19 0.35 1.087 0.10 0.016 1.22
rs1805007 MC1R 0.069 0.60 1.16 0.43 0.25 0.88
rs78378222 TP53 0.037 0.17 1.34 0.13 0.39 1.49
rs12203592 IRF4 7.7E-05 0.063 1.31 0.35 0.30 0.89
rs12202284 EXOC2 0.12 0.35 1.096 0.88 0.13 1.017
rs8015138 14q22.1 0.79 0.088 0.99 0.91 0.72 0.99
rs214782 TGM3 1.2E-05 0.0070 1.27 0.056 0.19 1.22
rs7006527 RGS22 0.0018 0.17 0.82 0.49 0.85 1.088
Abbreviations: BCC, basal cell carcinoma; mBCC, multiple basal cell carcinomas; OR, odds 
ratio; sBCC, single basal cell carcinoma; SNP, single-nucleotide polymorphism. Numbers in bold 
display significant differences (P-value <0.05). The gene-based P-value for mBCC versus sBCC 
should be corrected for multiple testing.
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Finally, we conducted a pilot GWAS using logistic regression (additive model) to test 
for associations between markers and mBCC, adjusting for age at diagnosis, sex, and four 
PCs (Supplementary Material online). A meta-analysis of the GWAS results per cohort 
was performed. Despite the low overall power to detect genome-wide significant hits 
(Supplementary Figure S1 online), we identified genome-wide suggestive associations 
in chromosomes 2, 3, 18, and 22 (P-values <5 × 10-6, Supplementary Figure S2 online 
and Table 2). The most significant SNP was rs78857623 (P-value =1.2 × 10-7, Table 2), 
which mapped to an intron in FHIT, and it was in linkage disequilibrium (r2=0.65) with 
another significantly associated intronic FHIT SNP (rs78316259; P-value=4.6 × 10-6). 
FHIT is a tumor suppressor gene that encodes a diadenosine polyphosphate hydrolase 
involved in purine metabolism (Barnes et al., 1996). Aberrant FHIT transcripts as well 
as germline mutations in this gene have been found in different cancers including BCC 
(Ohta et al., 1996; Goldberg et al., 2006; Ding et al., 2008).
Given the high proportion of SCCs and melanomas in mBCC cases, a sensitivity 
analysis investigating the influence of other cutaneous cancers was performed 
(Supplementary Table S1 online). We observed changes in the P-values of the associations 
due to a 13% decrease in sample size, but all top SNPs remained significant with a 
P-value <5 × 10-5 (data not shown), showing that our findings were driven by BCC 
cases. 
In contrast to other BCC GWASs, we performed a GWAS on histopathologically 
confirmed mBCC. By combining national pathology data with genomewide SNP data 
from a population-based study, we accurately distinguished between sBCC and mBCC. 
It is a pilot GWAS because the sample size is small and replication data are not easily 
available. All existing cohorts, which have performed genetic epidemiology on skin 
cancer, do not have data on mBCC. Like in other GWASs, the significant associations 
are only statistical and therefore any inference about the functional impact of the 
variants to the risk of mBCC needs to be investigated with other approaches. Despite 
these limitations, our data set contains the largest collection of cases with mBCC to 
date and may serve as a valuable reference for future studies. 
Because of the high risk of subsequent BCCs in individuals with a first BCC, we 
expected that loci predisposing to sBCCs would also contribute to the risk of mBCC. 
However, the CGA analysis did not support this hypothesis, suggesting that other 
biological factors, including genes, may confer an increased risk to mBCC. The earlier 
onset of first BCCs in patients with mBCC may indeed suggest that these patients have 
a stronger genetic burden compared with those with sBCC (68.7 vs. 72.4 years; P-value 
<0.05, Supplementary Table S1 online). A heritability analysis comparing mBCC 
against sBCC in well-powered samples will help validate this hypothesis. It could also 
be argued that other yet-to-be-identified loci conferring susceptibility to BCC may also 
increase risk of mBCC, which will require larger consortia on the genetics of BCC. 
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In conclusion, genetic loci previously associated with BCC do not increase the risk 
of mBCC. A pilot GWAS on mBCC identified to our knowledge previously unreported 
susceptibility variants, but these findings need to be replicated in other mBCC cohorts.
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SuPPlEMENTARy MATERIAl
Materials and methods
Study population
The Rotterdam Study (RS) is a prospective population-based follow-up study of the 
determinants and prognosis of chronic diseases, including skin diseases and cancer, in 
the elderly. Only participants living in Rotterdam, The Netherlands, are included. The 
RS consists of a major cohort (RS-I) and two extensions (RS-II and RS-III). RS-I started 
in 1990 and initially included 7,983 participants living in the Ommoord district in 
Rotterdam. RS-II started in 2000 and now includes 3,011 participants. RS-III is a further 
extension of the cohort, started in 2006, and now includes 3,932 participants. By the end 
of 2008, the RS comprised 14,926 subjects aged 45 years or over. The overall response 
rate for all three cycles at baseline was 72.0%. The cohort consists predominantly 
(90%) of participants of North-European ancestry. A detailed description of the design 
of the RS is presented in Hofman et al. (2013). The Medical Ethics Committee of the 
Erasmus Medical Center and the review board of the Dutch Ministry of Health, Welfare 
and Sport have ratified the RS. Our study was conducted according to Declaration of 
Helsinki Principles. From each participant, written informed consent was obtained.
Ascertainment of (multiple) basal cell carcinoma cases
All the participants of the RS who gave informed consent (n = 14,628) were linked 
with the nationwide network and registry of histopathology and cytopathology in 
The Netherlands (PALGA; up to 31st December 2013) to identify histopathologically 
confirmed BCCs, squamous cell carcinomas and melanomas. PALGA was founded in 
1971 and achieved complete national coverage in 1991. Every obtained pathology 
excerpt contains encrypted patient data, a report identifier, the conclusion of the 
pathologist and a PALGA diagnosis line derived from the Systematized Nomenclature 
of Medicine (Casparie et al., 2007). The majority of excerpts extracted from PALGA 
include an anatomical location, which makes it possible to distinguish between 
participants with single or subsequent tumors. If location was not available, we assumed 
that a biopsy followed by an excision for the same type of skin cancer, concerned the 
same tumor. The next BCC following a radical excision was always counted as a new 
neoplasm. If an excision was incomplete, the next reported tumor on the same/adjacent 
location was regarded as recurrent and not a new BCC. If the diagnosis or the number 
of unique BCCs remained unclear, the medical files were searched by hand and a 
consensus decision was made based on these data.
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DNA collection, genotyping, imputation and quality control
DNA from whole blood was extracted following standard protocols (Hofman et al., 2013). 
The Illumina Infinium II HumanHap550 BeadChips were used to genotype the RS-I (n = 
6,291) and RS-II (n = 2,157) cohorts while Illumina Human610-Quad BeadChips were 
used to genotype the RS-III cohort (n = 3,048). Quality control criteria included the 
removal of SNPs with Hardy-Weinberg equilibrium deviations (p<10-6), genotyping 
call rate < 97%, gender mismatch and a high mean autosomal heterozygosity. We also 
excluded duplicates or first-degree relatives using identity-by-descent (IBD) estimates 
and outliers (three standard deviations away from the population mean) using multi-
dimensional scaling (MDS) analysis with four principal components. After excluding 
related participants, 9,810 participants remained in our dataset. 
To increase the coverage of the genome, we imputed the RS-I, RS-II and RS-III cohorts 
separately, using 1000Genomes (GIANT Phase I version 3) as the reference panel and 
using a two-step procedure imputation algorithm implemented in the program MACH-
Minimac v1.0.18 using default parameters (Howie et al., 2012). In total 30,072,738 
markers were genotyped and/or imputed. We filtered out markers with a MAF < 3% 
and an imputation quality score (r2_pihat) < 0.3. This resulted in 7,260,691 markers that 
passed quality control and were used in the meta-analysis.
Selection of SNPs and candidate loci associated with BCC
We selected English publications indexed in PubMed until December 2013 that reported 
associations between common SNP variants (MAF > 1%) and BCC or keratinocyte 
carcinoma. To reduce the burden of multiple testing for our CGA we limited our CGA 
to variants identified in high-powered GWASs and CGAs of BCC in humans. For a 
GWAS we considered SNPs with a p-value < 10-6 to choose candidate genes.
To select the candidate gene/locus of an associated SNP located within a gene/
locus, we retrieved the coordinates of the RefSeq longest transcript from the UCSC 
Genome Browser (http://www.http://genome.ucsc.edu/; GRCh37/hg19 assembly) and 
added 15Kb downstream and upstream of the locus region (Kent et al., 2002). The 30Kb 
region was selected to only include regulatory regions nearby the locus to which the 
variants have been previously annotated. For intergenic SNPs located more than 15Kb 
from a gene, we added 30Kb (15Kb downstream and 15Kb upstream) to the position 
of the candidate SNP. Further, we used the genomic coordinates of the selected loci 
and extracted all SNPs available from the RS genome-wide SNP data for the gene/locus 
association analyses. The list of SNPs and loci associated with the SNPs from the studies 
we included for our analysis, are shown in Supplementary Table S2 online.
131
Common variants for multiple basal cell carcinomas
Statistics and analyses
Candidate SNP and gene association analyses on (m)BCC
To test for associations between (m)BCC and common SNPs and candidate genes, best-
guessed genotypes of the three RS cohorts were estimated from the imputed data using 
the Genome wide Complex Trait Analysis (GCTA) software with default parameters 
(Yang et al., 2011). 
We first carried-out a SNP-based association analysis on SNPs that were previously 
associated with BCC using two case-control designs, namely: all prevalent cases of BCC 
against no BCC (BCC/controls), and all prevalent cases with mBCC against all prevalent 
cases with sBCC. We used the first design as a validation dataset and the second design 
to address the research questions. For the SNP association we carried-out a logistic 
regression analysis, adjusting the model for age at study entry/age at first BCC, sex and 
four principal components. Since the SNPs were already replicated in previous GWAS 
we only adjusted for multiple testing in the mBCC/sBCC design using the Bonferroni 
correction. These analyses were carried-out in PLINK v1.07 (Purcell et al., 2007). 
To screen for additional variants in the genomic region (15Kb up- and downstream) 
to which the candidate SNPs are mapped to, a gene-based logistic regression analysis 
using a set-based test implemented in PLINK v1.07 was performed with the following 
parameters: r2 = 0.5, p-value = 0.05, maximum number of SNPs = 15 and permutations 
= 1000. This test calculates whether the mean statistics of SNP associations within 
a gene are larger than those calculated under the null hypothesis of no association, 
taking into account the linkage disequilibrium (LD) between SNPs within a set/gene 
and adjusting for multiple testing per gene using permutations. For these analyses we 
adjusted for the same covariates as in the SNP-based associations. P-values were further 
adjusted for the number of evaluated genes in the mBCC/sBCC dataset.
Genome-wide association analysis
To discover to our knowledge previously unreported loci associated with an increased 
risk for mBCC, a pilot GWAS per RS cohort with participants with mBCC as cases and 
subjects with sBCC as controls was performed. We used logistic regression with an 
additive model to test for associations between SNPs and the phenotype, adjusting for 
age at diagnosis, sex and four principal components. The significance of the association 
was tested using the likelihood ratio test with one degree of freedom. The GWAS analyses 
were implemented in the ProbABEL package, which incorporates dose imputed data 
within a logistic regression framework (Aulchenko et al., 2010). Subsequently, because 
the standard error of the effects may not be accurate due to the small sample size, we 
used the p-values from the likelihood-ratio tests as summary statistics to meta-analyze. 
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The meta-analysis of the three RS cohorts was carried out using the METAL software, 
allowing for genomic control correction and heterogeneity (Willer et al., 2010).
Supplementary table S1. Study population characteristics
Characteristics sBCC1 mBCC2
  
Number of participants 747 472
Mean age (range) at study entry, years 66.4 (46-99) 65.8 (48-92)
Mean age (range) at first BCC diagnosis, years 72.4 (36-99) 68.7 (30-96)
Sex (%)  
     Female 429 (57.4) 233 (49.4)
     Male 318 (42.6) 239 (50.6)
Other cutaneous cancers (%)  
     SCC3 62 (8.3) 76 (16.1)
     Melanoma 6 (0.8) 13 (2.8)
     SCC & Melanoma 2 (0.3) 4 (0.8)
     All combined 70 (9.4) 93 (19.7)
1 Single basal cell carcinoma
2 Multiple basal cell carcinoma
3 Squamous cell carcinoma
Numbers in bold display significant differences (p-value < 0.05) according to the independent-
samples t-test or Chi-squared test
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Common variants for multiple basal cell carcinomas
Supplementary figure S1. Q-Q-plot of the meta-analysis of the Rotterdam Study on mBCC
The –log10 of observed p-values of the associations between mBCC and SNPs (Y-axis) are plotted 
against the expected p-values under the assumption of no association (X-axis).
Supplementary figure S2. Manhattan plot of the meta-analysis of the Rotterdam Study on mBCC
The –log10 of observed p-values of the associations between mBCC and SNPs (Y-axis) for all 
SNPs (dots) are represented per chromosome (X-axis). The horizontal lines indicate the significant 
threshold of p-value = 5×10-6 (blue) and p-value = 5x10-8 (red).
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ABSTRACT
There is strong evidence for a role of environmental risk factors involved in susceptibility 
to develop multiple keratinocyte cancers (mKCs), but whether genes are also involved 
in mKCs susceptibility has not been thoroughly investigated. We investigated whether 
single nucleotide polymorphisms (SNPs) are associated with susceptibility for mKCs. 
A genome-wide association study (GWAS) of 1,666 cases with mKCs and 1,950 cases 
with single KC (sKCs; controls) from Harvard cohorts (the Nurses’ Health Study [NHS], 
NHS II, and the Health Professionals Follow-Up Study) and the Framingham Heart 
Study was carried-out using over 8 million SNPs (stage-1). We sought to replicate the 
most significant statistical associations (p-value ≤ 5.5x10-6) in an independent cohort of 
574 mKCs and 872 sKCs from the Rotterdam Study. In the discovery stage, 40 SNPs with 
suggestive associations (p-value ≤ 5.5x10-6) were identified, with eight independent 
SNPs tagging all 40 SNPs. The most significant SNP was located at chromosome 9 
(rs7468390; p-value = 3.92x10-7). In stage-2, none of these SNPs replicated and only 
two of them were associated with mKCs in the same direction in the combined meta-
analysis. We tested the associations for 19 previously reported basal cell carcinoma-
related SNPs (candidate gene association analysis), and found that rs1805007 (MC1R 
locus) was significantly associated with risk of mKCs (p-value = 2.80x10-4). Although 
the suggestive SNPs with susceptibility for mKCs were not replicated, we found that 
previously identified BCC variants may also be associated with mKC, which the most 
significant association (rs1805007) located at the MC1R gene.
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INTRODuCTION
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin are known 
together as keratinocyte carcinomas (KC), since they both originate from keratinocytes 
of the epidermal layer of the skin, and share similar risk factors, treatments and 
prognosis [1]. KC is the most common cancer in adults of northern-European descent 
and is becoming a major health burden due to the high prevalence and increasing 
incidence in Western countries [2, 3]. A systematic review showed that patients with 
a primary BCC or SCC are likely to develop subsequent KCs with proportions as high 
as 44% in USA and 32% in The Netherlands [4]. However, it was recently shown that 
patients with only single KCs have a lower risk for subsequent KCs when compared 
with patients with a history of two or more KCs suggesting a differential risk profile of 
patients with single KCs than patients with a history of prior multiple KCs [3]. 
Environmental, tumour, and individual risk factors, including ultraviolet radiation 
(UVR), pale hair and skin, and male gender have been associated with an increased 
risk for multiple KCs (mKCs) [5-7]. There is also suggestive evidence for a genetic 
predisposition to mKCs, since genetic mutations in PTCH1 [1, 8] and PTCH2 [9] cause 
multiple BCCs [10] in individuals with nevoid BCC syndrome (NBCCS), a Mendelian 
disease. In addition, over 19 loci have been associated with sporadic BCC [11-13] and 
two with SCC. However, these previous studies included all prevalent non-melanoma 
skin cases and therefore it is not clear whether mKCs patients share the same genetic 
susceptibility variants as these with single KC. 
In a recent study we found that common variants associated with BCC did not 
predict susceptibility for mBCC [14]. Other studies assessing genetic susceptibility in 
patients with mKCs are scarce. Here, we carried out a meta-analysis of GWAS on 
mKCs to investigate genetic susceptibility for mKCs comparing 1,241 mKCs to 2,822 
single KCs (sKCs). We used patients with single KC as controls to increase the chance of 
identifying variants associated with susceptibility for having multiple KCs.
MATERIAlS AND METhODS
Study population
The nurses’ health study (NHS), NHS II and the health professionals follow-up study 
(HPFS)-harvard cohorts.
Study participants were included from three ongoing longitudinal cohorts: NHS, NHS II 
and HPFS. The NHS was established in 1976 when 121,701 married, female registered 
nurses aged 30-55 in the US were enrolled using a mailed questionnaire inquiring about 
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their medical history and lifestyle practices. Between 1989 and 1990, blood samples 
were collected from 32,826 cohort members. NHS II began in 1989 when 116,430 
female nurses aged 25-42 completed a mailed questionnaire. Between 1996 and 1998, 
blood samples were collected from 29,616 cohort members. The HPFS consisted of 
51,529 male health professionals who completed their baseline questionnaire in 1986. 
Between 1993 and 1994, blood samples were collected from 18,159 cohort members. 
Information on lifestyle factors and medical history was collected biennially by mailed 
questionnaire. The follow-up rate exceeds 90% in each cohort. The study protocol was 
approved by the Institutional Review Board of Brigham and Women’s Hospital and the 
Harvard School of Public Health.
We combined data from several case-control studies nested within the cohorts 
for type 2 diabetes (NHS and HPFS), coronary heart disease (NHS and HPFS), breast 
cancer (NHS and NHS II), colon cancer (NHS and HPFS), kidney stone (NHS, NHS II 
and HPFS), advanced prostate cancer (HPFS), endometrial cancer (NHS), gout (NHS 
and HPFS), glaucoma (NHS and HPFS), mammographic density (NHS), and pancreatic 
cancer (NHS and HPFS). The description of the studies is presented elsewhere [13].
mKCs case ascertainment
Participants reported diagnoses of cancers biennially. Medical records were reviewed 
to confirm the diagnoses. Medical records were not obtained for self-reported cases of 
BCC, but previous studies showed high validity of BCC self-reports [15, 16]. Information 
on the cumulative number of KCs was collected in 2004 (NHS), 2005 (NHS II) and 2008 
(HPFS); details are presented elsewhere [5, 7]. A validation study among 200 cases who 
reported 5-10 and ≥11 KC showed a confirmation rate of 92% [7]. All the participants 
included in the analysis were Caucasians who reported at least one pathologically 
confirmed diagnosis of SCC or self-reported BCC in the cohort follow-up. For this study, 
cases were defined as individuals with more than one KC (mKCs) and controls were 
defined as those with single KC (sKCs).
The framingham heart study
The Framingham Heart Study (FHS) is a community-based prospective study that began 
in 1948 to characterize cardiovascular disease and its risk factors. The Original Cohort 
was composed of 5,209 Framingham residents primarily of white European-ancestry. 
In 1971, 5,124 offspring of the Original Cohort and their spouses were recruited into 
the Offspring Cohort. In 2002, 4095 children of the offspring cohort were invited to 
the Third Generation Cohort. The study design and participant descriptions of the three 
cohorts have been published elsewhere [17-19].
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mKCs case ascertainment
Participants have undergone routine research examinations every two to six years. Cancer 
cases were identified at the research examinations or by medical history updates for 
participants who did not attend an examination. Two independent reviewers examined 
the medical records of all cancer cases and used the World Health Organization ICD-O 
coding and in 2010 ICD-10 coding to classify all primary tumours. All skin cancer 
cases were verified with pathology reports. FHS participants with GWAS genotype 
information and with pathologically confirmed skin cancer (until December 31 2013, 
melanoma excluded) were included in the current study. Participants with more than 
one KC were defined as cases and these with single KCs were defined as controls.
The rotterdam study (RS)
The RS is a prospective population-based follow-up study of the determinants and 
prognosis of chronic diseases, including skin cancer, in the elderly [20]. The RS 
consists of a major cohort (RS-I) and two extensions (RS-II and RS-III). RS-I started 
in 1990 and included 7,983 participants living in the Ommoord district (Rotterdam, 
the Netherlands). RS-II began in 2000 and now includes 3,011 participants. RS-III 
was started in 2006 and now includes 3,932 participants. By the end of 2008, the RS 
comprised 14,926 subjects aged 45 years or over. The RS consists predominantly (90%) 
of participants of North-European ancestry. A detailed description of the design of the 
RS is presented elsewhere [20].The Medical Ethics Committee of the Erasmus Medical 
Center and the review board of the Dutch Ministry of Health, Welfare and Sports have 
ratified the RS. Written informed consent was obtained from each participant.
mKCs case ascertainment
To identify histopathologically confirmed BCCs, SCCs and melanomas, RS participants 
were linked with the nationwide registry of histo- and cytopathology in the Netherlands 
(PALGA; up to 31st December 2013) [21]. The case definition for KC has been described 
previously [14]. In the majority of reports extracted from PALGA it was possible to 
distinguish between participants with single or subsequent tumours. If the diagnosis or 
the number of unique KC remained unclear, the medical files were searched by hand 
and a consensus decision was made. The number of KC was recorded separately for 
BCC and SCC. Individuals with either a single BCC or SCC were considered as controls 
while multiple BCC and/or SCC were taken as mKCs cases.
Genotyping and imputation
Details of DNA collection, genotyping and quality control for the Harvard cohorts [13, 
22], the FHS [23] and the RS [20] cohorts has been detailed elsewhere. A summary of 
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the genotyping quality control for the all cohorts is presented in the supplementary file 
S1 Appendix. 
Harvard GWAS
Genotyping was performed on three platforms: Affymetrix (n = 1230: 539 controls, 
691 cases), Illumina HumanHap (n = 845: 363 controls, 482 cases), and Illumina 
Omni Express (n = 645: 287 controls, 358 cases). The genotypes per platform were 
merged from the different cohorts (NHS, NH II and HPFS) [13] and thus, had men and 
women. Based on combined GWAS genotypes on each genotyping platform and the 
1000 Genomes Project ALL Phase I Integrated Release Version 3 Haplotypes (2010-11 
data freeze, 2012-03-14 haplotypes) as reference panel, we imputed the genotypes of 
markers in the 1000 Genomes Project using MACHv.1.0.18.c [24]. Only SNPs with 
imputation Rsq > 0.95 and minor allele frequency (MAF) >1% were included in meta-
analysis.
FHS GWAS
Genotyping was conducted using the Affymetrix 500K mapping array and the 
Affymetrix 50K gene-focused molecular imprinted polymer array. We imputed using 
1000Genomes Phase I Version 3 as the reference panel using MACH-Minimac [24]. 
SNPs with MAF ≤1% and imputation quality value <0.3 were excluded.
RS GWAS
Details of genotyping approach is presented elsewhere [20]. Briefly, cohorts RS-I and 
RS-II were genotyped with the Infinium II HumanHap550K Genotyping BeadChip 
version 3 (Illumina, San Diego, California USA) and the cohort RS-II was genotyped 
using the Illumina Human 610 Quad Arrays. We imputed the RS-I, RS-II and RS-III 
cohorts separately, using 1000Genomes (GIANT Phase I version 3) as the reference 
panel and using MACH-Minimac with default parameters [24]. Next, markers with a 
MAF ≤1% and an imputation quality score (Rsq) <0.3 were removed.
Statistical analysis
Stage-1; discovery phase
The discovery samples (stage-1) consisted of the Harvard cohorts (NHS, NHS II, and 
HPFS) and the FHS cohort. The association analyses between the SNPs and mKCs were 
performed using an additive logistic regression model on subjects with more than 
one KC as cases and subjects with only one KC as controls. As the Harvard cohorts 
were genotyped on three different platforms [13], GWAS analyses were conducted for 
each platform, adjusting for age at first diagnosis of SCC/BCC, sex and four principal 
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components of genetic variance (PCAs) using ProbABEL [25]. The association for each 
SNP from three platforms for the Harvard cohorts was combined in an inverse-variance-
weighted meta-analysis using METAL [26]. 
The FHS GWAS was carried out using an additive generalized estimation equation 
(GEE) model [27] that takes into account the pedigree structure of the FHS study. The 
model was adjusted for age at first diagnosis, sex and four PCAs. These analysis were 
performed using the R package [27]. 
The quality control of the GWAS summary statistics from Harvard cohorts and the 
FHS GWAS summary statistics was performed using the EasyQC software [28]. After 
quality control there were 9,001,799 markers from Harvard cohorts and 8,246,930 
markers from FHS. The cleaned files of both datasets (Harvard cohorts and FHS) were 
meta-analysed using the inverse variance approach implemented in METAL[26]. SNP 
heterogeneity was tested using I2 and Cochran’s Q, both of which are implemented in 
METAL. The inflation factor lambda (genomic control) was close to 1.0 (ć = 1.08) and 
therefore no further adjustments for genomic control were done The SNPs that showed 
significant associations with mKCs (p-value ≤5.5x10-6) were selected for stage-2 phase.
Stage-2 phase; replication and joint meta-analysis
The stage-2 analysis of the top SNPs identified in the discovery phase was carried out 
in the RS cohort. A logistic regression with an additive model to test for associations 
between SNPs and mKCs was implemented adjusting for age at diagnosis, sex and four 
PCs. The significance of the association was tested using the likelihood ratio test (LRT) 
with one degree of freedom. To correct for multiple testing, we calculated the pair-wise 
linkage disequilibrium (LD; r2) between the top SNPs using SNAP [29] and the p-values 
were adjusted by dividing the nominal p-value by the number of independent tests 
(SNPs were considered independent with r2 ≤0.6). 
We also carried out a GWAS on the RS cohort as described previously [14] and 
used thep-values from the LRT [25] of the three cohorts for a meta-analysis. The quality 
control of the GWAS summary statistics per cohort was done with EasyQC [28]. After 
QC there were 7,898,815 markers. The cleaned files of the RS were then meta-analyzed 
with the FHS and Harvard cohorts using the weighted Z-score method, implemented 
in METAL [26]. SNP heterogeneity was tested using I2 and Cochran’s Q methods. The 
top SNPs were annotated to genes using Ensembl (http://browser.1000genomes.org/
index.html).
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RESulTS
The age and sex distribution of cases (mKCs) and controls (sKCs) for the stage-1 
(discovery) and stage-2 cohorts are presented in Table 1. The discovery cohorts consisted 
of 1,666 subjects with mKCs and 1,950 subjects with sKCs. The ascertainment of KC 
was done primarily using self-reports in the Harvard cohorts. There were differences in 
the proportion of males in the cohorts, since the NHS and NHS II are women’s cohorts 
and HPFS is men’s cohort. We also observed that cases were older than controls. 
In the discovery stage, suggestive genome-wide associations (p-value ≤5.5x10-6) 
were identified for 40 SNPs (Figure 1 and S1 Table). Due to the strong LD (r2 >0.6) 
among these 40 SNPs (eight SNPs tagged 32 of the top SNPs), only eight of them were 
considered independent signals (S1 Table). The most significant hit was an intergenic 
SNP on the short arm of chromosome 9 (rs7468390, p-value = 3.92x10-7), with an 
OR (95% CI) of 0.73 (0.64-0.82) for the C allele (Table 2). This is a common SNP in 
strong LD with 13 other SNPs with suggestive associations (S1 Table and S1 Figure). 
The region of LD of rs7468390 spans approximately 13 kb. Of the 40 SNPs with 
Table 1. Demographic characteristics of the population-based cohorts
Cohorts
kC
ascertainment
Cases 
(mkC)
Controls 
(skC)
Sex
(%male 
cases)
Sex
(%male 
controls)
Median 
agea cases 
(IQR)
Median 
agea 
controls
(IQR)
Stage 1
Harvardb Self-report 1,531 1,189 38.3 28.5 66 (59-73)  64 (58-71)
NHS Self-report 920 817 0 0 64 (57-70) 66 (59-72)
NHS II Self-report 23 33 0 0 45 (40-52) 50 (46-54)
HPFS Self-report 588 339 100 100 67 (60-73) 69 (62-73)
FHS Pathology records 135 761 60 50 66 (58-78)  66 (54-77)
Stage 2
RS combined Pathology records 574 872 40 50 73 (66-81) 69 (72-77)
RS1 Pathology records 345 542 43 52 78 (72-84) 74 (68-90)
RS2 Pathology records 142 178 53 52 68 (62-72) 70 (66- 76)
RS3 Pathology records 88 152 39 36 57 (51-64) 60 (53-65)
KC: keratinocyte carcinoma; mKC: multiple KC; sKC: single KC; IQR: inter-quantile range; NHS: 
Nurses' Health Study; HPFS: Health Professionals Follow-up Study; RS: Rotterdam Study
a Median age at first diagnosis
b Combined; dataset from the combined NHS, NHS II and HPFS cohorts. GWAS analysis for 
the Harvard cohorts were performed per GWAS platforms (see Materials and Methods) not per 
cohort.
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suggestive associations, 29 were intergenic, three mapped to non-coding RNA, four 
within regulatory regions and four to the NCKAP5 gene (S1 Table). 
For the stage-2, we tested for associations between the 40 top SNPs from the 
stage-1 and mKC in an independent sample of 574 mKCs and 872 sKCs from the 
RS using an adjusted p-value of 0.006 (corresponding to a p-value of 0.05 divided 
by eight independent SNPs/tests). None of the SNPs replicated at this threshold (S2 
Table). A combined analysis of both the stage-1 and stage-2 datasets showed suggestive 
associations for the 40 signifi cant SNPs, but none reached genome-wide signifi cance, 
and there was signifi cant heterogeneity in the estimates, most likely due to the different 
direction of the effects in the RS [30] (Table 2 and S2 Table). 
Other than the above-described 40 SNPs, we found suggestive statistical signals in 
the combined meta-analysis (p-values ≤5.5x10-6, S3 Table) for other SNPs. The most 
signifi cant SNP was rs4761496 that mapped to an intergenic region of chromosome 
12 (p-value = 4.5x10-7). Other SNPs with suggestive associations mapped to protein 
coding genes including CSMD1 (rs11777268, rs116045237, rs17393453) and PRF1 
(rs35401316), both of which have an indirect involvement with SCC [31, 32]. 
Since up to 80% of KCs are BCCs, we also looked at whether SNPs previously 
associated with susceptibility for BCC conferred susceptibility to mKCs. Six of the 
figure 1. Manhattan plot of the GWAS associations for mKCs in the discovery sample (FHS and 
Harvard cohorts)
The observed -log10 p-values (Y-axis) of the association between the SNPs and susceptibility for 
mKC are shown. All SNP are represented by dots and displayed per chromosome (X-axis).
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19 SNPs tested were significantly associated with susceptibility for mKCs (Table 3). 
However, only rs1805007, which that mapped to MC1R was significant (p-value = 
2.8x10-4) after Bonferroni correction (adjusted p-value ≤0.0026, 0.05/19). This gene is a 
well-known susceptibility locus for melanoma and KC. Other candidate loci identified 
in a recent GWAS for mBCC [14] were investigated but none were significantly 
associated with mKCs after Bonferroni correction (data not shown).
Table 3. Association analysis of BCC-loci and mKC susceptibility from the combined analyses 
(Harvard cohorts, FHS and RS)
SNP id Gene Allelesa freqb Z-scorec P-value Directiond I2e ChiSqf
rs1126809 TYR A/G 0.270 2.523 0.012 +++ 0 1.97 (0.37)
rs4911414 20q11.22 T/G 0.345 0.892 0.373 +-+ 0 1.65 (0.44)
rs1015362 20q11.22 T/C 0.276 -0.652 0.514 +-- 52.9 4.25 (0.12)
rs7538876 PADI6 A/G 0.382 -0.049 0.961 -++ 57.2 4.67 (0.10)
rs801114 1q42.13 T/G 0.65 0.109 0.913 ++- 0 1.55 (0.46)
rs11170164 KRT5 T/C 0.081 0.639 0.523 -++ 0 1.40 (0.50)
rs2151280 CDKN2B-AS1 A/G 0.470 -1.94 0.052 --- 0 1.02 (0.60)
rs157935 LINC-PINT T/G 0.704 0.991 0.322 +++ 0 0.10 (0.95)
rs16891982 SLC45A2 C/G 0.051 -1.427 0.154 --- 0 0.79 (0.67)
rs401681 CLPTM1L T/C 0.427 -2.748 6.00x10-3 --- 53.6 4.31 (0.12)
rs12210050 EXOC2 T/C 0.167 2.04 0.041 +++ 0 1.20 (0.55)
rs7335046 UBAC2 C/G 0.871 1.569 0.117 +++ 0 0.45 (0.80)
rs1805007 MC1R T/C 0.083 3.633 2.80x10-4 +++ 0 1.63 (0.44)
rs78378222 TP53 T/G 0.985 -1.689 0.091 -?? 0 0.00 (1.00)
rs12203592 IRF4 T/C 0.171 2.37 0.018 +?+ 0 0.19 (0.67)
rs12202284 EXOC2 A/C 0.214 2.224 0.026 +?+ 0 0.00 (0.97)
rs8015138 GNG2 A/C 0.486 -1.3 0.194 -++ 69.7 6.61 (0.04)
rs214782 TGM3 A/G 0.815 -1.953 0.051 --- 0 0.81 (0.67)
rs7006527 RGS22 A/C 0.851 0.735 0.462 +++ 0 0.08 (0.96)
BCC: basal cell carcinoma; mKC: multiple keratinocyte carcinoma; FHS: Framingham Heart 
Study; RS: Rotterdam Study; SNP: single nucleotide polymorphism; Freq: frequency; ChiSq: chi-
squared
a Alleles for the SNP (left reference, right other)
b Frequency of the first allele selected by the METAL software as the reference allele
c Z-scores from the meta-analysis
d Direction of the effect of the first allele, with +/- indicating a higher/lower disease risk for 
Harvard, FHS and RS cohorts, respectively
e I2 statistic of the amount of heterogeneity
f Cochran’s Q-test statistics for heterogeneity with degrees of freedom equal to number of studies 
-1
Significant p-value after Bonferroni correction (adjusted p-value≤ 0.0026) is highlighted in bold
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DISCuSSION
In this two-stage GWAS of mKCs, we did not identify genome-wide significant 
associations between SNPs and mKCs. Several SNPs with suggestive associations 
mapped to genes involved in cancer pathology, but the findings need to be confirmed 
in larger samples. A candidate SNP-based analysis of previous BCC/SCC variants 
showed significant associations between mKCs and only one SNP (rs1805007) at 
MC1R, known to be associated with BCC, SCC and melanoma was significant. This 
suggests that genetic susceptibility for mKCs may partly overlap with that for BCC, 
which is expected given that up to 80% of KC are BCCs. 
The lack of replication of the suggestive associations in might be due to several 
factors. First, phenotypic heterogeneity due to a differential ascertainment of KCs 
(pathology-confirmed versus self-reports) in the cohorts could have led to some 
phenotypic heterogeneity, although common variants for KCs have been replicated 
in the NHS, NHS II and HPFS cohorts [13] as well as in RS [14]. In addition, the ratio 
BCC/SCC may be different for the American and the European populations. In the RS, 
BCCs accounted for 82% of all mKCs. For the USA cohorts, BCC/SCC ratios were not 
available, but a higher proportion of SCCs after prior KCs in the USA were shown 
previously [4]. In addition, this study was underpowered to detect variants with small 
to moderate effects (S2 Figure). Indeed, in the joint meta-analysis it was shown that the 
eight variants with the most significant associations in the discovery samples had the 
opposite direction in the RS, which led to significant heterogeneity (Table 2). This may 
have caused a drop in the significance of the associations in the meta-analysis [30]. 
Interestingly, we found other SNPs hits in the joint analysis that had the same direction 
in the three cohorts, although the sample size was not large enough to reach genome-
wide significance (lowest p-value was 4.5x10-7). Most likely, the lack of replication 
is a combination of both phenotype heterogeneity and low power to detect variants 
with moderate to low effects in the RS. Last but not least, one may argue that due to 
differences in the imputation quality thresholds between the Harvard cohorts and the 
RS and FHS, we may have missed GWAS hits. However, we did not expect a dramatic 
drop in power due to this reason because the Harvard cohorts, where a very stringent 
threshold was used to include SNPs for final meta-analysis (Rsq ≥0.95) provided most 
of the markers (9,001,799 SNPS). 
In the candidate SNP analysis nested within the GWAS, we found thatMC1R, a gene 
previously associated with BCC was also associated with an increased risk for mKCs. 
This contrasts with a recent study from the RS where no association between known 
BCC-SNPs and susceptibility for mBCC was found [14]. Since the BCC cases were 
included in the replication dataset of this study, this shows that the previous findings 
were most likely due to a lack of power of the RS. Although only one of the 19 BCC-
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related SNPs was significant after Bonferoni correction, we found nominal associations 
for six of the previously identified BCC SNPs, suggesting that larger sample sizes will 
be necessary to validate these associations. 
As shown previously [33], most variants identified through GWAS are expected 
to have low to moderate risks effects and therefore large consortia of participants 
with phenotype and GWA-SNP data are needed. While this is feasible for traits such 
weight or blood pressure for disease-related phenotypes this can be challenging. As 
mentioned above, all previous GWAS studies of BCC or non-melanoma skin cancer 
published so far did not separate cases with mKCs from those with sKC, and thus our 
series of mKCs cases could be considered as a rare phenotype. With our findings one 
may argue that there are no common variants with strong effects contributing to the 
genetic susceptibility for mKCs, although we only tested eight million common SNPs 
(frequencies higher than 2%). Whether the differential risk between patients with mKC 
and sKCs is due to genes or mostly due to environmental factors, or an interaction of 
genes and environmental factors remains to be elucidated. We did not test for SNP 
and environmental interactions that may be relevant in explaining susceptibility to 
mKCs, because we did not have all environmental risk factors assessed in all cohorts 
and the sample size was already small to detect SNP main effects. Heritability studies 
could help to determine to what extent genetic risk factors explain susceptibility for 
mKC. We found an heritability of 8% using GWAS data from the RS(data not shown), 
but the power was low to have a significant estimate. Determining the heritability for 
mKC as well as to identify individual susceptibility loci will require larger consortia of 
well characterized cases and controls. In addition, rare variants were not evaluated. 
Although such variants may not be clinically relevant to predict disease risk, they may 
reveal new pathways predisposing to mKCs and new targets for drug discovery, as in 
the example of vismodegib, a drug used to treat patients with NBCCS and sporadic, 
metastatic BCC [34].
Conclusion
We found suggestive associations of common variants that were not replicated. To 
identify new loci and to confirm the suggestive associations found in this study, larger 
mKCs cohorts will be required.
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SuPPlEMENTARy MATERIAl
Materials and Methods
Quality control of the NHSI-II-HPFS GWAS
SNPs with deviations from Hardy-Weinberg equilibrium (HWE, p<10-07), call rates 
<95%, or MAF <1% were excluded. Samples with genotype call rates ≤95%, gender 
mismatch, non-European ancestry or outliers from the population sample were 
removed.
Quality control of the FHS GWAS
Quality control was performed by excluding samples with high heterozygosity 
(mean±3×s.d.), gender mismatch or sample call rates of <95%. SNPs with the following 
criteria were included for the GWAS: Hardy-Weinberg equilibrium test with a p-value 
>10-06, MAF ≥1% and SNP call rate of ≥98%. 
Quality control of RS GWAS
The quality control included the removal of SNPs with Hardy-Weinberg equilibrium 
deviations (p<5x10-06), genotyping call rate <97%, gender mismatch and a high 
heterozygosity. Duplicates or first-degree relatives using identity-by-descent (IBD) 
estimates and outliers (three standard deviations away from the population mean) using 
multi-dimensional scaling (MDS) analysis with four principal components (PCs) were 
excluded.
157
Genome-wide association studies of multiple keratinocyte cancers
Su
pp
le
m
en
ta
ry
 t
ab
le
 1
. S
um
m
ar
y 
st
at
is
tic
s 
of
 th
e 
m
os
t s
ig
ni
fic
an
t s
ta
tis
tic
al
 a
ss
oc
ia
tio
ns
 b
et
w
ee
n 
SN
Ps
 a
nd
 m
K
C
s 
in
 th
e 
di
sc
ov
er
y 
sa
m
pl
e
G
en
om
ic
 r
eg
io
ns
a
M
ar
ke
rN
am
e
R
S_
ID
A
lle
le
s
fr
eq
b
Ef
fe
ct
St
dE
rr
O
dd
s 
ra
ti
o 
(C
I)
c
P-
va
lu
e
D
ir
d
I2
e
Q
 S
ta
ti
st
ic
f
A
ss
oc
ia
te
d 
ge
ne
s
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
63
94
5
rs
11
68
91
42
a/
g
0.
85
-0
.3
27
2
0.
07
15
0.
72
 (0
.6
3-
0.
83
)
4.
68
E-
06
--
0
0.
13
 (0
.7
2)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
64
36
6
rs
11
69
05
87
t/c
0.
85
-0
.3
26
9
0.
07
15
0.
72
 (0
.6
3-
0.
83
)
4.
77
E-
06
--
0
0.
13
 (0
.7
2)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
64
69
3
rs
13
40
77
70
t/c
0.
15
0.
32
66
0.
07
15
1.
39
 (1
.2
0-
1.
59
)
4.
86
E-
06
+
+
0
0.
13
 (0
.7
2)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
65
12
2
rs
74
85
97
t/c
0.
85
-0
.3
26
1
0.
07
14
0.
72
 (0
.6
3-
0.
83
)
4.
90
E-
06
--
0
0.
13
 (0
.7
2)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
65
14
4
rs
74
85
98
t/c
0.
15
0.
32
6
0.
07
14
1.
39
 (1
.2
0-
1.
59
)
4.
92
E-
06
+
+
0
0.
13
 (0
.7
2)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
66
79
7
rs
10
17
07
38
a/
g
0.
16
0.
32
65
0.
07
16
1.
39
 (1
.2
0-
1.
59
)
5.
19
E-
06
+
+
0
0.
12
 (0
.7
3)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
68
84
5
rs
72
85
10
82
a/
g
0.
15
0.
33
92
0.
07
19
1.
40
 (1
.2
2-
1.
62
)
2.
35
E-
06
+
+
0
0.
22
 (0
.6
4)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
68
87
5
rs
78
28
24
80
a/
g
0.
85
-0
.3
39
3
0.
07
19
0.
71
 (0
.6
2-
0.
82
)
2.
33
E-
06
--
0
0.
22
 (0
.6
4)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
69
49
5:
ID
2:
12
97
69
49
5:
ID
d/
i
0.
85
-0
.3
36
8
0.
07
21
0.
71
 (0
.6
2-
0.
82
)
3.
03
E-
06
--
0
0.
25
 (0
.6
2)
in
te
rg
en
ic
_v
ar
ia
nt
2:
12
97
63
94
5-
12
97
70
25
3
2:
12
97
70
25
3
rs
58
84
80
26
t/
c
0.
85
-0
.3
39
0.
07
19
0.
71
 (
0.
62
-0
.8
2)
2.
43
E-
06
--
0
0.
23
 (
0.
63
)
in
te
rg
en
ic
_v
ar
ia
nt
2:
13
39
63
82
7-
13
39
72
36
2
2:
13
39
63
82
7
rs
11
69
58
54
a/
g
0.
50
-0
.2
39
4
0.
05
25
0.
79
 (0
.7
1-
0.
87
)
5.
03
E-
06
--
34
.4
1.
53
 (0
.2
2)
N
C
K
A
P5
 (i
nt
ro
n)
2:
13
39
63
82
7-
13
39
72
36
2
2:
13
39
72
36
2
rs
95
65
60
t/c
0.
50
0.
23
81
0.
05
23
1.
27
 (1
.1
5-
1.
41
)
5.
40
E-
06
+
+
38
.2
1.
62
 (0
.2
0)
N
C
K
A
P5
 (i
nt
ro
n)
2:
13
39
63
82
7-
13
39
72
36
2
2:
13
39
73
00
7
rs
67
06
03
7
a/
t
0.
50
0.
23
68
0.
05
21
1.
27
 (1
.1
4-
1.
40
)
5.
48
E-
06
+
+
40
.1
1.
67
 (0
.2
0)
N
C
K
A
P5
 (i
nt
ro
n)
2:
13
39
63
82
7-
13
39
72
36
2
2:
13
39
73
77
3
rs
10
16
73
36
t/
c
0.
51
0.
24
15
0.
05
22
1.
27
 (
1.
15
-1
.4
1)
3.
70
E-
06
+
+
52
.8
2.
12
 (
0.
15
)
N
C
K
A
P5
 (
in
tr
on
)
3:
35
19
07
94
-3
51
90
79
4
3:
35
19
07
94
rs
68
03
72
1
t/
c
0.
34
-0
.2
60
2
0.
05
57
0.
77
 (
0.
69
-0
.8
6)
3.
03
E-
06
--
0
0.
56
 (
0.
46
)
in
te
rg
en
ic
_v
ar
ia
nt
3:
35
19
07
94
-3
51
90
79
4
3:
35
19
28
91
rs
76
19
90
9
a/
g
0.
34
-0
.2
55
4
0.
05
61
0.
77
 (0
.6
9-
0.
86
)
5.
35
E-
06
--
0
0.
59
 (0
.4
4)
in
te
rg
en
ic
_v
ar
ia
nt
3:
35
19
07
94
-3
51
90
79
4
3:
35
19
50
59
rs
67
86
72
9
t/c
0.
66
0.
25
85
0.
05
59
1.
29
 (1
.1
6-
1.
44
)
3.
81
E-
06
+
+
0
0.
54
 (0
.4
6)
in
te
rg
en
ic
_v
ar
ia
nt
3:
35
19
07
94
-3
51
90
79
4
3:
35
19
72
12
rs
68
08
77
0
t/c
0.
34
-0
.2
57
2
0.
05
6
0.
77
 (0
.6
9-
0.
86
)
4.
32
E-
06
--
0
0.
79
 (0
.3
8)
in
te
rg
en
ic
_v
ar
ia
nt
3:
35
19
07
94
-3
51
90
79
4
3:
35
20
06
32
rs
46
78
50
1
a/
g
0.
33
-0
.2
60
1
0.
05
63
0.
77
 (0
.6
9-
0.
86
)
3.
92
E-
06
--
0
0.
51
 (0
.4
8)
in
te
rg
en
ic
_v
ar
ia
nt
3:
17
12
55
28
8
3:
17
12
55
28
8:
ID
3:
17
12
55
28
8:
ID
d/
i
0.
98
1.
13
08
0.
23
22
3.
10
 (
1.
97
-4
.8
8)
1.
11
E-
06
+
+
0
0.
06
 (
0.
81
)
in
te
rg
en
ic
_v
ar
ia
nt
7:
19
98
87
31
7:
19
98
87
31
rs
77
99
65
1
a/
g
0.
45
-0
.3
14
6
0.
06
85
0.
73
 (
0.
64
-0
.8
3)
4.
37
E-
06
--
60
.5
2.
53
 (
0.
11
)
LO
C
10
19
27
66
8 
 (
in
tr
on
) 
9:
13
51
79
15
-1
35
30
71
1
9:
13
51
79
65
rs
74
68
39
0
c/
g
0.
64
-0
.3
18
4
0.
06
28
0.
73
 (
0.
64
-0
.8
2)
3.
92
E-
07
--
0
0.
61
 (
0.
44
)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
51
82
09
rs
12
00
09
70
t/c
0.
69
-0
.3
26
7
0.
06
86
0.
72
 (0
.6
3-
0.
83
)
1.
95
E-
06
--
0
0.
77
 (0
.3
8)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
00
83
rs
15
43
71
2
a/
g
0.
40
0.
27
74
0.
05
87
1.
32
 (1
.1
8-
1.
48
)
2.
32
E-
06
+
+
0
0.
93
 (0
.3
3)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
01
90
rs
15
43
71
3
a/
g
0.
40
0.
27
8
0.
05
86
1.
32
 (1
.1
8-
1.
48
)
2.
14
E-
06
+
+
0
0.
92
 (0
.3
4)
in
te
rg
en
ic
_v
ar
ia
nt
Chapter 9
158
Su
pp
le
m
en
ta
ry
 t
ab
le
 1
. S
um
m
ar
y 
st
at
is
tic
s 
of
 th
e 
m
os
t s
ig
ni
fic
an
t s
ta
tis
tic
al
 a
ss
oc
ia
tio
ns
 b
et
w
ee
n 
SN
Ps
 a
nd
 m
K
C
s 
in
 th
e 
di
sc
ov
er
y 
sa
m
pl
e 
(c
on
tin
ue
d)
G
en
om
ic
 r
eg
io
ns
a
M
ar
ke
rN
am
e
R
S_
ID
A
lle
le
s
fr
eq
b
Ef
fe
ct
St
dE
rr
O
dd
s 
ra
ti
o 
(C
I)
c
P-
va
lu
e
D
ir
d
I2
e
Q
 S
ta
ti
st
ic
f
A
ss
oc
ia
te
d 
ge
ne
s
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
02
24
rs
15
43
71
4
a/
g
0.
25
0.
33
24
0.
07
11
1.
39
 (1
.2
1-
1.
60
)
2.
98
E-
06
+
+
0
0.
24
 (0
.6
2)
EN
SR
00
00
14
69
25
4*
*
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
05
69
rs
10
96
11
02
c/
g
0.
41
0.
27
66
0.
05
8
1.
32
 (1
.1
8-
1.
48
)
1.
86
E-
06
+
+
0
0.
68
 (0
.4
1)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
05
98
rs
10
96
11
03
t/c
0.
41
0.
27
57
0.
05
79
1.
32
 (1
.1
8-
1.
48
)
1.
95
E-
06
+
+
0
0.
67
 (0
.4
1)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
28
09
rs
47
41
30
8
a/
c
0.
58
-0
.2
83
9
0.
05
87
0.
75
 (0
.6
7-
0.
84
)
1.
31
E-
06
--
0
0.
37
 (0
.5
4)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
39
61
rs
78
64
56
9
a/
t
0.
58
-0
.2
86
7
0.
05
9
0.
75
 (0
.6
7-
0.
84
)
1.
20
E-
06
--
0
0.
51
 (0
.4
7)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
88
55
rs
23
82
39
8
a/
g
0.
58
-0
.2
82
6
0.
05
74
0.
75
 (0
.6
7-
0.
84
)
8.
42
E-
07
--
0
0.
42
 (0
.5
2)
EN
SR
00
00
13
00
19
6
9:
13
51
79
15
-1
35
30
71
1
9:
13
52
89
05
rs
13
33
98
8
a/
g
0.
58
-0
.2
82
6
0.
05
74
0.
75
 (0
.6
7-
0.
84
)
8.
42
E-
07
--
0
0.
41
 (0
.5
2)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
53
01
05
rs
78
70
72
6
t/c
0.
41
0.
26
87
0.
05
53
1.
31
 (1
.1
7-
1.
46
)
1.
17
E-
06
+
+
0
0.
46
 (0
.5
0)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
53
02
95
rs
93
30
35
t/g
0.
56
-0
.2
78
9
0.
05
69
0.
76
 (0
.6
8-
0.
85
)
9.
66
E-
07
--
0
0.
42
 (0
.5
2)
in
te
rg
en
ic
_v
ar
ia
nt
9:
13
51
79
15
-1
35
30
71
1
9:
13
53
07
11
rs
93
30
34
a/
g
0.
41
0.
27
01
0.
05
52
1.
31
 (1
.1
8-
1.
46
)
9.
97
E-
07
+
+
0
0.
45
 (0
.5
0)
in
te
rg
en
ic
_v
ar
ia
nt
10
:2
82
96
55
8-
28
30
04
09
10
:2
82
96
55
8
rs
70
76
78
6
a/
g
0.
65
0.
25
32
0.
05
42
1.
29
 (1
.1
6-
1.
43
)
2.
98
E-
06
+
+
15
.9
1.
19
 (0
.2
8)
R
P1
1-
21
8D
6.
4
10
:2
82
96
55
8-
28
30
04
09
10
:2
83
00
40
9
rs
47
49
29
6
t/
g
0.
36
-0
.2
48
1
0.
05
3
0.
78
 (0
.7
0-
0.
87
)
2.
83
E-
06
--
1.
6
1.
02
 (
0.
31
)
R
P1
1-
21
8D
6.
4
11
:2
32
46
77
1-
23
24
81
77
11
:2
32
46
77
1
rs
49
23
07
6
a/
t
0.
52
0.
24
37
0.
05
25
1.
28
 (
1.
15
-1
.4
1)
3.
46
E-
06
+
+
0
0.
32
 (
0.
57
)
in
te
rg
en
ic
_v
ar
ia
nt
11
:2
32
46
77
1-
23
24
81
77
11
:2
32
48
15
7
rs
13
51
64
0
t/c
0.
52
0.
24
23
0.
05
26
1.
27
 (1
.1
5-
1.
41
)
4.
03
E-
06
+
+
0
0.
27
 (0
.6
0)
EN
SR
00
00
10
52
09
3
11
:2
32
46
77
1-
23
24
81
77
11
:2
32
48
17
7
rs
13
51
63
9
a/
t
0.
48
-0
.2
42
5
0.
05
26
0.
78
 (0
.7
1-
0.
87
)
3.
95
E-
06
--
0
0.
28
 (0
.6
0)
EN
SR
00
00
10
52
09
3
a  G
en
om
ic
 r
eg
io
ns
 o
f S
N
Ps
 in
 s
tr
on
g 
LD
 w
ith
 th
e 
m
os
t s
ig
ni
fic
an
t S
N
P 
(b
ol
d)
b  
Fr
eq
ue
nc
y 
of
 th
e 
fir
st
 a
lle
le
 u
se
d 
by
 M
ET
A
L 
as
 r
ef
er
en
ce
 a
lle
le
c  O
dd
s 
ra
tio
 a
nd
 c
on
fid
en
ce
 in
te
rv
al
s 
w
er
e 
ca
lc
ul
at
ed
 u
si
ng
 th
e 
w
ei
gh
te
d 
re
gr
es
si
on
 c
oe
ffi
ci
en
ts
 o
f t
he
 m
et
a-
an
al
ys
is
 u
si
ng
  t
he
 in
ve
rs
e-
va
ri
an
ce
 a
pp
ro
ac
h
d  
D
ir
ec
tio
n 
of
 th
e 
ef
fe
ct
 (fi
rs
t) 
al
le
le
 w
ith
 +
/-
 in
di
ca
tin
g 
a 
hi
gh
er
/lo
w
er
 d
is
ea
se
 r
is
k 
fo
r 
H
ar
va
rd
 a
nd
 F
H
S 
co
ho
rt
s,
 r
es
pe
ct
iv
el
y
e  I
2  
st
at
is
tic
s 
to
 te
st
 fo
r 
he
te
ro
ge
ne
ity
  
f  C
oc
hr
an
’s 
Q
 te
st
 s
ta
tis
tic
s 
fo
r 
he
te
ro
ge
ne
ity
 w
ith
 d
eg
re
es
 o
f f
re
ed
om
 e
qu
al
 to
 n
um
be
r 
of
 s
tu
di
es
 -
1 
(p
-v
al
ue
 in
 b
ra
ck
et
s)
**
 r
eg
ul
at
or
y 
va
ri
an
t
159
Genome-wide association studies of multiple keratinocyte cancers
Su
pp
le
m
en
ta
ry
 t
ab
le
 2
. 
Su
m
m
ar
y 
st
at
is
tic
s 
of
 t
he
 m
os
t 
si
gn
ifi
ca
nt
 s
ta
tis
tic
al
 a
ss
oc
ia
tio
ns
 f
ro
m
 t
he
 d
is
co
ve
ry
 p
ha
se
 i
n 
th
e 
re
pl
ic
at
io
n 
an
d 
jo
in
t 
m
et
a-
an
al
ys
is
 p
ha
se
 
D
is
co
ve
ry
 d
at
as
et
s 
(h
ar
va
rd
 
co
ho
rt
s,
 f
h
S)
R
ep
lic
at
io
n 
da
ta
se
t 
(R
ot
te
rd
am
 
St
ud
y)
 
 
 
 
Jo
in
t 
m
et
a-
an
al
ys
is
 o
f h
ar
va
rd
 c
oh
or
ts
,  
fh
S 
an
d 
R
S
 
 
SN
P 
na
m
e
fr
eq
a
Ef
fe
ct
St
dE
rr
D
ir
b
Pv
al
ue
fr
eq
a
w
ei
gh
t
Z
-s
co
re
c
P-
va
lu
e 
I2
d
h
et
C
hi
Sq
e
fr
eq
a
w
ei
gh
t
Z
-s
co
re
c
P-
va
lu
e 
D
ir
f
I2
d
h
et
C
hi
Sq
e
rs
11
68
91
42
0.
85
-0
.3
3
0.
07
--
5E
-0
6
0.
85
14
47
0.
66
6
0.
50
5
0
0.
20
 (0
.9
1)
0.
85
50
63
-3
.5
23
4.
26
E-
04
--
+
78
.1
9.
12
 (0
.0
1)
rs
11
69
05
87
0.
85
-0
.3
3
0.
07
--
5E
-0
6
0.
85
14
47
0.
66
6
0.
50
6
0
0.
20
 (0
.9
1)
0.
85
50
63
-3
.5
21
4.
30
E-
04
--
+
78
9.
10
 (0
.0
1)
rs
13
40
77
70
0.
15
0.
33
0.
07
+
+
5E
-0
6
0.
15
14
47
-0
.6
67
0.
50
5
0
0.
20
 (0
.9
0)
0.
15
50
63
3.
51
9
4.
33
E-
04
+
+
-
78
9.
10
 (0
.0
1)
rs
74
85
97
0.
85
-0
.3
3
0.
07
--
5E
-0
6
0.
85
14
47
0.
66
7
0.
50
5
0
0.
20
 (0
.9
0)
0.
85
50
63
-3
.5
15
4.
39
E-
04
--
+
78
9.
10
 (0
.0
1)
rs
74
85
98
0.
15
0.
33
0.
07
+
+
5E
-0
6
0.
15
14
47
-0
.6
67
0.
50
5
0
0.
20
 (0
.9
0)
0.
15
50
63
3.
51
5
4.
40
E-
04
+
+
-
78
9.
09
 (0
.0
1)
rs
10
17
07
38
0.
16
0.
33
0.
07
+
+
5E
-0
6
0.
16
14
47
-0
.7
55
0.
45
0
0
0.
22
 (0
.9
0)
0.
16
50
63
3.
45
9
5.
43
E-
04
+
+
-
79
9.
51
 (0
.0
1)
rs
72
85
10
82
0.
15
0.
34
0.
07
+
+
2E
-0
6
0.
15
14
47
-0
.6
37
0.
52
4
0
0.
20
 (0
.9
1)
0.
15
50
63
3.
66
8
2.
45
E-
04
+
+
-
78
.9
9.
47
 (0
.0
1)
rs
78
28
24
80
0.
85
-0
.3
4
0.
07
--
2E
-0
6
0.
85
14
47
0.
63
7
0.
52
4
0
0.
20
 (0
.9
1)
0.
85
50
63
-3
.6
69
2.
43
E-
04
--
+
78
.9
9.
48
 (0
.0
1)
2:
12
97
69
49
5:
ID
0.
85
-0
.3
4
0.
07
--
3E
-0
6
0.
84
14
47
0.
63
9
0.
52
3
0
0.
20
 (0
.9
1)
0.
85
50
63
-3
.6
24
2.
91
E-
04
--
+
78
.6
9.
33
 (0
.0
1)
rs
58
84
80
26
0.
85
-0
.3
4
0.
07
--
2E
-0
6
0.
85
14
47
0.
62
9
0.
52
9
0
0.
20
 (
0.
91
)
0.
85
50
63
-3
.6
64
2.
48
E-
04
--
+
78
.7
9.
41
 (
0.
01
)
rs
11
69
58
54
0.
50
-0
.2
4
0.
05
--
5E
-0
6
0.
48
14
47
-0
.0
83
0.
93
4
0
1.
71
 (0
.4
3)
0.
50
50
63
-3
.7
07
2.
09
E-
04
--
-
76
.8
8.
62
 (0
.0
1)
rs
95
65
60
0.
50
0.
24
0.
05
+
+
5E
-0
6
0.
52
14
47
0.
13
6
0.
89
2
0
1.
68
 (0
.4
3)
0.
50
50
63
3.
74
6
1.
79
E-
04
+
+
+
75
.9
8.
30
 (0
.0
2)
rs
67
06
03
7
0.
50
0.
24
0.
05
+
+
5E
-0
6
0.
52
14
47
0.
11
5
0.
90
9
0
1.
78
 (0
.4
1)
0.
50
50
63
3.
74
2
1.
83
E-
04
+
+
+
76
.1
8.
37
 (0
.0
2)
rs
10
16
73
36
0.
51
0.
24
0.
05
+
+
4E
-0
6
0.
53
14
47
0.
28
6
0.
77
5
0
0.
89
 (
0.
64
)
0.
51
50
63
3.
89
4
9.
88
E-
05
+
+
+
76
.3
8.
45
 (
0.
01
)
rs
68
03
72
1
0.
34
-0
.2
6
0.
06
--
3E
-0
6
0.
36
14
47
1.
53
8
0.
12
4
54
4.
35
 (
0.
11
)
0.
34
50
63
-2
.9
64
3.
04
E-
03
--
+
87
.3
15
.7
8 
(0
.0
0)
rs
76
19
90
9
0.
34
-0
.2
6
0.
06
--
5E
-0
6
0.
35
14
47
1.
51
5
0.
13
0
53
.7
4.
32
 (0
.1
2)
0.
34
50
63
-2
.8
77
4.
01
E-
03
--
+
86
.9
15
.2
3 
(0
.0
0)
rs
67
86
72
9
0.
66
0.
26
0.
06
+
+
4E
-0
6
0.
64
14
47
-1
.4
98
0.
13
4
51
.4
4.
11
 (0
.1
3)
0.
66
50
63
2.
94
8
3.
20
E-
03
+
+
-
87
15
.3
4 
(0
.0
0)
rs
68
08
77
0
0.
34
-0
.2
6
0.
06
--
4E
-0
6
0.
36
14
47
1.
54
0.
12
4
55
4.
44
 (0
.1
1)
0.
34
50
63
-2
.8
86
3.
90
E-
03
--
+
87
.3
15
.8
0 
(0
.0
0)
rs
46
78
50
1
0.
33
-0
.2
6
0.
06
--
4E
-0
6
0.
35
14
47
1.
67
0.
09
5
51
.7
4.
14
 (0
.1
3)
0.
34
50
63
-2
.8
54
4.
31
E-
03
--
+
87
.8
16
.3
4 
(0
.0
0)
3:
17
12
55
28
8:
ID
0.
98
1.
13
0.
23
+
+
1E
-0
6
0.
98
88
7
-0
.8
98
0.
36
9
0
0.
00
 (
1.
00
)
0.
98
50
63
3.
55
1
3.
84
E-
04
+
+
-
83
.3
11
.9
9 
(0
.0
0)
rs
77
99
65
1
0.
45
-0
.3
1
0.
07
--
4E
-0
6
0.
44
14
47
2.
04
3
0.
04
1
0
0.
25
 (
0.
88
)
0.
45
50
62
-2
.5
53
0.
01
1
--
+
90
.6
21
.2
6 
(0
.0
2)
Chapter 9
160 161
Genome-wide association studies of multiple keratinocyte cancers
Su
pp
le
m
en
ta
ry
 t
ab
le
 2
. 
Su
m
m
ar
y 
st
at
is
tic
s 
of
 t
he
 m
os
t 
si
gn
ifi
ca
nt
 s
ta
tis
tic
al
 a
ss
oc
ia
tio
ns
 f
ro
m
 t
he
 d
is
co
ve
ry
 p
ha
se
 i
n 
th
e 
re
pl
ic
at
io
n 
an
d 
jo
in
t 
m
et
a-
an
al
ys
is
 p
ha
se
 (c
on
tin
ue
d)
 
D
is
co
ve
ry
 d
at
as
et
s 
(h
ar
va
rd
 
co
ho
rt
s,
 f
h
S)
R
ep
lic
at
io
n 
da
ta
se
t 
(R
ot
te
rd
am
 
St
ud
y)
 
 
 
 
Jo
in
t 
m
et
a-
an
al
ys
is
 o
f h
ar
va
rd
 c
oh
or
ts
,  
fh
S 
an
d 
R
S
 
 
SN
P 
na
m
e
fr
eq
a
Ef
fe
ct
St
dE
rr
D
ir
b
Pv
al
ue
fr
eq
a
w
ei
gh
t
Z
-s
co
re
c
P-
va
lu
e 
I2
d
h
et
C
hi
Sq
e
fr
eq
a
w
ei
gh
t
Z
-s
co
re
c
P-
va
lu
e 
D
ir
f
I2
d
h
et
C
hi
Sq
e
rs
74
68
39
0
0.
64
-0
.3
2
0.
06
--
4E
-0
7
0.
64
14
47
1.
45
9
0.
14
5
0
0.
99
 (
0.
61
)
0.
64
50
63
-3
.3
9.
69
E-
04
--
+
88
.7
17
.6
4 
(0
.0
0)
rs
12
00
09
70
0.
69
-0
.3
3
0.
07
--
2E
-0
6
0.
69
14
47
1.
94
2
0.
05
2
0
0.
15
 (0
.9
3)
0.
69
50
63
-2
.7
53
5.
90
E-
03
--
+
89
.8
19
.5
8 
(0
.0
6)
rs
15
43
71
2
0.
40
0.
28
0.
06
+
+
2E
-0
6
0.
39
14
47
-1
.0
24
0.
30
6
0
0.
70
 (0
.7
0)
0.
40
50
63
3.
18
9
1.
43
E-
03
+
+
-
85
.8
14
.1
3 
(0
.0
0)
rs
15
43
71
3
0.
40
0.
28
0.
06
+
+
2E
-0
6
0.
39
14
47
-1
.0
6
0.
28
9
0
0.
79
 (0
.6
7)
0.
40
50
63
3.
18
9
1.
43
E-
03
+
+
-
86
.1
14
.4
2 
(0
.0
0)
rs
15
43
71
4
0.
25
0.
33
0.
07
+
+
3E
-0
6
0.
25
14
47
-1
.6
32
0.
10
3
0
0.
08
 (0
.9
6)
0.
25
50
63
2.
90
1
3.
72
E-
03
+
+
-
87
.7
16
.2
8 
(0
.0
0)
rs
10
96
11
02
0.
41
0.
28
0.
06
+
+
2E
-0
6
0.
40
14
47
-1
.1
37
0.
25
6
0
0.
73
 (0
.6
9)
0.
41
50
63
3.
18
4
1.
45
E-
03
+
+
-
86
.3
14
.6
0 
(0
.0
0)
rs
10
96
11
03
0.
41
0.
28
0.
06
+
+
2E
-0
6
0.
40
14
47
-1
.1
39
0.
25
5
0
0.
84
 (0
.6
6)
0.
41
50
63
3.
17
8
1.
48
E-
03
+
+
-
86
.3
14
.5
5 
(0
.0
0)
rs
47
41
30
8
0.
58
-0
.2
8
0.
06
--
1E
-0
6
0.
58
14
47
1.
01
9
0.
30
8
0
0.
73
 (0
.6
9)
0.
58
50
63
-3
.3
40
8.
37
E-
04
--
+
85
.4
13
.7
1 
(0
.0
0)
rs
78
64
56
9
0.
58
-0
.2
9
0.
06
--
1E
-0
6
0.
59
14
47
0.
79
7
0.
42
6
0
0.
70
 (0
.7
1)
0.
58
50
63
-3
.4
42
5.
78
E-
04
--
+
84
.5
12
.8
9 
(0
.0
0)
rs
23
82
39
8
0.
58
-0
.2
8
0.
06
--
8E
-0
7
0.
58
14
47
0.
68
8
0.
49
2
0
0.
67
 (0
.7
2)
0.
58
50
63
-3
.5
70
3.
57
E-
04
--
+
83
.9
12
.4
4 
(0
.0
0)
rs
13
33
98
8
0.
58
-0
.2
8
0.
06
--
8E
-0
7
0.
58
14
47
0.
68
7
0.
49
2
0
0.
67
 (0
.7
2)
0.
58
50
63
-3
.5
71
3.
55
E-
04
--
+
83
.9
12
.4
4 
(0
.0
0)
rs
78
70
72
6
0.
41
0.
27
0.
06
+
+
1E
-0
6
0.
40
14
47
-0
.5
35
0.
59
3
0
0.
89
 (0
.6
4)
0.
41
50
63
3.
57
8
3.
46
E-
04
+
+
-
82
.8
11
.6
1 
(0
.0
0)
rs
93
30
35
0.
56
-0
.2
8
0.
06
--
1E
-0
6
0.
57
14
47
0.
75
7
0.
44
9
0
0.
46
 (0
.7
9)
0.
56
50
63
-3
.5
06
4.
54
E-
04
--
+
84
.3
12
.7
5 
(0
.0
0)
rs
93
30
34
0.
41
0.
27
0.
06
+
+
1E
-0
6
0.
40
14
47
-0
.5
37
0.
59
1
0
0.
89
 (0
.6
4)
0.
41
50
63
3.
60
0
3.
18
E-
04
+
+
-
82
.9
11
.7
0 
(0
.0
0)
rs
70
76
78
6
0.
65
0.
25
0.
05
+
+
3E
-0
6
0.
63
14
47
1.
01
2
0.
31
2
0
1.
57
 (0
.4
6)
0.
65
50
63
4.
34
9
1.
37
E-
05
+
+
+
60
.4
5.
05
 (0
.0
8)
rs
47
49
29
6
0.
36
-0
.2
5
0.
05
--
3E
-0
6
0.
38
14
47
-0
.9
47
0.
34
4
0
1.
95
 (
0.
38
)
0.
36
50
63
-4
.3
58
1.
31
E-
05
--
-
58
.1
4.
77
 (
0.
09
)
rs
49
23
07
6
0.
52
0.
24
0.
05
+
+
3E
-0
6
0.
52
14
47
-0
.4
31
0.
66
6
0
0.
86
 (
0.
65
)
0.
52
50
63
3.
60
2
3.
15
E-
04
+
+
-
78
.1
9.
11
 (
0.
01
)
rs
13
51
64
0
0.
52
0.
24
0.
05
+
+
4E
-0
6
0.
52
14
47
-0
.3
91
0.
69
6
0
0.
86
 (0
.6
5)
0.
52
50
63
3.
60
0
3.
18
E-
04
+
+
-
77
.1
8.
73
 (0
.0
1)
rs
13
51
63
9
0.
48
-0
.2
4
0.
05
--
4E
-0
6
0.
48
14
47
0.
39
0.
69
7
0
0.
87
 (0
.6
5)
0.
48
50
63
-3
.6
03
3.
15
E-
04
--
+
77
.2
8.
75
 (0
.0
1)
a  F
re
qu
en
cy
 o
f t
he
 fi
rs
t a
lle
le
 u
se
d 
by
 M
ET
A
L 
as
 r
ef
er
en
ce
 a
lle
le
b  
D
ir
ec
tio
n 
of
 th
e 
ef
fe
ct
 (fi
rs
t) 
al
le
le
 w
ith
 +
/-
 in
di
ca
tin
g 
a 
hi
gh
er
/lo
w
er
 d
is
ea
se
 r
is
k 
fo
r 
H
ar
va
rd
 a
nd
 F
H
S 
co
ho
rt
s,
 r
es
pe
ct
iv
el
y
c  Z
-s
co
re
s 
fr
om
 th
e 
m
et
a-
an
al
ys
is
 (s
ee
 r
es
ul
ts
)
d  
I2
 S
ta
tis
tic
s 
to
 te
st
 fo
r 
he
te
ro
ge
ne
ity
  
e  C
oc
hr
an
’s 
Q
 te
st
 s
ta
tis
tic
s 
fo
r 
he
te
ro
ge
ne
ity
 w
ith
 d
eg
re
es
 o
f f
re
ed
om
 e
qu
al
 to
 n
um
be
r 
of
 s
tu
di
es
 -
1 
(p
-v
al
ue
 in
 b
ra
ck
et
s)
f  D
ir
ec
tio
n 
of
 th
e 
ef
fe
ct
 o
f t
he
 fi
rs
t a
lle
le
, w
ith
 +
/-
 in
di
ca
tin
g 
a 
hi
gh
er
/lo
w
er
 d
is
ea
se
 r
is
k 
fo
r 
H
ar
va
rd
, F
H
S,
 R
S 
 c
oh
or
ts
, r
es
pe
ct
iv
el
y
Chapter 9
160 161
Genome-wide association studies of multiple keratinocyte cancers
Su
pp
le
m
en
ta
ry
 t
ab
le
 3
. S
um
m
ar
y 
st
at
is
tic
s 
of
 th
e 
m
os
t s
ig
ni
fic
an
t s
ta
tis
tic
al
 a
ss
oc
ia
tio
ns
 fo
r 
ot
he
r 
SN
Ps
 a
nd
 m
K
C
s 
in
 th
e 
jo
in
t m
et
a-
an
al
ys
is
 p
ha
se
R
S_
id
A
lle
le
sa
Z
-s
co
re
b
P-
va
lu
e
D
ir
ec
ti
on
c
I2
d
h
et
C
hi
Sq
e
A
ss
oc
ia
te
d 
ge
ne
s
rs
47
61
49
6
t/c
-5
.0
46
4.
51
E-
07
--
-
39
.7
3.
32
 (0
.1
9)
in
te
rg
en
ic
_v
ar
ia
nt
rs
75
79
00
06
t/g
4.
83
6
1.
33
E-
06
+
+
+
0
0.
50
 (0
.7
8)
R
P1
1-
39
5F
4.
1 
(i
nt
ro
n)
3:
80
13
64
27
a/
g
-4
.8
25
1.
40
E-
06
?-
?
0
0.
00
 (1
.0
0)
in
te
rg
en
ic
_v
ar
ia
nt
15
:8
94
32
44
8
a/
g
4.
75
1
2.
02
E-
06
+
+
?
0
0.
65
 (0
.4
2)
H
A
PL
N
3 
(i
nt
ro
n)
3:
79
84
88
80
a/
c
-4
.7
39
2.
15
E-
06
?-
?
0
0.
00
 (1
.0
0)
in
te
rg
en
ic
_v
ar
ia
nt
rs
17
39
34
53
a/
t
-4
.7
34
2.
20
E-
06
--
-
0
1.
60
 (0
.4
5)
C
SM
D
1 
(i
nt
ro
n)
rs
59
11
27
43
a/
g
-4
.6
99
2.
61
E-
06
--
-
0
0.
12
 (0
.9
4)
in
te
rg
en
ic
_v
ar
ia
nt
rs
20
40
60
9
t/c
4.
67
8
2.
89
E-
06
+
+
+
0
1.
62
 (0
.4
5)
in
te
rg
en
ic
_v
ar
ia
nt
rs
80
06
98
61
a/
g
4.
66
4
3.
10
E-
06
+
+
+
13
.6
2.
31
 (0
.3
1)
in
te
rg
en
ic
_v
ar
ia
nt
rs
35
40
13
16
t/c
-4
.6
46
3.
38
E-
06
--
-
13
2.
30
 (0
.3
2)
PR
F1
 (
up
st
re
am
 g
en
e)
rs
11
86
75
66
a/
g
4.
64
3
3.
43
E-
06
+
+
+
0
1.
62
 (0
.4
4)
in
te
rg
en
ic
_v
ar
ia
nt
2:
49
72
57
08
t/c
-4
.6
17
3.
90
E-
06
--
?
52
.7
2.
12
 (0
.1
5)
in
te
rg
en
ic
_v
ar
ia
nt
rs
93
81
95
2
a/
g
-4
.5
91
4.
41
E-
06
--
-
0
0.
12
 (0
.9
4)
in
te
rg
en
ic
_v
ar
ia
nt
rs
10
94
86
06
t/c
-4
.5
89
4.
45
E-
06
--
-
0
0.
07
 (0
.9
7)
in
te
rg
en
ic
_v
ar
ia
nt
4:
63
38
33
1:
ID
d/
i
4.
58
5
4.
53
E-
06
+
??
0
0.
00
 (1
.0
0)
PP
P2
R
2C
rs
11
60
45
23
7
a/
t
-4
.5
78
4.
69
E-
06
--
-
0
1.
83
 (0
.4
0)
C
SM
D
1 
(i
nt
ro
n)
17
:5
97
12
01
9:
D
d/
i
-4
.5
77
4.
71
E-
06
--
-
0
1.
35
 (0
.5
1)
in
te
rg
en
ic
_v
ar
ia
nt
17
:5
97
12
01
8:
D
d/
i
-4
.5
77
4.
72
E-
06
--
-
0
1.
34
 (0
.5
1)
in
te
rg
en
ic
_v
ar
ia
nt
4:
63
35
96
6
t/c
-4
.5
71
4.
86
E-
06
-?
?
0
0.
00
 (1
.0
0)
PP
P2
R
2C
2:
49
76
21
65
a/
g
-4
.5
68
4.
92
E-
06
--
?
41
.5
1.
71
 (0
.1
9)
in
te
rg
en
ic
_v
ar
ia
nt
6:
51
12
65
77
:D
d/
i
-4
.5
65
5.
01
E-
06
--
-
0
0.
05
 (0
.9
8)
in
te
tg
en
ic
rs
11
77
72
68
t/c
4.
55
5
5.
24
E-
06
+
+
+
0
1.
71
 (0
.4
3)
C
SM
D
1 
(i
nt
ro
n)
rs
93
70
01
9
a/
g
4.
54
6
5.
47
E-
06
+
+
+
0
0.
08
 (0
.9
6)
in
te
rg
en
ic
_v
ar
ia
nt
a  F
re
qu
en
cy
 o
f t
he
 fi
rs
t a
lle
le
 u
se
d 
by
 M
ET
A
L 
as
 r
ef
er
en
ce
 a
lle
le
b  
Z
-s
co
re
s 
fr
om
 th
e 
m
et
a-
an
al
ys
is
 (s
ee
 r
es
ul
ts
)
c  D
ir
ec
tio
n 
of
 th
e 
ef
fe
ct
 (fi
rs
t) 
al
le
le
 w
ith
 +
/-
/?
  i
nd
ic
at
in
g 
a 
hi
gh
er
/lo
w
er
/a
lle
le
 n
ot
 p
re
se
nt
 d
is
ea
se
 r
is
k 
fo
r 
H
ar
va
rd
 c
oh
or
ts
, F
H
S 
an
d 
R
S,
 r
es
pe
ct
iv
el
y.
d  
I2
 S
ta
tis
tic
s 
to
 te
st
 fo
r 
he
te
ro
ge
ne
ity
  
e  C
oc
hr
an
’s 
Q
 te
st
 s
ta
tis
tic
s 
fo
r 
he
te
ro
ge
ne
ity
 w
ith
 d
eg
re
es
 o
f f
re
ed
om
 e
qu
al
 to
 n
um
be
r 
of
 s
tu
di
es
 -
1 
(p
-v
al
ue
 in
 b
ra
ck
et
s)
Chapter 9
162
Supplementary figure 1. Regional plot of the most signifi cant associations between SNPs in the 
short arm of chromosome 9 and mKCs
The plots represents the LD patterns of the most signifi cant SNP in the study (rs7468390) and 
nearby SNPs from this study (+/- 500 kb). Pairwise r2 is represented in colours. The log p-values of 
the associations of the rs7468390 SNP and markers from the study is presented in the left Y-axis 
and the recombination rates is presented in the right Y-axis. The physical position of the markers 
is presented in Mb. The fi gure was generated using LocusZoom35
Supplementary figure 2. Power calculation of the study design
The power of the study was calculated using the program CaTS36 with sample size, p-value (1x10-6 
) and a disease prevalence of 10% as fi xed parameters. An 80% power was expected for markers 
with MAF>25% and Odd ratios of >1.3.
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General discussion
The research presented in this thesis provides insight into the epidemiology of basal cell 
carcinoma (BCC), in particular into the epidemiology of patients with metachronous 
BCC (mBCC). An update of the knowledge on the occurrence of mBCC is warranted as 
the burden of BCC is still increasing (chapter 2). In this chapter I will first shortly answer 
the five research questions posed in the introduction of this thesis. Then I will show 
the limitations of the included studies. Finally, I will discuss potential implications and 
future perspectives of my research.
RESEARCh QuESTIONS
1. What is already known about the epidemiology of BCC and where are the gaps?
These questions were answered in chapter 2 and 3 in a broad non-systemic review 
of the literature on BCC. Numerous studies on BCC incidence in white-skinned 
individuals worldwide all point out the high and still increasing incidence. In addition, 
approximately one third of all individuals with a first BCC will develop at least a second 
BCC and are at risk of other ultraviolet radiation (UVR) related skin cancers,1 which 
is in line with the concept of field cancerization.2 Nevertheless, the majority of BCC 
research has been done in patients with one BCC, or without differentiating between 
single or mBCC or different keratinocyte carcinomas (KC, i.e., BCC and squamous cell 
carcinoma (SCC)), which is the reason little is known about the true burden of disease 
(i.e., disability-adjusted life year and health care costs) and both the non-genetic and 
genetic risk factors (i.e., predictors) of patient with mBCC. The latter makes targeted 
secondary prevention and tailored follow-up difficult, and screening programs less 
likely to be cost effective, since it is not known who the high-risk patients exactly are. 
Thus there is a need for skin cancer consortia and large prospective population-based 
cohort studies with a long follow-up up in which prediction models for mBCC patients 
can be developed and validated/replicated.
2. What are the non-genetic and genetic predictors of a superficial first BCC?
These questions were addressed in chapter 4 using histopathologically confirmed skin 
cancer data gathered through a linkage between the prospective population-based 
cohort study named the Rotterdam Study3 and the Dutch nationwide network and 
registry of histopathology and cytopathology (PALGA).4 Based on several previous 
observational studies eleven non-genetic predictors were included in the binary logistic 
regression analyses of which three were significantly associated with a superficial first 
BCC. We found that patients with a superficial first BCC were significantly younger 
(odds ratio (OR) 0.95, 95% confidence interval (CI) 0.93-0.98), almost two times more 
often female (OR 1.88, 95% CI 1.16-3.03) and 12-18 times more likely to have their 
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BCC on the trunk or extremities (truncal OR 12.20, 95% CI 7.08-21.03; extremities 
OR 17.57, 95% CI 10.06-30.70) than patients with a non-superficial first BCC. We 
did not find a significant association between a superficial first BCC and having more 
than 1 BCC at initial diagnosis or having at least another mBCC (last statement is based 
on unpublished data). Based on several previous genome-wide association studies 
(GWAS) of loci that confer risk of BCC or non-melanoma skin cancer twenty single 
nucleotide polymorphisms (SNPs) were included in the binary logistic regression 
analyses of which one SNP (rs12203592), mapped to IRF4, looked promising (OR 1.83, 
95% CI 1.13-2.97), but after adjustment for multiple testing, no significant differences 
in genetic make-up between superficial first BCC and non-superficial first BCC patients 
were found. Overall, superficial first BCCs could have a different etiology than the other 
subtypes. Although we did not find a significant association between SNPs previously 
associated with BCC and risk for superficial first BCC, we cannot rule out that there 
is no genetic susceptibility for a superficial first BCC, since our cohort of patients was 
small. Larger genetic studies will be needed to investigate whether this is indeed the 
case.
3. How to deal with the competing risk of death when analyzing metachronous BCCs?
This question was answered in chapter 5 with histopathologically confirmed skin 
cancer data gathered through a linkage between the Rotterdam Study and PALGA. We 
first pointed out that the competing risk problem could be a real problem in survival 
analysis of metachronous KC data and then we compared two different methods 
of estimating the survival probability, namely the Kaplan Meier (KM) curve and the 
cumulative incidence curve (CIC). After ten years of follow-up the probability of a 
subsequent KC was 40% using the KM method and only 34% using the CIC method. 
The KM method gave an overestimation of the real probability by not taking the 
competing risk of death into account. Twenty years after diagnosis, the difference was 
even larger (74% for KM vs 52% for CIC) because the problem of competing risk due 
to death of included patients became larger. Thus, the competing risks problem can 
occur for all end points other than overall mortality when using the KM method and 
could be avoided using the CIC method. In chapter 6 and 7 we used this knowledge 
and showed that the Fine and Gray semiparametric proportional hazards model could 
be used to deal with competing risk of death and generate valid hazard ratios (HR) for 
the included predictors.
4. What are the non-genetic predictors, absolute risks and cumulative incidences of 
metachronous BCCs?
These questions were addressed in chapter 6 and 7 using histopathologically confirmed 
skin cancer data gathered through a linkage between the Rotterdam Study and PALGA. 
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Based on a scarce amount of literature on non-genetic predictors of mBCC several 
phenotypic, lifestyle, and tumor-specific characteristics were included in the initial 
prediction models. In chapter 6 the follow-up was stopped after the second new BCC 
(i.e., first mBCC) whereas in chapter 7 the follow-up was extended up to the fifth new 
BCC (i.e., fourth mBCC). 
In chapter 6 we showed that of the thirteen non-genetic predictors included in our 
prediction model, only five remained in the multivariable Fine and Gray semiparametric 
proportional hazards model. These were: age at first BCC, sex, coffee consumption, 
superficial subtype of the first BCC and more than one BCC at first date of diagnosis. 
The latter being the strongest predictor of a second BCC (HR 2.5, 95% CI 1.9-3.3). The 
apparent concordance index (i.e., discriminative ability) of the multivariable model 
was reasonable, ranging between 0.63-0.65 from 1-5 years after the first BCC diagnosis. 
A score chart was developed, which makes it easier for a physician to calculate the 
absolute risk of a second BCC. For example: a 65-year-old (two points) man (one point) 
who drinks no coffee (two points) presenting with one (zero points) superficial (one 
point) BCC has a total score of 6, which corresponds to a 3-year risk of 21% of a second 
BCC. This patient could be regarded as a high-risk patient, however this is a grey area 
in which dermatologists should come together and define new guidelines on follow-up/
screening.
In chapter 7 we showed that of the fourteen included non-genetic predictors nine 
remained in the multivariable Fine and Gray semiparametric proportional hazards 
model, namely age at BCC diagnosis, sex, pigment status, easily sunburned, coffee 
consumption, more than one BCC at diagnosis, superficial subtype of BCC, localization 
of BCC and the number of previous BCC diagnosis dates (newly added variable 
compared to the other prediction model). The strongest predictors were more than one 
BCC at diagnosis (HR 1.9, 95% CI 1.5-2.4) and the number of previous BCC diagnosis 
dates (increasing HR with increasing number of previous diagnosis dates; HR 3 previous 
dates 3.9, 95% 2.5-6.2), which could be proxies of field cancerization. In contrast to 
the prognostic model for a second BCC, pigment status, easily sunburned and location 
of BCC at diagnosis now did remain in the model, but the univariable HRs and 95% CIs 
were small and quite similar. The discriminative ability of the multivariable model was 
reasonable, ranging between 0.67-0.70 from 1-5 years after any BCC diagnosis. Again 
a score chart was developed showing that for example a 65-year-old (five points) man 
(one point) with a light pigment status (two points) who burns easily (one point), drinks 
no coffee (four points), presenting with one (zero points) superficial (one point) truncal 
(one point) BCC on his fourth BCC diagnosis date (nine points) has a total score of 24, 
which corresponds to a 3-year risk of approximately 34% of a fifth BCC. The cumulative 
incidence of a mBCC at 3 years was 15%, and 34%, 45% and 67% for the second, 
third, fourth and fifth BCC, respectively.
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In conclusion, a combination of readily available clinical characteristics, especially 
more than one BCC at diagnosis and number of previous BCC diagnosis dates, can 
reasonably identify patients at high risk of mBCC. Risk of a mBCC was highest in the 
first 2-3 years after diagnosis.
5. What are the genetic predictors of multiple/metachronous BCCs?
This question was first answered in chapter 8 performing a candidate gene approach 
(CGA) and a pilot GWAS of multiple BCC using data gathered through a linkage 
between the Rotterdam Study and PALGA. We used the word “multiple” instead of 
“metachronous” because a small part of the included patients only had multiple BCCs 
on their first diagnosis date and no further BCCs in time. The CGA comparing single 
BCC to multiple BCC included nineteen candidate SNPs from GWAS and CGA of BCC 
or KC and yielded no significant associations between these BCC-related SNPs and the 
risk of multiple BCC. In addition, the pilot GWAS identified genome-wide suggestive 
associations in chromosomes 2, 3, 18, and 22 (P-values <5x10-6) of which the most 
significant SNP was rs78857623 (P-value 1.2×10-7) mapped to an intron in the tumor 
suppressor gene FHIT.
In chapter 9 we presented the results of a combined effort between our dermatology 
department and two research groups in the USA to identify gene variants for multiple 
KCs. A CGA and GWAS of multiple KC was performed combining our data with data 
from three large USA prospective cohort studies, namely the Nurses’ Health Study (NHSI 
and II), Health Professionals Follow-up Study5 and the Framingham Heart Study.6 The 
GWAS on multiple KC identified eight independent SNPs with suggestive associations 
(p-value <5.5x10-6) of which the most significant SNP was located at chromosome 
9 (rs7468390; p-value 3.92x10-7). However, in stage two none of these SNPs were 
replicated in an independent sample of 574 multiple KCs from the Rotterdam Study 
and only two of them were associated with multiple KCs in the same direction in 
the combined meta-analysis. The nineteen previously reported candidate BCC SNPs 
were included in a CGA and we found that rs1805007 (MC1R locus) was significantly 
associated with risk of multiple KCs (p-value2.80x10-4).
Overall, it remains likely that there are genetic differences between patients with 
multiple BCC and single BCC, but we could not confirm this in our genetic analyses. 
The latter could be explained by our relatively small sample sizes.
lIMITATIONS Of ThE STuDIES
The articles on which chapters 2 and 3 are based, compiled previous literature on 
BCC epidemiology, which led to some inherent limitations. Chapter 2 consisted of a 
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scholarly review, which means that a non-systematic search of the scientific literature 
took place before the article was written. However, since the purpose of the article 
was to give a broad epidemiologic overview of BCC, it was practically impossible and 
not the scope to perform one systematic search. This may have biased the information 
presented and therefore affected the generalizability of our conclusions. However, we 
included as many different studies and outcomes as possible (>200 scientific articles). 
In chapter 3 we gave our opinion on the scarcity of large population-based cohort 
studies on mBCC by writing a commentary on an original mBCC article. This means 
that due to the scope of this commentary only several articles could be included, which 
therefore could have affected the generalizability of our conclusions.
Chapters 4-9 are all based on data obtained from a linkage between the Rotterdam 
Study and PALGA. The use of a pathology registry (i.e., PALGA) coupled with a large 
long ongoing prospective cohort study (i.e., Rotterdam Study) gave us the opportunity 
to include multiple detailed predictors and distinguish between (metachronous) BCC 
and SCC, which helped us to discover predictors specific to either KC. This is important 
because there exist differences in risk factor profiles between BCC and SCC patients 
(e.g., smoking, UVR exposure patterns). Even though the Rotterdam Study data we used 
consisted of 14,926 participants, of whom approximately 10% developed at least one 
BCC, these are still small numbers when performing GWAS, because SNPs often have 
relatively low allele frequencies and small effect sizes. Therefore we collaborated with 
three different prospective USA cohort studies (chapter 9) to increase the sample size 
and power for our genetic studies, but it was no longer possible to differentiate between 
BCC and SCC, since the USA cohorts did not have the same phenotypes available. 
Likewise we could not (yet) replicate and validate our prediction models (chapter 6 
and 7) because we could not find external cohorts which had the same detailed data 
as we had.
Other potential limitations of our studies were:
1) a limited generalizability (i.e., external validity) because the Rotterdam Study 
population is aged 45 years or older and mainly exists of white-skinned people, 
whereas current BCC incidence trends show an increasing incidence in young 
women.7-9 However, these young women seem to represent a special group and 
overall BCC is still considered to be a skin disease of the older white-skinned 
population, suggesting this bias played only a minor role.
2) underestimation of the absolute number of BCCs and potential non-differential 
misclassification because
a. we only included histopathologically confirmed BCCs. However, a recent 
observational study showed that only a small percentage (ca. 7%) of patients 
with mBCC had subsequent non-histologically confirmed BCCs.10 In addition, 
Chapter 10
172
the evidence based guideline regarding BCC from the Dutch Society for 
Dermatology and Venereology (NVDV) states that all biopsied/excised BCCs 
should be sent for a histopathological diagnosis.11 Besides, including non-
histopathological BCCs could have led to a significant misclassification bias 
because a clinical BCC diagnosis, even made by a dermatologist, has a relatively 
low diagnostic accuracy.12,13
b. of incomplete PALGA coverage. The Rotterdam Study cohort members could 
have developed BCCs before PALGA had complete nationwide coverage in 
1991. However, between 1971 and 1991 partial coverage was achieved and 
the mean age of the included participants in 1991 was 61 years, which is seven 
years younger compared with the mean BCC age of diagnosis,14 suggesting that 
the impact of this bias is small.
IMPlICATIONS AND fuTuRE PERSPECTIVES 
In 1973 Epstein already observed that a relatively large part of patients who were 
previously treated for a BCC developed mBCC.15 An observation that is in line with 
the concept of field cancerization2 and with regard to the skin has been called actinic 
neoplasia syndrome to emphasize that patients with a first UVR-related cutaneous 
(pre)malignancy frequently develop other cutaneous (pre)malignancies, in part due 
to the field dysplasia from which they chronically suffer.16 These observations were 
corroborated in a recent meta-analysis, which showed that approximately one third of 
the BCC patients will at least develop a second BCC and are at risk of SCC (4,3%) and 
melanoma (0,5%) as well.1 The risks of developing other UVR-related skin cancers after 
a first BCC are increased, however, the majority of patients who develop a first BCC 
will develop BCCs only, something which could be a consequence of particular genetic 
susceptibilities.17,18
Since Epstein’s observation no prediction models for mBCC have been developed 
(until now) and relatively few studies have been conducted to identify patients at risk 
of mBCC, but plenty of observational studies have pointed out the risk factors of a 
BCC, and the growing incidence numbers, burden of disease and health care costs.19-21 
It is clear that there is an increased risk of mBCC on a population level, but on an 
individual level it is still unclear who these patients at risk are. Looking at the increasing 
incidence and burden it is time we find the missing pieces and translate this into a 
clinical relevant prediction model for mBCC to help physicians in their therapeutic 
approach, something which has been done in multiple other research areas as well. 
A good example is the cardiovascular risk table for Dutch general practitioners which 
gives a 10-year risk of cardiovascular disease or mortality using age, sex, blood pressure, 
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smoking and cholesterol, and helps these physicians in determining their treatment 
plan (e.g., nothing, diet and/or medication).22 The data presented in this thesis fill some 
of these knowledge gaps and support the aforementioned findings concerning risks of 
mBCC and field cancerization. We noticed that approximately 30% of the analyzed 
Rotterdam Study participants developed mBCC, which is similar to risks found in 
previous studies. The results presented in chapters 2-3 and 6-7 demonstrate that proxies 
of field cancerization, namely more than one BCC at diagnosis and number of previous 
BCC diagnoses, were the strongest predictors of mBCC (HR varying from 1.9-3.9). 
However, BCC is a complex disease and the discriminative ability of our models was 
only reasonable, which most likely could be explained by residual confounding and 
the fact that we could not include all possible other predictors (because of the sample 
size) that could add to the total explained variability of mBCC.
In the last decades numerous observational studies (e.g., cohort, case-control, 
cross-sectional) have been conducted to find BCC risk factors. This has led to the 
discovery of multiple universally accepted predictors, but also to a lot of questionable 
(i.e., probably false) risk factors, often with small effect sizes and sometimes opposite 
effect directions. One could wonder if we should keep looking for (m)BCC predictors 
or should focus on the strongest and/or most easy to determine risk factors only. I think 
we should keep looking, as it seems that a significant part of the mBCC risk variation 
cannot be explained by known predictors, which also shows that risk factors for a first 
event are not automatically relevant for a second event (pigment status, UVR-related 
characteristics), and the finding of new predictors (even with small effect sizes) could 
lead to more focused prevention strategies and new therapeutic options. In the search 
for mBCC risk factors we should be non-conventional and look into new research areas 
like the (skin) microbiome as well.23 In the interest of improving research quality it 
would be better if we would perform these studies (in particular genetic) in large (inter)
national research consortia in order to the increase the validity of study findings and find 
new risk predictors with small effects sizes and low frequencies as well24 and stimulate 
laboratory scientists to study underlying mechanisms in detail. The classical paradigm 
that most of the explained cancer variability is due to non-genetic/environmental factors 
(or as more recently stated due to bad luck)25 seems erroneous and the attributable 
risk of genetic factors should not be overlooked.26 Fortunately a paradigm shift took 
place and the last decade several studies were performed that looked into the genetic 
epidemiology of BCC. Most of these studies were CGAs or GWASs and the significant 
genetic predictors found in there usually had small effect sizes (OR <1,5) and only 
explain a small fraction of the total BCC heritability. Unfortunately, our CGAs and 
GWASs yielded no relevant significant predictors of multiple BCCs, most likely due 
to our small sample sizes (chapter 8-9). Based on our results one might argue that it is 
unlikely that there exist common variants (i.e., SNPs) with strong effects contributing 
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to the susceptibility for multiple BCC. Nevertheless, significant SNPs with weak effects 
and rare variants might be clinically irrelevant, but could lead to new pathways and 
therefore new treatment options. The missing heritability could be hidden in SNPs 
with small effect sizes and low frequencies that were not picked up in the current 
sample sizes, but another likely explanation is that we should look into for example 
gene-environment interactions, exome sequencing and epigenetics.27 Recently, a 
GWAS found a potential gene-caffeine interaction which could be involved in caffeine-
mediated BCC inhibition.28 
The question remains if we should aim for a perfectly discriminating prediction 
model, as adding dozens of significant predictors (with small effect sizes) will decrease 
the applicability of such a model in clinical practice. Even if we would have the ideal 
(i.e., flawless discrimination, perfectly calibrated and externally validated) prediction 
model for mBCC, physicians should still be encouraged to think about their follow-up 
schemes because we, as physicians, would like to give personalized care and pursue 
shared decision making. However, a recently published cross-sectional study in USA 
elderly skin cancer patients showed that there were no differences in given treatments 
(61% surgical) between BCC patients with limited life expectancy and normal life 
expectancy.29 A one-size-fits-all approach is not the answer to the growing skin cancer 
problem in our BCC patients, of whom the majority is over 65 years of age. 
Another question concerns the duration and frequency of follow-up once we 
identified the patients at risk of mBCC. Previous observational studies have shown 
that most mBCC occur within approximately 3 years after a diagnosis, but that risks 
remain elevated over time.30-32 This was in line with our results (chapter 6-7) in which 
we noticed that the median follow-up time until the second BCC was 3.0 years and 
seemed to shorten until it reached 1.8 years after the fourth BCC. Fortunately, BCCs 
are rarely lethal33 and increase slowly in size, with a median growth of approximately 
3 millimeters per year as pointed out in a recently published systematic review.34 This 
review, which was based on the WHO criteria for screening, also showed that small 
changes in size can affect treatment options, their effectiveness and associated costs, 
especially in the H-zone and that current data supports early detection of BCCs on 
the face. In contrast to this systematic review, the U.S. Preventive Services Task Force 
concluded in 2016 that “the current evidence is insufficient to assess the balance of 
benefit and harms of screening for skin cancer in adults with a clinical visual skin 
examination”.35 Important data in this field comes from the first nationwide skin 
cancer screening program in Germany,36 however seven years after the introduction 
of this program no discernible beneficial effect was found.37 In addition, an Australian 
cost-effectiveness analysis of an educational intervention encouraging self-skin 
examinations for early detection of skin cancers showed that the overall costs and 
effects outweighed the positive health gains.38 A way to increase the cost-effectiveness 
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is to restrict screening to high-risk patients, but the downside of this targeted screening 
is the so-called ‘prevention paradox’ in which you do not address the overwhelming 
majority of low-risk BCC patients that develop mBCC.39 In the international dermatology 
society there is currently no consensus on the follow-up scheme of BCC patients, but 
they almost all promote self-monitoring (Table 1). The national dermatology guidelines 
differ in the advice on the length and frequency of follow-up, which could depend on 
a countries’ BCC incidence and population composition, and lack prediction models 
that could define high-risk groups. The Dutch BCC guideline advices not to do regular 
follow-up (except in well-known high risk groups like immunosuppressed), whereas 
the German guideline advices, in a population that is similar to that of the Netherlands, 
half-yearly visits the first 3 years after which lifelong yearly follow-up. The Australian 
guideline advices lifelong follow-up every 6-12 months, which was expected because 
they have the highest UVR-related skin cancer incidences rates in the world. Based on 
these findings I would suggest to follow Dutch BCC patients at risk for a mBCC once 
per year at least 3-5 years after every new BCC, without forgetting the patients’ health 
status and wishes. Since skin cancer patients already determine a significant amount 
of the workload of dermatologists, we should consider translocating less complex skin 
cancer care to general practitioners. Recent studies show that general practitioners 
are willing to do this but currently often lack the diagnostic capabilities and tools.40 
However, education sessions can improve diagnostic accuracy and surgery skills and 
diminish unnecessary referrals.41-43
The prediction models we created to identify mBCC patients were as far as we know 
the first prediction models reported for this outcome. However, recently an Australian 
group developed another prediction model based on prospective population-based 
cohort data to estimate the future risks of metachronous KC in patients with and without 
prior KCs.44 Although this study did not differentiate between BCC and SCC, it did 
show that the strongest predictors were signs of field cancerization, namely number of 
prior skin cancers excised and number of skin lesions destroyed. Both our models and 
the Australian model have room for improvement when looking at the discriminative 
capacities and have not been externally validated yet. This points to the fact that there 
are still too few large prospective cohort studies and skin cancer consortia with the 
same data, which can be used to replicate and validate findings from other BCC studies. 
CONCluSION
The diagnosis, treatment and follow-up of BCC (and other UVR-related cutaneous (pre)
malignancies) currently consumes a relatively large part of the dermatological care (in 
the Netherlands/Western countries) and it is unlikely that this will change in the near 
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future, as BCC incidence is still increasing. Identifying and focusing on BCC patients 
at high risk of developing mBCC will optimize BCC care and reduce the strain on 
dermatological care. This thesis can assist dermatologists and general practitioners 
to accomplish this as it presents research on non-genetic and genetic epidemiology 
of mBCC patients, including prediction models to identify these patients. However, 
replication and external validation of these models and larger genetic studies on mBCC 
are needed.
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Summary / Samenvatting
In hoofdstuk 1 geef ik een algemene inleiding op dit proefschrift waarin ik uiteenzet 
waarom ik onderzoek heb gedaan naar multipele/metachrone basaalcelcarcinomen 
(mBCCs) en welke onderzoeksvragen er beantwoord gaan worden. Daarnaast geef ik 
kort aan uit welke hoofdstukken mijn thesis bestaat, wat hierin besproken wordt en wat 
voor data ik gebruikt heb.
In hoofdstuk 2 worden alle facetten van de epidemiologie van het BCC besproken in 
een uitgebreid non-systematisch review. Hieruit komt naar voren dat het BCC de meest 
voorkomende kanker is bij de blanke mens (>1:2 Australiërs ontwikkelen minimaal 1 
BCC) en de incidentiecijfers wereldwijd nog steeds toenemen (jaarlijks >5% toename 
in Europa). Daarbij zijn de ziektelast en zorgkosten significant toegenomen. Vanwege 
deze problemen en het verhoogde risico (>30%) op een volgende ultraviolette straling 
(UV)-gerelateerde huidkanker zorgen BCC patiënten voor een toenemende druk op 
het zorgsysteem. Ook wordt duidelijk dat het BCC een complexe ziekte is waarbij 
het samenspel tussen omgevingsfactoren (o.a. UV), fenotype (o.a. UV-gevoeligheid) en 
genotype (o.a. mutaties en polymorfismen) een sleutelrol speelt in de ontstaanswijze. 
Preventieprogramma’s die continu worden verbeterd, kunnen van grote waarde zijn in 
het aanpakken van het groeiende huidkankerprobleem. Om de meest adequate BCC-
zorg te leveren dienen artsen ‘shared decision-making’ toe te passen en hun beleid 
zorgvuldig te kiezen.
In hoofdstuk 3 wordt middels een commentaar op een ander wetenschappelijk artikel 
over multipele keratinocyten huidkankers (mKCs, BCCs en plaveiselcarcinomen) uit 
Australië uiteen gezet waarom patiënten met een eerste KC een interessante doelgroep 
voor preventieprogramma’s zijn. Daarnaast wordt duidelijk gemaakt dat investeren in 
grote en goed opgezette cohort studies/consortia noodzakelijk is om de betrouwbaarheid 
van de resultaten te verhogen en de basale wetenschap hopelijk stimuleert om meer 
onderzoek te doen naar onderliggende mechanismen.
In hoofdstuk 4 worden de niet-genetische en genetische predictoren van patiënten met 
een superficieel eerste BCC onderzocht in een prospectieve cohort studie, omdat er 
mogelijk verschillen zouden bestaan in het risicofactor profiel tussen patiënten met een 
superficieel eerste en niet-superficieel eerste BCC en hun risico op een volgende BCC. 
De data werden verzameld door gebruik te maken van de deelnemers van het Erasmus 
Rotterdam Gezondheid Onderzoek (ERGO / ‘Rotterdam Study’) en de koppeling tussen 
ERGO en het Pathologisch Anatomisch Landelijk Geautomatiseerd Archief (PALGA). 
ERGO is een langlopend (1989-heden) prospectief bevolkingsonderzoek onder 
mensen van veelal noordwesters Europese afkomst van 45 jaar en ouder, woonachtig 
in de wijk Ommoord in Rotterdam. PALGA is de nationale histopathologie databank 
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en bestaat sinds 1971 en heeft sinds 1991 volledige landelijke dekking. De follow-up/
koppelingsperiode liep van 01-07-1989 t/m 31-12-2013. Er werden 14.628 deelnemers 
gekoppeld waarvan uiteindelijk 948 BCC patiënten geschikt waren voor niet-genetische 
- en 1.014 voor genetische analysen. We includeerden 11 fenotypische -, omgevings- 
en tumor-specifieke karakteristieken als variabelen voor de niet-genetische analysen 
en 20 enkel nucleotide polymorfismen (SNPs, ‘single nucleotide polymorphisms’) als 
variabelen voor de genetische analysen, waarbij we binaire logistische multivariabele 
regressie-analysen verrichtten met als uitkomstmaat het wel/niet hebben van een 
superficieel eerste BCC. We ontdekten dat patiënten met een superficieel eerste BCC 
significant jonger zijn, ongeveer tweemaal vaker vrouw en 12-18 keer vaker een BCC 
op de romp of extremiteiten ontwikkelen dan patiënten met een niet-superficieel eerste 
BCC. Daarnaast vonden we geen significante genetische verschillen tussen beide BCC 
groepen. Patiënten met een superficieel eerste BCC verschillen dus van patiënten met 
een niet-superficieel eerste BCC met betrekking tot fenotypische (leeftijd en geslacht) 
en tumor-specifieke kenmerken (locatie). Ook zou er nog steeds een niet ontdekt 
genotypisch verschil kunnen bestaan. Aangezien patiënten met een superficieel eerste 
BCC hun eerste BCC op jongere leeftijd ontwikkelen, zouden ze een hoger levenslang 
risico op een volgende huidkanker (e.g., BCC) kunnen hebben en daardoor een 
interessante groep zijn voor secundaire preventie.
In hoofdstuk 5 wordt middels een commentaar op een ander wetenschappelijk artikel 
over de absolute risico’s op het ontstaan van nieuwe KCs in een Amerikaans cohort 
uiteen gezet waarom rekening houden met mortaliteit in overlevingsstatistiek belangrijk 
is. We laten zien door gebruik te maken van ERGO-data, dat een overschatting van 
het absolute risico op een volgende KC kan ontstaan als men geen rekening houdt 
met het concurrerende risico op dood binnen een cohort. We vergelijken de ‘foutieve’ 
Kaplan-Meier methode met de cumulatieve incidentie curve waarbij duidelijk wordt 
dat de verschillen in kansen op een volgende KC uiteen kunnen lopen van 74% 
(Kaplan-Meier methode) tot 52% (cumulatieve incidentie curve) na 20 jaar follow-
up, omdat het probleem van het concurrerende risico op dood groter wordt. Dit 
probleem kan voor alle uitkomstmaten (behoudens algemene mortaliteit) voorkomen 
in overlevingsstatistiek en wordt vooral gezien in studies met een oudere populatie en 
een lange follow-up.
In hoofdstuk 6 wordt een model ontwikkeld voor het voorspellen van het absolute risico 
op een tweede BCC, omdat ongeveer 30% van alle patiënten met een BCC minimaal 
één volgende BCC in de tijd ontwikkelen en we niet precies weten wie dit zijn. De 
data werden verzameld door gebruik te maken van de deelnemers van de prospectieve 
ERGO-studie en de koppeling met PALGA. Er werden 13 omgevings-, fenotypische 
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- en tumor karakteristieken als predictoren geselecteerd. Het predictiemodel werd 
gebaseerd op het Fine en Gray regressie model waarbij rekening werd gehouden met 
het concurrerend risico op dood. Onder de 1.077 geïncludeerde ERGO-deelnemers 
met minimaal 1 BCC, ontwikkelden er 293 minimaal een tweede BCC na gemiddeld 
3 jaar. Enkele welbekende risico factoren voor een eerste BCC waren niet prognostisch 
voor een tweede BCC, terwijl het hebben van meer dan 1 BCC bij initiële presentatie 
de sterkste predictor was. Het discriminerend vermogen van het model was redelijk 
(bootstrap gevalideerde c-index= 0.65 op 3 jaar). Er werden 3 risico groepen gemaakt, 
waarbij de risico’s op een tweede BCC na 3 jaar uiteen liepen van 7-28%. Een 
combinatie van gemakkelijk verkrijgbare klinische karakteristieken kan met redelijke 
betrouwbaarheid patiënten identificeren die een hoog risico hebben op een tweede 
BCC. Externe validatie en uitbreiding met sterkere predictoren is wenselijk om het 
predictiemodel te verbeteren.
In hoofdstuk 7 wordt voortgeborduurd op het predictiemodel uit hoofdstuk 6, omdat 
het onduidelijk is wie er meer dan 2 BCCs ontwikkelen, hoe hoog dit risico is en 
hoe snel dit gebeurt. De data werden wederom verzameld door gebruik te maken van 
de deelnemers van de prospectieve ERGO-studie en de koppeling met PALGA. De 
follow-up werd uitgebreid tot en met het 5e nieuwe BCC. Er werden 14 omgevings-, 
fenotypische - en tumor karakteristieken als predictoren geselecteerd, waarbij het aantal 
voorgaande BCC diagnosen als nieuwe predictor werd toegevoegd. Het predictiemodel 
werd gebaseerd op het Fine en Gray regressie model waarbij rekening werd gehouden 
met het concurrerend risico op dood. Bootstrapping werd gebruikt om het model 
verder te verbeteren en valideren. Onder de 1.077 geïncludeerde ERGO-deelnemers 
ontstonden er tweede tot en met vijfde BCCs in respectievelijk 293, 122, 58 en 36 
patiënten, na gemiddeld 3,0 , 2,1 , 1,7 en 1,8 jaar follow-up na de vorige BCC. Het 
risico op een volgende mBCC was hoger voor patiënten met meer voorgaande BCCs. 
Het hebben van meer dan 1 BCC tijdens een diagnose moment was een andere sterke 
predictor van mBCC. Het discriminerende vermogen van het model was redelijk met 
een voor optimisme gecorrigeerde c-index van 0,70 na 3 jaar. Wanneer het aantal 
voorgaande BCC diagnosen wordt gecombineerd met andere gemakkelijk verkrijgbare 
klinische kenmerken in een predictiemodel, kunnen patiënten met een hoog risico op 
een volgende BCC geïdentificeerd worden.
In hoofdstuk 8 wordt onderzocht of er genetische aanleg bestaat voor het ontwikkelen 
van mBCC, omdat er nog nauwelijks genetische onderzoeken zijn verricht naar 
patiënten met meerdere BCCs en het niet bekend is of de reeds ontdekte BCC loci 
ook geassocieerd zijn met mBCC. De data werden verzameld door gebruik te maken 
van de deelnemers van de prospectieve ERGO-studie en de koppeling met PALGA. 
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Er werd zowel een kandidaatgen analyse (CGA, ‘candidate gene approach’) met 19 
kandidaat SNPs verspreid over 17 loci, als een genoomwijde associatie studie (GWAS, 
‘genome-wide association study’) verricht. Na kwaliteitschecks bleven er 7.260.691 
markers over voor genetische analysen. Er werden 1.219 deelnemers met ten minste 
1 BCC geïncludeerd, waarvan er 472 (38,7%) mBCC hadden. De CGA werd verricht 
middels een SNP- en gen-gebaseerde logistische regressie analyse waarbij patiënten 
met 1 BCC vergeleken werden met patiënten met mBCC, gecorrigeerd voor leeftijd, 
geslacht en 4 principale componenten (PCs). De Bonferroni methode werd gebruikt 
om aan te passen voor ‘multiple testing’. Er werden geen significante genetische 
verschillen gevonden tussen beide groepen m.b.t. de geïncludeerde kandidaat SNPs/
genen. De pilot GWAS, d.m.v. logistische regressie aangepast voor leeftijd, geslacht 
en 4 PCs, leverde een aantal opvallende niet-significante associaties op, waarvan de 
meest significante SNP rs78857623 (P-waarde 1,2×10-7) was, gelegen in een intron op 
het tumorsuppressor gen FHIT. Het lijkt er dus op dat genetische loci die geassocieerd 
zijn met BCC niet geassocieerd zijn met mBCC. Daarnaast leverde de GWAS enkele 
interessante associaties op, maar deze bevindingen moet worden gerepliceerd in 
andere cohorten gezien de beperkte power.
In hoofdstuk 9 wordt voortgeborduurd op de genetische associatie analysen uit hoofdstuk 
8 waarbij ditmaal mKC als uitkomstmaat wordt genomen (twee typen huidkanker die 
veel overeenkomsten vertonen) ten einde de power te vergroten. De data werden 
verzameld door niet alleen gebruik te maken van de deelnemers van de prospectieve 
ERGO-studie en de koppeling met PALGA, maar ook een samenwerking aan te gaan 
met enkele Amerikaanse prospectieve cohortonderzoeken, te weten de Nurses’ Health 
Study (NHS), NHS II, Health Professionals Follow-Up Study en de Framingham Heart 
Study. Er werd een GWAS verricht met hierin >8 miljoen SNPs bij 1.666 patiënten 
met mKC en 1.950 controles met een enkele KC. De meest significante (P-waarde 
5,5x10-6) SNPs (40) uit de ontdekkingsfase werden geïncludeerd in de replicatiefase 
in een onafhankelijk cohort van de ERGO-studie van 574 patiënten met mKC en 872 
met een enkele KC. Er werden geen genoomwijde significante SNPs gevonden. Ook 
de reeds 19 bekende BCC loci werden getest voor eventuele associatie met mKC in 
een CGA en het bleek dat rs1805007 (MC1R locus) significant (P-waarde 2,80x10-4) 
geassocieerd was met mKC. Om de nieuwe genetische markers te vinden voor mKC 
zijn er grotere consortia nodig.
In hoofdstuk 10 geef ik antwoord op mijn eerder (hoofdstuk 1) gestelde onderzoeksvragen 
door gebruik te maken van mijn onderzoeksresultaten en bespreek ik de beperkingen 
van de door ons verrichtte studies. Tot slot bespreek ik de mogelijke implicaties van 
mijn bevindingen met het oog op de toekomst.
joris arnoldus cornelis verkouteren
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List of abbreviations
lIST Of ABBREVIATIONS
BCC  basal cell carcinoma
mBCC  metachronous / multiple basal cell carcinomas
GWAS  genome-wide association study
PALGA   Dutch nationwide network and registry of histopathology and 
cytopathology
UVR  ultraviolet radiation
SCC  squamous cell carcinoma
KC  keratinocyte carcinoma
CI  confidence interval
OR  odds ratio
ERGO / RS  Rotterdam Study 
SNP  single nucleotide polymorphism
c-index  concordance index
HR  hazard ratio
CGA  candidate gene approach
MAF  minor allele frequency 
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Beste prof. dr. Prens, dr. Kelleners – Smeets, dr. Wakkee en dr. Mureau: hartelijk dank 
voor de bereidheid om zitting te nemen in mijn grote promotiecommissie en met mij 
van gedachten te wisselen tijdens de verdediging.
Beste ERGO-team: mijn proefschrift zou er niet zijn geweest zonder de data die wordt 
verzameld op dit onderzoekscentrum. Ik heb mijn werkdagen op het ERGO-centrum 
altijd ervaren als een prettige afwisseling op het dagelijks onderzoekswerk. Veel dank 
hiervoor.
Beste PALGA (in het bijzonder dr. Overbeek en dr. Van den Broek): hartelijk dank 
voor de fijne samenwerking en de hulp bij het verzamelen van de histopathologische 
informatie.
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Beste co-auteurs: ontzettend bedankt voor jullie tijd en inzet.
Beste prof. dr. Steyerberg, dr. Vergouwe en Hilde: hartelijk dank voor de fijne 
samenwerking, zonder jullie hulp waren de predictiemodellen er nooit geweest. Hilde, 
ik vond ons een topteam en ik heb veel van je kunnen leren, dank hiervoor! Ik hoop 
dat ook jij binnenkort klaar bent.
Beste onderzoeksgroep: 
Loes, je bent een topper en het was mooi om te zien hoe jij door de jaren heen door 
alle onderzoekers op onze afdeling werd omgedoopt tot een statistisch orakel.
Sophie, Emmilia, Robert, Enes, Leonie, Merel, Kirtie, Joan en Martijn, jullie hebben 
er voor gezorgd dat mijn promotietraject in alle fases leuker en makkelijker werd. We 
waren (en zijn) een goed team waardoor de kwaliteit van ons werk en het plezier erin 
toenam.
Beste collegae / medewerkers van de afdeling dermatologie: jullie hebben er voor 
gezorgd dat ik altijd met veel plezier naar mijn werk ga en me thuis voel op onze 
prachtige afdeling. Ik ben blij dat ik mijn opleiding mag doorlopen met jullie. Veel 
dank hiervoor!
Beste paranimfen:
Niels, wat fijn dat ik jou heb leren kennen in de brugklas. Tijdens de middelbare 
school periode waren we een onafscheidelijk duo waarin we zowel gedurende als buiten 
schooltijd veel lol hadden. Tijdens onze studiejaren zagen we elkaar minder vaak, maar 
zodra we elkaar zagen, was het altijd weer direct ouwe-jongens-krentenbrood. Ik ben 
er dan ook blij mee dat je nu in Rotterdam bent komen wonen samen met Anne-Marije 
(die moet je koesteren ;)). Leuk dat ook jij nu bezig bent met een promotietraject en ik 
weet zeker dat jij een prachtig boekwerk zult afleveren. Je bent een geweldige vent en 
ik ben er trots op jou als vriend te hebben!
Maarten, wat fijn dat ik jou heb leren kennen tijdens ons eerste geneeskundejaar. 
We hebben de afgelopen jaren veel mooie dingen gedaan en beleefd waardoor jij 
mijn studententijd en de periode erna nog meer kleur hebt gegeven. Ik kan altijd op je 
bouwen en ik zal proberen je door de laatste fase van jouw PhD-traject te slepen. Je 
bent een kanjer en ik ben er trots op jou als vriend te hebben!
Lieve Dorien en Yvette: ook jullie mogen natuurlijk niet ontbreken, samen met Niels 
vormden wij op de middelbare school een viereenheid en heb ik ontzettend veel leut 
met jullie gehad. Ook al zien we elkaar nu minder vaak, blijven de momenten dat wij 
samen zijn mij erg dierbaar.
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Word of thanks / Dankwoord
Beste (tennis)vrienden: ontzettend bedankt voor alle gezelligheid en de vele uren op 
en rond de tennisbaan.
Lieve schoonfamilie, lieve Anneke, Kees, Wiljan en Mirna: ontzettend bedankt voor 
jullie warmte en interesse de afgelopen jaren. Ik voel me echt onderdeel van de familie 
en daar ben ik jullie zeer dankbaar voor!
Lieve familie, lieve pap en mam, Daan & Eline, Babette, Maxime & Luuk: jullie zijn 
er altijd voor mij geweest en hebben mij grotendeels gevormd tot de persoon die ik 
vandaag de dag ben. Jullie hebben altijd in mij geloofd en mij veel liefde en warmte 
gegeven. Het feit dat ik vandaag niet alleen dokter maar ook een doctor word, heb ik 
mede aan jullie te danken! Ik ben er ontzettend trots op dat jullie mijn familie zijn!
Tot slot, lieve Lot: jij bent echt geweldig, het was liefde op het eerste gezicht en dit zal 
nooit meer verdwijnen. Jij bent er altijd voor mij en ik zal er nu weer voor zorgen dat 
we weer meer tijd samen hebben. Ik hou zielsveel van je en hoop de rest van mijn 
leven met je te mogen doorbrengen!
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